
<html lang="en"     class="pb-page"  data-request-id="27edc312-4872-41c4-a22a-42d24824127e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2018.61.issue-24;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b01612;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold" /></meta><meta name="dc.Creator" content="Yilan  Ju" /></meta><meta name="dc.Creator" content="Jintao  Wu" /></meta><meta name="dc.Creator" content="Xi  Yuan" /></meta><meta name="dc.Creator" content="Luqing  Zhao" /></meta><meta name="dc.Creator" content="Ganlin  Zhang" /></meta><meta name="dc.Creator" content="Chao  Li" /></meta><meta name="dc.Creator" content="Renzhong  Qiao" /></meta><meta name="dc.Description" content="Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC..." /></meta><meta name="Description" content="Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 3, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01612" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01612" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01612" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01612" /></link>
        
    
    

<title>Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01612" /></meta><meta property="og:title" content="Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0008.jpeg" /></meta><meta property="og:description" content="Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC). Unfortunately, some marketed drugs affect a transient beneficial response in EGFR mutant NSCLC patients. We reported a series of potential EGFR inhibitors through incorporation of macrocyclic polyamine into 4-anilinoquinazoline scaffold. It is expected that anilinoquinazoline part effectively bind to EGFR domain, while ATP molecules are captured by a macrocyclic polyamine moiety. In vitro experiments exhibited that most of tested compounds suppressed tumor cell proliferation more strongly than Gefitinib and Lapatinib (dual inhibitor of EGFR/HER2) as controls. In kinase assays, the compound 1f showed excellent dual inhibition activity toward EGFRWT (IC50 = 1.4 nM) and HER2 (IC50 = 2.1 nM). In vivo pharmacology evaluation of 1f showed significant antitumor activity (TGI = 44.2%) in A549 xenografts mice. The current work provided a feasible solution to optimize anilinoquinazoline-based inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01612"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01612">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01612&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01612&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01612&amp;href=/doi/10.1021/acs.jmedchem.8b01612" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 11372-11383</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01578" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01622" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yilan Ju</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yilan Ju</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yilan++Ju">Yilan Ju</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jintao Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jintao Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jintao++Wu">Jintao Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xi Yuan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xi Yuan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xi++Yuan">Xi Yuan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luqing Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luqing Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luqing++Zhao">Luqing Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ganlin Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ganlin Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Department, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ganlin++Zhang">Ganlin Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#bcd0d5dfd4ddd3fcd1ddd5d092dec9dfc892d9d8c992dfd2"><span class="__cf_email__" data-cfemail="bad6d3d9d2dbd5fad7dbd3d694d8cfd9ce94dfdecf94d9d4">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Li">Chao Li</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Renzhong Qiao</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Renzhong Qiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</div><div class="loa-info-affiliations-info">State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100871, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 86 10 64413899. E-mail: <a href="/cdn-cgi/l/email-protection#deafb7bfb181b9acb1abae9eefe8edf0bdb1b3"><span class="__cf_email__" data-cfemail="d1a0b8b0be8eb6a3bea4a191e0e7e2ffb2bebc">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Renzhong++Qiao">Renzhong Qiao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6672-9609" title="Orcid link">http://orcid.org/0000-0002-6672-9609</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01612&amp;href=/doi/10.1021%2Facs.jmedchem.8b01612" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 11372–11383</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 3, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 October 2018</li><li><span class="item_label"><b>Published</b> online</span>3 December 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 December 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01612</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11372%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYilan%2BJu%252C%2BJintao%2BWu%252C%2BXi%2BYuan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D24%26contentID%3Dacs.jmedchem.8b01612%26title%3DDesign%2Band%2BEvaluation%2Bof%2BPotent%2BEGFR%2BInhibitors%2Bthrough%2Bthe%2BIncorporation%2Bof%2BMacrocyclic%2BPolyamine%2BMoieties%2Binto%2Bthe%2B4-Anilinoquinazoline%2BScaffold%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11383%26publicationDate%3DDecember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01612"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2158</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01612" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yilan&quot;,&quot;last_name&quot;:&quot;Ju&quot;},{&quot;first_name&quot;:&quot;Jintao&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Xi&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Luqing&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Ganlin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Renzhong&quot;,&quot;last_name&quot;:&quot;Qiao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;11372-11383&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01612&quot;},&quot;abstract&quot;:&quot;Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC). Unfortunately, some marketed drugs affect a transient beneficial response in EGFR mutant NSCLC patients. We reported a series of potential EGFR inhibitors through incorporation of macrocyclic polyamine into 4-anilinoquinazoline scaffold. It is expected that anilinoquinazoline part effectively bind to EGFR domain, while ATP molecules are captured by a macrocyclic polyamine moiety. In vitro experiments exhibited that most of tested compounds suppressed tumor cell proliferation more strongly than Gefitinib and Lapatinib (dual inhibitor of EGFR/HER2) as controls. In kinase assays, the compound 1f showed excellent dual inhibition activity toward EGFRWT (IC50 = 1.4 nM) and HER2 (IC50 = 2.1 nM). In vivo pharmacology evaluation of 1f showed significant antitumor activity (TGI = 44.2%) in A549 xenografts mice. The current&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01612&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01612" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01612&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01612" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01612&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01612" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01612&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01612&amp;href=/doi/10.1021/acs.jmedchem.8b01612" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01612" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01612" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01612%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DJu%26date%3D2018%26atitle%3DDesign%2Band%2BEvaluation%2Bof%2BPotent%2BEGFR%2BInhibitors%2Bthrough%2Bthe%2BIncorporation%2Bof%2BMacrocyclic%2BPolyamine%2BMoieties%2Binto%2Bthe%2B4-Anilinoquinazoline%2BScaffold%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D24%26spage%3D11372%26epage%3D11383%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (5)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291503" title="Organic polymers">Organic polymers</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/jmcmar.2018.61.issue-24/20181227/jmcmar.2018.61.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Adenosine triphosphate (ATP)-competitive inhibitors of the epidermal growth factor receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC). Unfortunately, some marketed drugs affect a transient beneficial response in EGFR mutant NSCLC patients. We reported a series of potential EGFR inhibitors through incorporation of macrocyclic polyamine into 4-anilinoquinazoline scaffold. It is expected that anilinoquinazoline part effectively bind to EGFR domain, while ATP molecules are captured by a macrocyclic polyamine moiety. <i>In vitro</i> experiments exhibited that most of tested compounds suppressed tumor cell proliferation more strongly than Gefitinib and Lapatinib (dual inhibitor of EGFR/HER2) as controls. In kinase assays, the compound <b>1f</b> showed excellent dual inhibition activity toward EGFR<sup>WT</sup> (IC<sub>50</sub> = 1.4 nM) and HER2 (IC<sub>50</sub> = 2.1 nM). <i>In vivo</i> pharmacology evaluation of <b>1f</b> showed significant antitumor activity (TGI = 44.2%) in A549 xenografts mice. The current work provided a feasible solution to optimize anilinoquinazoline-based inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The human epidermal growth factor receptor (HER) family kinases play a crucial regulatory role associated with a variety of malignancies, making this protein family an attractive drug target.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Among these kinases, EGFR and HER2 are both expressed at low levels in normal human tissues but overexpressed in 20–40% of solid tumors such as breast, ovarian, prostate, and colon cancer.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> They are often associated with increased metastasis and poor prognosis.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Overexpression of HER2 increases glucose uptake, lactate production, and oxygen consumption, resulting in the reprogramming of tumor metabolism.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Several drugs have been approved by the Food and Drug Administration (FDA) for clinical use as EGFR inhibitors. Gefitinib was the first orally targeted therapy drug to be approved for the treatment of NSCLC (nonsmall cell lung cancer).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Its good tolerability, response rates, and symptomatic improvements were demonstrated in early trials,<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14">(10−14)</a> with accelerated approval for Gefitinib treatment in patients with advanced NSCLC who had advanced on chemotherapy. However, the emergence of acquired point mutations, particularly T790M mutation, has weakened their therapeutic efficacy, leading to drug resistance.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> Previous studies showed that the interactions of gefitinib in the active site of the wild-type EGFR consists of hydrogen bonding between quinazoline ring with the main chain amide of Met793.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> However, the morpholine moiety in Gefitinib is not involved in any interaction with EGFR and is randomly ordered due to its lower electron density. Thus, the suitable 6-substituted group in anilinoquinazoline instead of morpholine probably provided the inhibitors with improved potency.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18−21)</a></div><div class="NLM_p">It is known that several macrocyclic polyamines can catalyze the chemical hydrolysis of ATP<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and even bind in the ATP pocket as potent Mer tyrosine kinase (MerTK)-specific inhibitor.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> Some reports indicated depletion of cellular ATP related to growth inhibition of tumor cell lines and to drug resistance in multidrug resistance (MDR) cells.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Frydman et al. investigated five macrocyclic polyamines, related to the budmunchamine family of alkaloids, to inhibit human prostate tumor cell proliferation through catalyzing the hydrolysis of ATP.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Only 2 μM of the most efficient macrocycle reduced cellular ATP levels by 3 orders of magnitude after a 24 h of incubation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> A rough correlation was established between the cytotoxic effect of the macrocyclic polyamines and their ATP-ase like activity in cancer cell line, which may depend on the ring size of the macrocycle.</div><div class="NLM_p">Herein, we reported a group of novel quinazoline derivatives with macrocyclic polyamine side chain at the C-6 position as potent protein kinase inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). 1,4,7,10-Tetraazacyclododecane (cyclen) and 1,4,7-triazonane (tacn) were used to replace the morpholine moiety in clinical drug Gefitinib, mainly considering its affinity to cellular ATP.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> If ATP molecules are captured and subsequent hydrolyzed as expected, it would effectively prevent the binding of ATP to hydrophobic cavity in EGFR, blocking the signals pathway and inducing cancer cell apoptosis. Meanwhile, protonated polyamine in acidic environment is more likely to combine and hydrolyze ATP molecules,<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> which facilitate the passive targeting of drugs in acidic tumor microenvironment. However, Lapatinib as a reversible dual TKI with proven effectiveness in clinical trials was approved by FDA in 2007.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Considering its selective inhibition of HER2 and EGFR as well as the corresponding SAR, the featured substituent in 4-position of quinazoline, 3-chloro-4-((3-fluorobenzyl)oxy)phenyl, was used in current design as one of the candidates. Thirty compounds with a series of 4-substituted anilines were investigated to optimize the inhibitor activity and further explore the structure–activity relationship. Most candidates showed much lower IC<sub>50</sub> compared to positive controls against A431 and A549 cancer cell lines, and further kinase testing on <b>1f</b> and <b>2f</b> revealed that both of them possessed high inhibitory activity against EGFR<sup>wt</sup> and HER2. Moreover, <i>in vivo</i> antitumor efficacy were evaluated using A549 NSCLC xenografts mice model, and results showed the favorable tumor growth inhibition (TGI). The current work attempted to explore the macrocyclic polyamine potential application in antitumor activity by its ATP-binding ability and to improve the physicochemical properties of clinical quinazoline compounds.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of Gefitinib, Lapatinib, and newly designed quinazoline derivatives as potential EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61410" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61410" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">A series of novel quinazoline derivatives linked with macrocyclic polyamine at C-6 position and different aniline at C-4 position were synthesized. The synthetic route of the titled compounds is depicted in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, starting from compound <b>3</b>, which is commercially available. After protection of 6-OH by acetic anhydride (step i), carbonyl in compound <b>3</b> was chlorinated by thionyl chloride to afford <b>4</b> in 74% yield (step ii). Subsequently, various substituted anilines were coupled to 4-Cl in quinazoline (step iii), and hydrolysis of the acetyl group using ammonium hydroxide gave corresponding phenol intermediates in average 75% yield (<b>5a</b>–<b>o</b>, step iv). The alkylation of the 6-OH on compounds <b>5a</b>–<b>o</b> were performed with two kinds of macrocyclic polyamine moieties containing bromopropyl (step v). Finally, the boc groups were removed with 12 M hydrochloride acid (HCl) in anhydrous methanol solution, to give the titled compounds <b>1a</b>–<b>o</b> and <b>2a</b>–<b>o</b> in average 70% yield (step vi), respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. General Procedure for the Synthesis of 4-Anilinoquinazoline Derivatives <b>1a</b>–<b>o</b> and <b>2a</b>–<b>o</b><a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0006.gif" alt="" id="gr2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0007.gif" alt="" id="gr100" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Reagents and conditions: (i) (CH<sub>3</sub>CO)<sub>2</sub>O, pyridine, reflux; (ii) SOCl<sub>2</sub>, DMF, reflux; (iii) substituted aniline, CH<sub>3</sub>CN, reflux; (iv) NH<sub>3</sub>·H<sub>2</sub>O, CH<sub>3</sub>OH, reflux; (v) cyclen (or tacn) moiety, DMF, reflux; (vi) HCl (l), CH<sub>3</sub>OH.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Antiproliferative Activity Assay</h3><div class="NLM_p">The antiproliferation activity of the titled compounds against A549 and A431 cell lines with abnormally high expressing EGFR was evaluated by MTT assay, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Gefitinib, the first selective inhibitor of EGFR, was used as control compound. All synthesized compounds showed more effective antiproliferative activities in A431 cell lines (IC<sub>50</sub> from 0.442 to 18.77 μM) than that in A549 cell lines. We were encouraged that antiproliferative activity of <b>1a</b> and <b>2a</b> with the same 4-substituted aniline (3-chloro-4-fluorophenyl) as Gefitinib was well accepted with IC<sub>50</sub> values of 1.01 and 1.31 μM against A431 cell lines, respectively. Macrocyclic polyamine substituted for morpholine could contribute to increased inhibitory effects. For A549 cell lines, the compounds with cyclen moiety (<b>1a</b>–<b>o</b>) showed better antiproliferative activity than those with tacn moiety (<b>2a</b>–<b>o</b>), while there was no such difference in A431 cell lines. The best results were from compound <b>1f</b> with IC<sub>50</sub> values of 0.958 and 3.4 μM against A431 and A549 cell lines, respectively, which were much better than the inhibitory effects of Gefitinib (IC<sub>50</sub> 2.47 μM against A431 and 11.08 μM against A549). It should be noted that the 4-substituted aniline, 3-chloro-4-((3-fluorobenzyl)oxy)phenyl, is the same as the featured substituent of Lapatinib, which may have a positive effect on the activity of <b>1f</b> or <b>2f</b>. Thus, Lapatinib was also used as control to evaluate the antiproliferative activity in both cell lines. Similarly, more than half of the tested compounds showed better antiproliferative activity than that of Lapatinib against A431 cell lines, but only <b>1f</b> gave acceptable IC<sub>50</sub> value of 3.4 μM in A549 cell lines. Compound <b>j</b>, <b>k</b>, <b>n</b>, and <b>o</b> hardly exhibited any inhibitory effects against A549 (IC<sub>50</sub> > 50 μM), which may result from electronic or steric effect of substituent. Despite the benefits from the featured side chain of Lapatinib, the positive effect of macrocyclic polyamine on antiproliferative activity is also not negligible.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activities of <b>1a</b>–<b>o</b> and <b>2a</b>–<b>o</b> against A549 and A431 Cells Harboring High Expressing EGFR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">Antiproliferation IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">Antiproliferation IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center" char="±">A431</th><th class="colsep0 rowsep0" align="center" char="±">A549</th><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center" char="±">A431</th><th class="colsep0 rowsep0" align="center" char="±">A549</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char="±">1.01 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">20.21 ± 3.24</td><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char="±">1.314 ± 0.356</td><td class="colsep0 rowsep0" align="char" char="±">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1b</b></td><td class="colsep0 rowsep0" align="char" char="±">1.11 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">28.55 ± 4.91</td><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char="±">2.231 ± 0.544</td><td class="colsep0 rowsep0" align="char" char="±">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1c</b></td><td class="colsep0 rowsep0" align="char" char="±">1.047 ± 0.014</td><td class="colsep0 rowsep0" align="char" char="±">14.68 ± 2.26</td><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char="±">2.322 ± 0.812</td><td class="colsep0 rowsep0" align="char" char="±">34.27 ± 3.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="char" char="±">1.839 ± 0.233</td><td class="colsep0 rowsep0" align="char" char="±">15.195 ± 1.036</td><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.561 ± 0.051</td><td class="colsep0 rowsep0" align="char" char="±">16.08 ± 2.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1e</b></td><td class="colsep0 rowsep0" align="char" char="±">1.578 ± 0.411</td><td class="colsep0 rowsep0" align="char" char="±">11.84 ± 2.31</td><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char="±">1.064 ± 0.341</td><td class="colsep0 rowsep0" align="char" char="±">34.27 ± 1.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.958 ± 0.034</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.4</td><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.442 ± 0.068</td><td class="colsep0 rowsep0" align="char" char="±">7.25 ± 0.89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1g</b></td><td class="colsep0 rowsep0" align="char" char="±">1.707 ± 0.129</td><td class="colsep0 rowsep0" align="char" char="±">5.35 ± 1.21</td><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="char" char="±">2.98 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">6.23 ± 0.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1h</b></td><td class="colsep0 rowsep0" align="char" char="±">1.952 ± 0.387</td><td class="colsep0 rowsep0" align="char" char="±">15.73 ± 3.66</td><td class="colsep0 rowsep0" align="left"><b>2h</b></td><td class="colsep0 rowsep0" align="char" char="±">1.562 ± 0.183</td><td class="colsep0 rowsep0" align="char" char="±">37.3 ± 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1i</b></td><td class="colsep0 rowsep0" align="char" char="±">1.424 ± 0.481</td><td class="colsep0 rowsep0" align="char" char="±">27.1 ± 3.49</td><td class="colsep0 rowsep0" align="left"><b>2i</b></td><td class="colsep0 rowsep0" align="char" char="±">1.125 ± 0.312</td><td class="colsep0 rowsep0" align="char" char="±">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1j</b></td><td class="colsep0 rowsep0" align="char" char="±">3.21 ± 0.53</td><td class="colsep0 rowsep0" align="char" char="±">>50</td><td class="colsep0 rowsep0" align="left"><b>2j</b></td><td class="colsep0 rowsep0" align="char" char="±">8.526 ± 0.569</td><td class="colsep0 rowsep0" align="char" char="±">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="char" char="±">1.86 ± 0.44</td><td class="colsep0 rowsep0" align="char" char="±">>50</td><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="char" char="±">7.914 ± 0.063</td><td class="colsep0 rowsep0" align="char" char="±">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1l</b></td><td class="colsep0 rowsep0" align="char" char="±">2.539 ± 0.512</td><td class="colsep0 rowsep0" align="char" char="±">14.53 ± 2.31</td><td class="colsep0 rowsep0" align="left"><b>2l</b></td><td class="colsep0 rowsep0" align="char" char="±">2.215 ± 0.991</td><td class="colsep0 rowsep0" align="char" char="±">26.16 ± 2.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1m</b></td><td class="colsep0 rowsep0" align="char" char="±">4.385 ± 0.302</td><td class="colsep0 rowsep0" align="char" char="±">23.79 ± 6.14</td><td class="colsep0 rowsep0" align="left"><b>2m</b></td><td class="colsep0 rowsep0" align="char" char="±">4.077 ± 0.517</td><td class="colsep0 rowsep0" align="char" char="±">44.24 ± 2.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1n</b></td><td class="colsep0 rowsep0" align="char" char="±">6.369 ± 0.981</td><td class="colsep0 rowsep0" align="char" char="±">>50</td><td class="colsep0 rowsep0" align="left"><b>2n</b></td><td class="colsep0 rowsep0" align="char" char="±">12.69 ± 0.71</td><td class="colsep0 rowsep0" align="char" char="±">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1o</b></td><td class="colsep0 rowsep0" align="char" char="±">5.653 ± 0.737</td><td class="colsep0 rowsep0" align="char" char="±">>50</td><td class="colsep0 rowsep0" align="left"><b>2o</b></td><td class="colsep0 rowsep0" align="char" char="±">18.77 ± 1.26</td><td class="colsep0 rowsep0" align="char" char="±">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Gefitinib</b></td><td class="colsep0 rowsep0" align="char" char="±">2.47 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">11.08 ± 2.29</td><td class="colsep0 rowsep0" align="left"><b>Lapatinib</b></td><td class="colsep0 rowsep0" align="char" char="±">2.66 ± 0.27</td><td class="colsep0 rowsep0" align="char" char="±">3.64 ± 0.77</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The data are the mean ± SD of at least three independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The antiproliferative effects of the synthesized compounds against human cancer cells gathered with MTT assay.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Kinase Inhibitory Activity</h3><div class="NLM_p">The inhibitory activity of the selected compounds against two EGFRs (WT and T790M) and HER2 were evaluated using a well-established LANCE Ultra kinase assay, with Gefitinib and Lapatinib employed as positive controls. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, most of the tested compounds exhibited inhibitory activities against EGFR<sup>WT</sup>, in which <b>2f</b> suppressed EGFR<sup>WT</sup> (IC<sub>50</sub> 0.3 nM) more potently relative to Gefitinib (IC<sub>50</sub> 5.8 nM) and Lapatinib (IC<sub>50</sub> 10.85 nM). Also, <b>1f</b> (IC<sub>50</sub>2.1 nM) and <b>2f</b> (IC<sub>50</sub>9.6 nM) showed better inhibitory activities against HER2 than Lapatinib (IC<sub>50</sub>32.7 nM). For mutant EGFR, <b>1f</b> and <b>2f</b> showed moderate inhibitory effect on T790M (with IC<sub>50</sub> of 16.5 and 40.6 nM, respectively), which was still much better than Gefitinib (IC<sub>50</sub>148.7 nM). These results suggested that <b>1f</b> and <b>2f</b> can serve as dual inhibitors against both EGFR<sup>WT</sup> and HER2 and were more active than Lapatinib.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> Enzymatic Inhibitory Activity of Selected Compounds against Different Statues of EGFR and HER2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">Kinase Inhibition IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center" char="±">EGFR<sup>wt</sup></th><th class="colsep0 rowsep0" align="center" char="±">HER2</th><th class="colsep0 rowsep0" align="center" char="±">EGFR<sup>T790M</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">NT<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char="±">8.3 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">NT</td><td class="colsep0 rowsep0" align="char" char="±">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char="±">28.2 ± 5.3</td><td class="colsep0 rowsep0" align="char" char="±">NT</td><td class="colsep0 rowsep0" align="char" char="±">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">NT</td><td class="colsep0 rowsep0" align="char" char="±">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1f</b></td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">16.5 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">9.6 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">40.6 ± 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Gefitinib</b></td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">NT</td><td class="colsep0 rowsep0" align="char" char="±">148.7 ± 6.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Lapatinib</b></td><td class="colsep0 rowsep0" align="char" char="±">10.85 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">32.7 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">>2500</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The data are the mean ± SD of at least three independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">NT means not test.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Cellular ATP Depletion</h3><div class="NLM_p">Cellular ATP levels in A549 cells were measured at 24 and 72 h after incubation with <b>1f</b>, <b>2f</b>, and control drugs. Cellular ATP concentrations were measured using the luciferase–luciferin system. After a 24 h treatment with 0–2 μM of all samples, no obvious change in ATP levels was obtained, but at 8 μM, <b>1f</b> was found to effectively deplete intracellular ATP, which was better than <b>2f</b> and Gefitinib under the same incubation conditions (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). After Lapatinib treatment with the maximal dosage of 6 μM, ATP remained at moderate levels. For a 72 h treatment, <b>1f</b> only required 2 μM concentration to deplete intracellular ATP to a low level (0.1 μM), while <b>2f</b> required 8 μM concentration to achieve comparable inhibition. Gefitinib and Lapatinib exhibited moderate inhibition of intracellular ATP at maximal dosage (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of macrocyclic polyamines on the intracellular ATP levels of A549 cells after incubating for (A) 24 h and (B) 72 h. The treated cells for each concentration of macrocycle were run in quadruplicate. ATP concentrations were determined using Enlitten reagent, and luminescence was read after a 1 min mixture time. Finally, relative light units were converted to ATP concentrations using a reference plot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Induction of Apoptosis <i>in Vitro</i></h3><div class="NLM_p">To further investigate the mechanism of inhibiting tumor cells, a flow cytometry-based apoptosis assay was performed, and cells under initiation of apoptosis were stained by Annexin V-FITC, while late apoptotic cells were labeled by PI (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). A549 cells harboring high expressing EGFR were treated with a variable level of <b>1f</b> (1, 4, and 8 μM) for 72 h. It was found that treatment with <b>1f</b> induced apoptosis in a dose-dependent manner, and total cellular apoptosis increased from 17.41–89.47%. At concentration of 8 μM, <b>1f</b> (89.47%) induced more cellular apoptosis of A549 cell than Gefitinib (27.77%) and Lapatinib (57.77%), in which early apoptosis (81.53%) accounted for a large proportion. The ability to significantly induce early apoptosis enabled compound <b>1f</b> to be a potential candidate for antitumor drugs.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell apoptosis analysis on A549 cells treated with compound <b>1f</b>, Gefitinib, and Lapatinib at indicated concentrations detected by flow cytometer. The inserted table showed quantitative early/late cellular apoptosis for tested compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Cytotoxicity</h3><div class="NLM_p">The inhibitory effect on nontumor cell line was also tested to verify the tumor-targeting potency of the best compound <b>1f</b>. The mouse fibroblast cells L929 without overexpressed EGFR or HER2 were used as nontumor cell model in cytotoxicity assay. As it can be seen from <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, Gefitinib, Lapatinib, and <b>1f</b> exhibited 25.95%, 35.03%, and 37.63% growth inhibition of L929 cells, respectively, implying low cell inhibition at 1 μM. Although Gefitinib showed the lowest inhibition rate, a surge of growth inhibition against L929 was observed with increasing drug concentration. Subsequently, the IC<sub>50</sub> of <b>1f</b> was tested with the value of 2.74 μM, indicating its comparable cytotoxicity to the clinical drugs Gefitinib (1.98 μM) and Lapatinib (2.05 μM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. IC<sub>50</sub> and Inhibition of Compounds and Positive Drugs against L929 at the Concentration of 1 μM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>1f</b></th><th class="colsep0 rowsep0" align="center">Gefitinib</th><th class="colsep0 rowsep0" align="center">Lapatinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">inhibition at the concentration of 1 μM</td><td class="colsep0 rowsep0" align="left">37.63%</td><td class="colsep0 rowsep0" align="left">25.95%</td><td class="colsep0 rowsep0" align="left">35.03%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">2.74 ± 0.42</td><td class="colsep0 rowsep0" align="left">1.98 ± 0.13</td><td class="colsep0 rowsep0" align="left">2.05 ± 0.78</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The data are the mean ± SD of at least three independent experiments.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> Antitumor Activity</h3><div class="NLM_p">The antitumor activity of compound <b>1f</b> and Gefitinib was compared by recording the tumor volumes and weights of A549 tumor-bearing nude mice at a dose of 30 mg/kg, and saline-treated mice were used as controls. After 19 days treatment, all animals in different treatment group were kept at stable body weight (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). The tumor sizes were averagely 2433 mm<sup>3</sup> for the control and 1598 mm<sup>3</sup> for Gefitinib, respectively, while those of <b>1f</b>-treated animals were 1357 mm<sup>3</sup> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B–C). The tumor weights treated by <b>1f</b> significantly reduced and showed statistical difference compared to those of control and Gefitinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). Tumor growth inhibition (TGI) values of Gefitinib and <b>1f</b> were also calculated by empirical equation (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>), with the values of 34.31% and 44.23%, respectively, at dosages of 30 mg/kg. These results indicate effective ability of <b>1f</b> to inhibit tumor growth in nude mice bearing A549 xenografts via proliferation suppression. The histologic images using H&E staining showed a massive cancer cell underwent necrosis in the tumor site with compound <b>1f</b> treatment, as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>E.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor efficacy of compound <b>1f</b> in the A549 xenografts mouse model. (A) Body weight and (B) tumor volume measurements from A549 xenografts mice after 19 days of <b>1f</b> administration. (C) Representative photographs of tumors in each group. (D) Comparison of the final tumor weights in each group after the 19 days treatment period of <b>1f</b>. *<i>p</i> < 0.05 compared with the control group. (E) H&E staining images of tumor tissue from each treatment group. The scale bar is 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Molecular Docking Studies</h3><div class="NLM_p">In order to predict the possible binding mode of this series of compounds with EGFR, the docking study of compound <b>1f</b> with EGFR kinase was performed using Gefitinib and Lapatinib as positive controls (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B). In the binding model, the nitrogen atoms in quinazoline of <b>1f</b> can bind to MET793 residue by hydrogen bonds, which is consistent with the binding site of Gefitinib and Lapatinib in EGFR domain.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking modes of compounds <b>1f</b> (green) with EGFR comparing with (A) Gefitinib (gray, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>) and (B) Lapatinib (gray, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>), respectively. Selected residues MET793 in EGFR are shown. Green dashed lines indicate hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of anilinoquinazoline derivatives containing macrocyclic polyamine were designed, synthesized, and evaluated as potential EGFR-competitive inhibitors. These compounds exhibited strong antiproliferative activity against A431 cells bearing overexpressed EGFR. Among them, both <b>1f</b> and <b>2f</b> showed stronger dual inhibition against EGFR<sup>WT</sup> and HER2 compared with Gefitinib and Lapatinib in kinase assays. Moreover, compound <b>1f</b> exhibited significant tumor inhibition in the human NSCLC xenografts mouse model of A431. The use of macrocyclic polyamine moiety in inhibitor is intended to selectively capture the native substrate ATP, thus assisting to block EGFR downstream signal pathway. This design offered an option for the optimization and development of anilinoquinazoline-based NSCLC agents and drugs.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85174" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85174" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Methods for Chemistry</h3><div class="NLM_p">All reagents and solvents were used as purchased from commercial sources. Flash chromatography was performed using 400 mesh silica gel. All reactions were monitored by TLC, using silica gel plates with fluorescence F254 and UV light visualization. <sup>1</sup>H NMR spectra and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (ppm) units relative to an internal standard (TMS). High-resolution mass spectra (HRMS) were recorded using an Agilent 6540 UHD Q-TOF MS equipped with a gas nebulizer probe, capable of analyzing ions up to <i>m</i>/<i>z</i> 6000. Purification of the final compounds were performed with reverse-phase high-performance liquid chromatography (HPLC). All final compounds were purified to ≥95% chemical purity as determined by HPLC with UV detection at 254 nm. Further details on the analytical conditions used for individual compounds may be found in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>. We further used the latest version of ZINC15 database to virtually test all final compounds for structural elements representing pan-assay interference compounds (PAINS). We did not get any PAIN hit from this database search.</div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>1a</b>)</h4><div class="NLM_p">General procedure for syntheses of <b>1a</b>–<b>o</b>. A mixture of compound (<b>5a</b>, 0.67 g, 2.1 mmol), 10-(3-chloropropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate (1.27 g, 2.3 mmol, 1.1 equiv), and K<sub>2</sub>CO<sub>3</sub> (0.9 g, 6.5 mmol, 3 equiv) was dissolved in DMF (30 mL). The solution was stirred at 130 °C for 6 h, filtered to discard inorganic salt, and concentrated in vacuo. The resulting solid was purified by chromatography on silica (petroleum ether/EtOAc, 10:1) to afford tri-<i>tert</i>-butyl 10-(3-((4-((3-chloro-4-fluorophenyl) amino)-7-methoxyquinazolin-6-yl)oxy)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate as a yellow solid (yield 92.8%).</div><div class="NLM_p">A mixture of product above (0.86 g, 1.03 mmol) was dissolved in CH<sub>3</sub>OH (45 mL), and hydrochloric acid (12 mol/L, 15 mL) was added at room temperature with continuos stirring. After stirring for an additional 6 h, the resulted solution was concentrated in vacuo. The acquired solid was redissolved in methanol, and subsequently, the solution was filtered, and the filter cake was washed with methanol. The resulted solid was dried under vacuum for 1 day to afford the yellow solid (yield 68.4%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.52(s,1H), 7.60–7.58 (m, 2H), 7.39–7.37 (m, 1H), 7.10–7.08 (t, <i>J</i> = 8.96, 7.03 Hz, 2H), 4.17–4.15 (t, <i>J</i> = 6.21 Hz, 2H), 3.98 (s, 3H), 3.16–3.10 (m, 8H), 2.93–2.85 (m, 10H), 2.02–2.05 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.27, 156.58, 154.09, 149.55, 147.83, 134.51, 132.60, 125.05, 123.42, 119.99, 116.44, 106.91, 103.46, 99.52, 68.30, 56.88, 49.61, 48.03, 44.04, 42.04, 23.19. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>35</sub>ClFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 532.2603. Found: 532.2597.</div><div class="NLM_p last">Compound <b>1b</b>–<b>o</b> were synthesized using similar route according to <b>1a</b>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-ethynylphenyl)-7-methoxyquinazolin-4-amine (<b>1b</b>)</h4><div class="NLM_p last">Compound <b>1b</b> was obtained as a light yellow solid (yield 70.2%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.53 (s, 1H), 7.75–7.73 (dd, <i>J</i> = 5.93, 2.54 Hz, 1H), 7.61 (s, 1H), 7.46–7.42 (m, 1H), 7.11–7.07 (t, <i>J</i> = 8.75 Hz, 2H), 4.20–4.17 (t, <i>J</i> = 5.65 Hz, 2H), 4.01 (s, 3H), 3.17–3.09 (m, 8H), 2.93–2.86 (m, 10H), 2.05–2.03 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.42, 156.50, 149.53, 147.72, 135.85, 134.51, 130.04, 129.08, 126.60, 124.19, 121.98, 106.99, 103.50, 99.55, 82.63, 79.24, 68.31, 56.85, 49.41, 47.91, 44.07, 41.98, 23.17. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>28</sub>H<sub>37</sub>N<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 504.3087. Found: 504.3097.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-bromophenyl)-7-methoxyquinazolin-4-amine (<b>1c</b>)</h4><div class="NLM_p last">Compound <b>1c</b> was obtained as a light yellow solid (yield 66.8%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.52 (s, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.46–7.44 (d, <i>J</i> = 8.30 Hz, 1H), 7.37–7.35 (d, <i>J</i> = 7.52 Hz, 1H), 7.26–7.22 (t, <i>J</i> = 8.04 Hz, 1H), 7.10 (s, 1H), 4.20–4.18 (t, <i>J</i> = 5.71 Hz, 2H), 4.00(s, 3H), 3.16–3.09 (m, 8H), 2.91–2.83 (m, 10H) 2.04–2.01 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.02, 156.38, 149.55, 147.56, 137.04, 134.38, 130.10, 129.05, 125.37, 121.53, 106.86, 103.32, 99.43, 68.33, 56.88, 49.60, 48.05, 44.02, 42.07, 23.15. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>36</sub>BrN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 558.2192. Found: 558.2185.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(4-bromo-2-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>1d</b>)</h4><div class="NLM_p last">Compound <b>1d</b> was obtained as a light yellow solid (yield 72.4%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.48 (s, 1H), 7.60–7.57 (d, <i>J</i> = 11.41 Hz, 2H), 7.50–7.48 (d, <i>J</i> = 7.06 Hz, 1H), 7.33–7.32 (m, 2H), 7.05 (s 1H), 4.15–4.12 (t, <i>J</i> = 5.98 Hz, 2H), 3.98 (s, 3H), 3.55 (s, 5H), 3.30–3.27 (t, <i>J</i> = 5.98 Hz, 4H), 2.99–2.96 (t, <i>J</i> = 5.98 Hz, 4H), 2.90–2.86 (m, 2H), 2.04–2.00 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 158.85, 157.28, 154.90, 149.68, 148.22, 135.02, 128.85, 128.01, 122.48, 121.09, 119.79, 107.26, 103.71, 99.75, 68.12, 56.93, 49.59, 48.00, 44.05, 42.00, 23.27. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>35</sub>BrFN<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 576.2098. Found: 576.2085.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-bromo-4-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>1e</b>)</h4><div class="NLM_p last">Compound <b>1e</b> was obtained as a light yellow solid (yield 74.3%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.50 (s, 1H), 7.59 (s, 1H), 7.34–7.26 (m, 3H), 7.17 (s 1H), 4.14–4.11 (t, <i>J</i> = 5.92 Hz, 2H), 4.02 (s, 3H), 3.56 (s, 4H), 3.32–3.29 (t, <i>J</i> = 5.92 Hz, 4H), 3.04–3.01 (t, <i>J</i> = 5.92 Hz, 4H), 2.96–2.92 (t, <i>J</i> = 7.82 Hz, 2H), 2.11–2.07 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 156.99, 156.59, 156.51, 149.53, 147.76, 134.41, 132.89, 127.45, 123.84, 116.07, 107.91, 106.83, 103.40, 99.51, 68.31, 56.91, 49.68, 48.08, 44.02, 42.07, 23.21. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>35</sub>BrFN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 576.2098. Found: 576.2096.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxyquinazolin-4-amine (<b>1f</b>)</h4><div class="NLM_p last">Compound <b>1f</b> was obtained as a yellow solid (yield 64.3%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.45 (s, 1H), 7.43 (s, 1H), 7.31 (s, 1H), 7.19 (t, <i>J</i> = 7.6 Hz, 2H), 6.90 (t, <i>J</i> = 8.2 Hz, 1H), 6.78 (d, <i>J</i> = 7.4 Hz, 1H), 6.62 (d, <i>J</i> = 13.7 Hz, 2H), 6.41 (d, <i>J</i> = 8.8 Hz, 1H), 4.18 (s, 2H), 4.04 (s, 2H), 3.41 (s, 3H), 3.22–2.74 (m, 18H), 2.01 (s, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 163.40, 160.95, 158.71, 155.22, 149.07, 147.13, 138.05, 133.79, 129.83, 123.04, 121.38, 120.32, 114.01, 111.37–111.17, 106.29, 102.73, 98.60, 67.78, 55.96, 49.68, 48.85, 48.21, 44.03, 42.03, 23.64. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>33</sub>H<sub>41</sub>ClFN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 638.3022. Found: 638.3009</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(4-chloro-3-(trifluoromethyl)phenyl)-7-methoxyquinazolin-4-amine (<b>1g</b>)</h4><div class="NLM_p last">Compound <b>1g</b> was obtained as a light yellow solid (yield 72.9%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.63 (s, 1H), 7.90 (d, <i>J</i> = 2.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 7.59 (s, 1H), 7.26 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (s, 1H), 4.17 (t, <i>J</i> = 5.8 Hz, 2H), 3.99 (s, 3H), 3.13 (dd, <i>J</i> = 17.4, 12.3 Hz, 8H), 3.02–2.80 (m, 10H), 2.04 (dd, <i>J</i> = 10.1, 5.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 156.68, 149.63, 147.62, 135.11, 134.38, 131.32, 127.12, 126.58, 126.07, 123.39, 120.75, 106.65, 103.10, 99.45, 68.46, 68.09, 67.85, 56.90, 49.45, 47.96, 44.08, 42.02, 23.14. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>27</sub>H<sub>35</sub>ClF<sub>3</sub>N<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 582.2571. Found: 582.2559</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-7-methoxy-<i>N</i>-(3-(trifluoromethyl)phenyl) quinazolin-4-amine (<b>1h</b>)</h4><div class="NLM_p last">Compound <b>1h</b> was obtained as a light yellow solid (yield 69.7%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.54 (s, 1H), 7.90 (s, 1H), 7.72 (dd, <i>J</i> = 5.4, 3.5 Hz, 1H), 7.66 (s, 1H), 7.52 (d, <i>J</i> = 0.9 Hz, 2H), 7.02 (s, 1H), 4.17 (s, 2H), 3.96 (s, 3H), 3.12 (dd, <i>J</i> = 13.3, 8.1 Hz, 8H), 3.04–2.75 (m, 10H), 2.05–1.89 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.72, 156.61, 149.61, 147.86, 136.32, 134.55, 130.31, 129.99, 127.21, 124.97, 123.34, 122.27, 120.68, 106.93, 103.50, 99.34, 68.35, 56.79, 49.31, 47.83, 44.07, 41.97, 23.03. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>27</sub>H<sub>36</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 548.2961. Found: 548.2947.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-chlorophenyl)-7-methoxyquinazolin-4-amine (<b>1i</b>)</h4><div class="NLM_p last">Compound <b>1i</b> was obtained as a white solid (yield 77.3%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.52 (s, 1H), 7.61 (s, 1H), 7.54 (t, <i>J</i> = 2.0 Hz, 1H), 7.44–7.36 (m, 1H), 7.26 (t, <i>J</i> = 8.1 Hz, 1H), 7.19–7.09 (m, 1H), 7.04 (s, 1H), 4.16 (t, <i>J</i> = 5.9 Hz, 2H), 3.98 (s, 3H), 3.12 (dd, <i>J</i> = 15.4, 10.2 Hz, 8H), 3.01–2.67 (m, 10H), 2.01 (dt, <i>J</i> = 8.1, 5.6 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.28, 156.48, 149.57, 147.66, 136.93, 134.50, 133.57, 130.00, 126.36, 122.94, 121.46, 106.95, 103.40, 99.45, 68.35, 56.84, 49.44, 47.93, 44.07, 42.00, 23.15. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>36</sub>ClN<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 514.2697. Found: 514.2682.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-7-methoxy-<i>N</i>-(3-methoxyphenyl) quinazolin-4-amine (<b>1j</b>)</h4><div class="NLM_p last">Compound <b>1j</b> was obtained as a light yellow solid (yield 74.5%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.47 (s, 1H), 7.59 (s, 1H), 7.24 (t, <i>J</i> = 8.1 Hz, 1H), 7.07 (t, <i>J</i> = 4.3 Hz, 2H), 7.02 (s, 1H), 6.79–6.74 (m, 1H), 4.14 (t, <i>J</i> = 5.9 Hz, 2H), 3.96 (s, 3H), 3.71 (s, 3H), 3.12 (dd, <i>J</i> = 14.6, 9.4 Hz, 8H), 3.00–2.69 (m, 10H), 2.05–1.93 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 158.86, 157.37, 156.33, 149.37, 147.65, 136.84, 134.38, 129.84, 116.14, 111.92, 109.46, 106.95, 103.56, 99.40, 68.29, 56.79, 55.34, 49.43, 47.94, 44.06, 42.01, 23.09. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>27</sub>H<sub>39</sub>N<sub>7</sub>O<sub>3</sub>[M + H]<sup>+</sup>: 510.3193. Found: 510.3176.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>1k</b>)</h4><div class="NLM_p last">Compound <b>1k</b> was obtained as a light yellow solid (yield 67.5%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.51 (s, 1H), 7.66 (s, 1H), 7.43–7.25 (m, 3H), 7.07 (s, 1H), 7.02 (td, <i>J</i> = 8.4, 1.8 Hz, 1H), 4.18 (t, <i>J</i> = 5.9 Hz, 2H), 3.96 (s, 3H), 3.12 (dd, <i>J</i> = 15.7, 10.5 Hz, 8H), 2.93 (d, <i>J</i> = 4.9 Hz, 8H), 2.87 (dd, <i>J</i> = 9.4, 6.4 Hz, 2H), 2.04 (dd, <i>J</i> = 10.6, 5.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 163.19, 160.78, 157.27, 156.48, 149.51, 147.65, 137.13, 134.46, 130.32, 119.17, 113.38, 110.59, 106.83, 103.34, 99.43, 68.21, 56.80, 49.89, 48.29, 43.91, 42.22, 23.01. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>36</sub>FN<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 498.2993. Found: 498.2980.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(3-iodophenyl)-7-methoxyquinazolin-4-amine (<b>1l</b>)</h4><div class="NLM_p last">Compound <b>1l</b> was obtained as a white solid (yield 68.6%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.43 (s, 1H), 7.73 (t, <i>J</i> = 1.8 Hz, 1H), 7.44 (s, 1H), 7.40–7.32 (m, 1H), 7.29 (d, <i>J</i> = 8.2 Hz, 1H), 6.91 (s, 1H), 6.88 (t, <i>J</i> = 8.0 Hz, 1H), 4.05 (t, <i>J</i> = 5.8 Hz, 2H), 3.92 (s, 3H), 3.05 (dd, <i>J</i> = 14.2, 9.1 Hz, 8H), 2.85 (d, <i>J</i> = 22.5 Hz, 8H), 2.74 (dd, <i>J</i> = 9.5, 6.4 Hz, 2H), 1.90 (dd, <i>J</i> = 10.3, 5.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 156.70, 156.27, 149.53, 147.46, 136.77, 134.82, 134.21, 130.84, 129.98, 121.70, 106.76, 103.28, 99.43, 93.42, 68.37, 56.95, 49.57, 48.03, 44.03, 42.06, 23.21. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>36</sub>IN<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 606.2053. Found: 606.2031.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(2,4-dichlorophenyl)-7-methoxyquinazolin-4-amine (<b>1m</b>)</h4><div class="NLM_p last">Compound <b>1m</b> was obtained as a light yellow solid (yield 67.8%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.48 (s, 1H), 7.73 (s, 1H), 7.58 (d, <i>J</i> = 2.3 Hz, 1H), 7.43 (d, <i>J</i> = 8.6 Hz, 1H), 7.35 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.22 (s, 1H), 4.20 (t, <i>J</i> = 5.9 Hz, 2H), 4.04 (s, 3H), 3.13 (dd, <i>J</i> = 17.9, 12.6 Hz, 8H), 3.02–2.76 (m, 10H), 2.09 (td, <i>J</i> = 11.2, 5.9 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 158.99, 157.08, 149.68, 148.11, 134.79, 133.97, 131.53, 129.78, 128.02, 107.04, 103.61, 99.61, 68.30, 56.94, 51.51, 47.22, 43.40, 41.87, 23.75. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 548.2308. Found: 548.2293.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 5-((6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-7-methoxyquinazolin-4-yl)amino)-2-fluorobenzonitrile (<b>1n</b>)</h4><div class="NLM_p last">Compound <b>1n</b> was obtained as a light yellow solid (yield 73.2%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.57 (s, 1H), 7.91 (dd, <i>J</i> = 5.3, 2.6 Hz, 1H), 7.85–7.75 (m, 1H), 7.64 (s, 1H), 7.22 (t, <i>J</i> = 8.9 Hz, 1H), 7.09 (s, 1H), 4.19 (t, <i>J</i> = 5.4 Hz, 2H), 3.99 (s, 3H), 3.18 (s, 4H), 3.12 (d, <i>J</i> = 4.7 Hz, 4H), 2.96 (d, <i>J</i> = 12.4 Hz, 8H), 2.94–2.87 (m, 2H), 2.08 (s, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 161.54, 158.98, 157.42, 156.90, 149.71, 148.10, 134.76, 132.80, 130.72, 127.70, 116.86, 113.64, 106.96, 103.47, 100.25–99.56 (m), 68.31, 56.97, 49.90, 48.26, 43.94, 42.17, 23.14. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>27</sub>H<sub>35</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 523.2945. Found: 523.2932.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-<i>N</i>-(4-bromo-2-ethylphenyl)-7-methoxyquinazolin-4-amine (<b>1o</b>)</h4><div class="NLM_p last">Compound <b>1o</b> was obtained as a white solid (yield 69.8%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.32 (s, 1H), 7.68 (s, 1H), 7.48 (d, <i>J</i> = 1.9 Hz, 1H), 7.22 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.12 (s, 1H), 7.02 (d, <i>J</i> = 8.4 Hz, 1H), 4.10 (s, 2H), 3.97 (d, <i>J</i> = 14.4 Hz, 3H), 3.08 (dd, <i>J</i> = 16.1, 11.1 Hz, 8H), 2.98–2.74 (m, 10H), 2.44 (q, <i>J</i> = 7.5 Hz, 2H), 2.01 (s, 2H), 0.92 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 159.65, 156.90, 149.59, 148.27, 143.91, 134.92, 132.65, 130.05, 129.60, 122.23, 107.14, 104.19, 99.99, 68.15, 56.83, 49.75, 48.10, 44.01, 42.05, 24.03, 23.25, 13.45. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>28</sub>H<sub>40</sub>BrN<sub>7</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 586.2505. Found: 586.2493.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>2a</b>)</h4><div class="NLM_p">General procedure for syntheses of <b>2a</b>–<b>o</b>. A mixture of compound (<b>5</b>) (0.67 g, 1.86 mmol), di<i>tert</i>-butyl 7-(3-chloropropyl)-1,4,7-triazonane-1,4-dicarboxylate (1.27g, 2.046 mmol, 1.1 equiv), and K<sub>2</sub>CO<sub>3</sub> (0.9 g, 6.5 mmol, 3 equiv) was dissolved in DMF (30 mL). The solution was stirred at 130 °C for 6 h, filtered to discard inorganic salt, and concentrated in vacuo. The resulting solid was purified by chromatography on silica (petroleum ether/EtOAc, 15:1) to afford di<i>tert</i>-butyl 7-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)-1,4,7-triazonane-1,4-dicarboxylate as a yellow solid (1.13 g, yield 89.8%).</div><div class="NLM_p">A mixture of above-mentioned product (0.96 g, 1.39 mmol) was dissolved in CH<sub>3</sub>OH (45 mL), and hydrochloric acid (12 mol/L, 15 mL) was added at room temperature with stirring. After stirring for an additional 6 h, the resulted solution was concentrated in vacuo, and the solid was redissolved in methanol. After the solution was filtered, the filter cake was washed with methanol. The solid was dried under vacuum for 1 days to afford the pure yellow solid (yield, 66.3%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.49 (s, 1H), 7.61–7.58 (d, <i>J</i> = 12.22 Hz, 2H), 7.50–7.48 (d, <i>J</i> = 7.06 Hz, 1H), 7.34–7.28 (m, 2H), 7.08 (s 1H), 4.17–4.15 (t, <i>J</i> = 5.98 Hz, 2H), 3.99 (s, 3H), 3.53 (s, 1H), 3.15–3.08 (m, 8H), 2.89–2.81 (m, 10H), 2.02–1.98 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.25, 156.56, 154.13, 149.61, 147.79, 134.46, 132.63, 125.11, 123.46, 120.02, 116.47, 106.89, 103.27, 99.44, 68.42, 56.85, 51.48, 47.21, 43.46, 41.89, 23.76. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>30</sub>ClFN<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 489.2181. Found: 489.2176.</div><div class="NLM_p last">Compound <b>2b</b>–<b>o</b> were synthesized using similar route according to <b>2a</b>.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-ethynylphenyl)-7-methoxyquinazolin-4-amine (<b>2b</b>)</h4><div class="NLM_p last">Compound <b>2b</b> was obtained as a yellow solid (yield 74.6%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.51 (s, 1H), 7.67 (s, 1H), 7.39–7.35 (m, 3H), 7.21 (s, 1H), 4.20–4.17 (t, <i>J</i> = 5.71 Hz, 2H), 4.03 (s, 3H), 3.17–3.09 (m, 8H), 2.94–2.87 (m, 10H), 2.08 (s, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.36, 156.45, 149.57, 147.66, 135.86, 134.43, 130.05, 129.11, 126.62, 124.19, 122.00, 106.95, 103.28, 99.45, 82.64, 79.25, 68.36, 56.81, 51.43, 47.18, 43.44, 41.87, 23.73. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 461.2665. Found: 461.2665.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-bromophenyl)-7-methoxyquinazolin-4-amine (<b>2c</b>)</h4><div class="NLM_p last">Compound <b>2c</b> was obtained as a white solid (yield 67.5%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.52 (s, 1H), 7.56–7.54 (dd, <i>J</i> = 6.79, 2.2 Hz, 1H), 7.48 (s, 1H), 7.38–7.35 (m, 1H), 7.02–6.98 (t, <i>J</i> = 8.96, 6.48 Hz 2H), 4.10–4.08 (t, <i>J</i> = 5.98 Hz, 2H), 3.95 (s, 3H), 3.57 (s, 4H), 3.32–3.29 (t, <i>J</i> = 5.45 Hz, 4H), 3.01–2.99 (t, <i>J</i> = 5.71 Hz, 4H) 2.91–2.87 (t, <i>J</i> = 8.3 Hz, 2H) 2.04–2.01 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.12, 156.40, 149.62, 147.57, 137.04, 134.36, 130.20, 129.19, 125.65, 121.66, 106.89, 103.21, 99.35, 68.46, 56.84, 51.45, 47.18, 43.44, 41.87, 23.76. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>31</sub>BrN<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 515.1770. Found: 515.1763.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(4-bromo-2-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>2d</b>)</h4><div class="NLM_p last">Compound <b>2d</b> was obtained as a light yellow solid (yield 69.8%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.53 (s, 1H), 7.76–7.74 (dd, <i>J</i> = 6.51, 2.48 Hz, 1H), 7.59 (s, 1H), 7.47–7.43 (m, 1H), 7.12–7.08 (t, <i>J</i> = 6.86 Hz, 2H), 4.19–4.16 (t, <i>J</i> = 5.92 Hz, 2H), 4.00 (s, 3H), 3.56 (s, 4H), 3.32–3.29 (t, <i>J</i> = 4.97 Hz, 4H), 3.02–3.00 (t, <i>J</i> = 5.68 Hz, 4H), 2.95–2.91 (t, <i>J</i> = 7.34 Hz, 2H), 2.09–2,05 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 158.65, 157.19, 154.77, 149.70, 148.13, 134.88, 128.73, 127.93, 122.44, 121.01, 119.72, 107.16, 103.42, 99.61, 68.21, 56.93, 51.53, 47.24, 43.44, 41.89, 23.75. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>30</sub>BrFN<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 533.1676. Found: 533.1665.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-bromo-4-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>2e</b>)</h4><div class="NLM_p last">Compound <b>2e</b> was obtained as a white solid (yield 76.7%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.51 (s, 1H), 7.68 (s, 1H), 7.54 (s, 1H), 7.44–7.42 (d, <i>J</i> = 8.19 Hz, 1H), 7.31–7.26 (d, <i>J</i> = 8.19 Hz, 1H), 7.19–7.15 (t, <i>J</i> = 8.53 Hz, 1H), 7.00 (s 1H), 4.13–4.10 (t, <i>J</i> = 5.92 Hz, 2H), 3.97 (s, 3H), 3.55 (s, 4H), 3.29–3.28 (d, <i>J</i> = 6.16 Hz, 4H), 2.98–2.96 (t, <i>J</i> = 5.68 Hz, 4H), 2.89–2.86 (t, <i>J</i> = 7.82 Hz, 2H), 2.02–1.98 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.03, 156.50, 154.98, 149.60, 147.72, 134.36, 132.86, 127.57, 123.88, 116.12, 107.94, 106.82, 103.23, 99.43, 68.45, 56.87, 51.51, 47.21, 43.47, 41.89, 23.78. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>30</sub>BrFN<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 533.1676. Found: 533.1675.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxyquinazolin-4-amine (<b>2f</b>)</h4><div class="NLM_p last">Compound <b>2f</b> was obtained as a yellow solid (yield 67.3%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.43 (s, 1H), 7.43 (d, <i>J</i> = 2.6 Hz, 1H), 7.30 (s, 1H), 7.26–7.14 (m, 2H), 6.93 (td, <i>J</i> = 8.7, 2.2 Hz, 1H), 6.83 (d, <i>J</i> = 7.6 Hz, 1H), 6.68 (d, <i>J</i> = 9.8 Hz, 1H), 6.63 (s, 1H), 6.44 (d, <i>J</i> = 9.1 Hz, 1H), 4.24 (s, 2H), 4.05 (s, 2H), 3.58 (s, 4H), 3.44 (s, 3H), 3.31 (t, <i>J</i> = 5.4 Hz, 4H), 3.01 (t, <i>J</i> = 5.6 Hz, 4H), 2.93–2.83 (m, 2H), 2.04 (d, <i>J</i> = 4.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 163.46, 161.04, 155.40, 149.49, 149.01, 147.28, 138.08, 133.74, 129.98, 123.17, 121.65, 120.50, 113.90, 111.50, 106.38, 102.71, 98.74, 68.21, 67.68, 56.00, 51.63, 47.25, 43.44, 41.88, 24.01. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>31</sub>H<sub>36</sub>ClFN<sub>6</sub>O<sub>3</sub>[M + H]<sup>+</sup>: 595.2600. Found: 595.2585.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(4-chloro-3-(trifluoromethyl)phenyl)-7-methoxy quinazolin-4-amine (<b>2g</b>)</h4><div class="NLM_p last">Compound <b>2g</b> was obtained as a yellow solid (yield 71.1%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.62 (s, 1H), 7.91 (d, <i>J</i> = 2.5 Hz, 1H), 7.77–7.68 (m, 1H), 7.57 (s, 1H), 7.28 (d, <i>J</i> = 8.8 Hz, 1H), 7.02 (s, 1H), 4.15 (t, <i>J</i> = 5.9 Hz, 2H), 3.98 (s, 3H), 3.58 (s, 4H), 3.32 (t, <i>J</i> = 5.6 Hz, 4H), 3.06–2.88 (m, 6H), 2.11–2.01 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 156.64, 149.69, 147.58, 135.11, 134.34, 131.35, 127.38, 126.94, 126.63, 126.09, 123.40, 120.79, 106.63, 102.96, 99.38, 68.61, 56.86, 51.43, 47.18, 43.46, 41.89, 23.69. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>30</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 539.2149. Found: 539.2142.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-7-methoxy-<i>N</i>-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (<b>2h</b>)</h4><div class="NLM_p last">Compound <b>2h</b> was obtained as a white solid (yield 74.9%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.51 (d, <i>J</i> = 1.1 Hz, 1H), 7.91 (s, 1H), 7.72 (d, <i>J</i> = 4.5 Hz, 1H), 7.56 (s, 1H), 7.52 (s, 2H), 6.94 (s, 1H), 4.11 (t, <i>J</i> = 5.3 Hz, 2H), 3.92 (s, 3H), 3.55 (s, 4H), 3.28 (s, 4H), 2.93 (d, <i>J</i> = 5.0 Hz, 4H), 2.88–2.77 (m, 2H), 1.93 (d, <i>J</i> = 9.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.48, 156.42, 149.59, 147.87, 136.37, 134.69, 130.28, 129.82, 127.10, 125.00, 123.23, 122.30, 120.58, 106.84, 103.16, 99.32, 68.42, 56.71, 51.28, 47.09, 43.41, 41.86, 23.64. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>25</sub>H<sub>31</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 505.2539. Found: 505.2531.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-chlorophenyl)-7-methoxyquinazolin-4-amine (<b>2i</b>)</h4><div class="NLM_p last">Compound <b>2i</b> was obtained as a white solid (yield 71.8%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.50 (s, 1H), 7.51 (dd, <i>J</i> = 4.0, 1.8 Hz, 2H), 7.38 (dd, <i>J</i> = 8.1, 1.1 Hz, 1H), 7.22 (t, <i>J</i> = 8.1 Hz, 1H), 7.11 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 6.96 (s, 1H), 4.09 (t, <i>J</i> = 6.0 Hz, 2H), 3.95 (s, 3H), 3.56 (s, 4H), 3.30 (t, <i>J</i> = 5.6 Hz, 4H), 2.97 (t, <i>J</i> = 5.8 Hz, 4H), 2.92–2.81 (m, 2H), 1.99 (td, <i>J</i> = 11.2, 6.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 157.03, 156.29, 149.55, 147.63, 136.99, 134.58, 133.53, 129.98, 126.23, 122.77, 121.30, 106.86, 103.08, 99.44, 68.44, 56.77, 51.40, 47.17, 43.45, 41.87, 23.73. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>31</sub>ClN<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 471.2275. Found: 471.2260.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-7-methoxy-<i>N</i>-(3-methoxyphenyl)quinazolin-4-amine (<b>2j</b>)</h4><div class="NLM_p last">Compound <b>2j</b> was obtained as a yellow solid (yield 69.6%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.46 (s, 1H), 7.53 (s, 1H), 7.24 (t, <i>J</i> = 8.5 Hz, 1H), 7.08 (dd, <i>J</i> = 4.4, 2.2 Hz, 2H), 6.97 (s, 1H), 6.77 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 4.10 (t, <i>J</i> = 6.0 Hz, 2H), 3.95 (s, 3H), 3.72 (s, 3H), 3.56 (s, 4H), 3.29 (t, <i>J</i> = 5.7 Hz, 4H), 2.97 (t, <i>J</i> = 5.8 Hz, 4H), 2.92–2.79 (m, 2H), 2.11–1.88 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 158.82, 157.16, 156.18, 149.36, 147.61, 136.91, 134.42, 129.80, 115.98, 111.84, 109.27, 106.89, 103.25, 99.36, 68.37, 56.73, 55.33, 51.35, 47.14, 43.43, 41.87, 23.68. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>25</sub>H<sub>34</sub>N<sub>6</sub>O<sub>3</sub>[M + H]<sup>+</sup>: 467.2771. Found: 467.2760.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-fluorophenyl)-7-methoxyquinazolin-4-amine (<b>2k</b>)</h4><div class="NLM_p last">Compound <b>2k</b> was obtained as a yellow solid (yield 75.1%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.50 (s, 1H), 7.59 (s, 1H), 7.38–7.32 (m, 2H), 7.32–7.27 (m, 1H), 7.05–6.94 (m, 2H), 4.12 (t, <i>J</i> = 6.0 Hz, 2H), 3.94 (s, 3H), 3.56 (s, 4H), 3.29 (dd, <i>J</i> = 10.8, 4.8 Hz, 4H), 2.99 (t, <i>J</i> = 5.8 Hz, 4H), 2.94–2.83 (m, 2H), 2.12–1.92 (m, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 163.20, 160.78, 157.17, 156.41, 149.57, 147.57, 137.13, 134.34, 130.33, 119.14, 113.38, 110.56, 106.78, 103.12, 99.31, 68.47, 56.76, 51.33, 47.12, 43.39, 41.84, 23.67. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>31</sub>FN<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 455.2571. Found: 455.2558.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(3-iodophenyl)-7-methoxyquinazolin-4-amine (<b>2l</b>)</h4><div class="NLM_p last">Compound <b>2l</b> was obtained as a yellow solid (yield 72.7%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.49 (s, 1H), 7.84 (t, <i>J</i> = 1.6 Hz, 1H), 7.49 (s, 1H), 7.43 (dd, <i>J</i> = 12.8, 4.9 Hz, 2H), 7.00 (d, <i>J</i> = 8.0 Hz, 1H), 6.97 (s, 1H), 4.10 (t, <i>J</i> = 5.9 Hz, 2H), 3.98 (s, 3H), 3.55 (s, 4H), 3.28 (dd, <i>J</i> = 9.9, 4.1 Hz, 4H), 2.96 (t, <i>J</i> = 5.7 Hz, 4H), 2.89–2.80 (m, 2H), 1.98 (td, <i>J</i> = 11.2, 5.9 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 156.81, 156.24, 149.56, 147.54, 136.81, 134.67, 131.23, 130.12, 122.03, 106.80, 103.13, 99.42, 93.40, 68.47, 57.41, 56.89, 51.50, 47.20, 43.47, 41.86, 23.81, 16.78. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>31</sub>IN<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 563.1631. Found: 563.1620.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(2,4-dichlorophenyl)-7-methoxyquinazolin-4-amine (<b>2m</b>)</h4><div class="NLM_p last">Compound <b>2m</b> was obtained as a yellow solid (yield 70.4%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.47 (s, 1H), 7.70 (s, 1H), 7.56 (d, <i>J</i> = 2.3 Hz, 1H), 7.42 (d, <i>J</i> = 8.6 Hz, 1H), 7.33 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.20 (s, 1H), 4.17 (t, <i>J</i> = 5.9 Hz, 2H), 4.03 (s, 3H), 3.56 (s, 4H), 3.31 (t, <i>J</i> = 5.6 Hz, 4H), 3.03 (t, <i>J</i> = 5.8 Hz, 4H), 2.98–2.87 (m, 2H), 2.11 (td, <i>J</i> = 11.1, 6.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 159.16, 157.14, 149.67, 148.20, 135.08, 134.06, 131.61, 129.84, 128.09, 107.14, 103.85, 99.77, 68.16, 56.95, 49.71, 48.11, 44.02, 42.06, 23.26. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>24</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 505.1886. Found: 505.1876.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-((6-(3-(1,4,7-Triazonan-1-yl)propoxy)-7-methoxyquinazolin-4-yl)amino)-2-fluorobenzonitrile (<b>2n</b>)</h4><div class="NLM_p last">Compound <b>2n</b> was obtained as a yellow solid (yield 69.6%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.56 (s, 1H), 7.94 (dd, <i>J</i> = 5.1, 2.4 Hz, 1H), 7.83 (dd, <i>J</i> = 8.6, 4.2 Hz, 1H), 7.64 (s, 1H), 7.29 (t, <i>J</i> = 8.9 Hz, 1H), 7.12 (s, 1H), 4.20 (t, <i>J</i> = 5.6 Hz, 2H), 4.00 (s, 3H), 3.57 (s, 4H), 3.31 (d, <i>J</i> = 5.2 Hz, 4H), 3.04 (t, <i>J</i> = 5.5 Hz, 4H), 2.99–2.92 (m, 2H), 2.11 (s, 2H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 161.57, 159.01, 157.38, 156.78, 149.74, 148.06, 135.04, 132.86, 130.79, 127.76, 116.90, 113.70, 107.00, 103.21, 100.31–99.43, 68.48, 56.89, 51.46, 47.22, 43.46, 41.90, 23.78. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>25</sub>H<sub>30</sub>FN<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 480.2523. Found: 480.2511.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 6-(3-(1,4,7-Triazonan-1-yl)propoxy)-<i>N</i>-(4-bromo-2-ethylphenyl)-7-methoxyquinazolin-4-amine (<b>2o</b>)</h4><div class="NLM_p last">Compound <b>2o</b> was obtained as a yellow solid (yield 71.8%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.40 (s, 1H), 7.74 (s, 1H), 7.55 (s, 1H), 7.29 (d, <i>J</i> = 8.4 Hz, 1H), 7.19 (s, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 1H), 4.15 (s, 2H), 4.02 (s, 3H), 3.57 (s, 4H), 3.30 (dd, <i>J</i> = 12.7, 7.0 Hz, 4H), 3.03 (t, <i>J</i> = 5.6 Hz, 4H), 2.95 (dd, <i>J</i> = 9.4, 6.4 Hz, 2H), 2.52 (q, <i>J</i> = 7.5 Hz, 2H), 2.09 (d, <i>J</i> = 5.7 Hz, 2H), 1.00 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 159.62, 156.87, 149.64, 148.21, 143.90, 134.84, 132.78, 132.53, 129.81, 122.22, 107.13, 103.93, 99.88, 68.18, 56.79, 51.53, 47.25, 43.42, 41.89, 24.04, 23.75, 13.42. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>26</sub>H<sub>35</sub>BrN<sub>6</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 543.2083. Found: 543.2072.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-Chloro-7-methoxyquinazolin-6-yl acetate (<b>4</b>)</h4><div class="NLM_p">A mixture of commercially available 6-hydroxy-7-methoxyquinazolin-4(3<i>H</i>)-one (<b>3</b>, 1 g, 5.2 mmol) and pyridine (4 mL) was dissolved in acetic anhydride (20 mL). The solution was stirred at 100 °C for 6 h. Cold water (200 mL) was added to the solution to precipitate the product, and stirring was continued for 20 min after the solution was cooled down to room temperature. The solid was filtered under vacuum and washed with water. The solid was dried under vacuum for 2 days to afford the white solid (yield 74%).</div><div class="NLM_p last">A mixture of product above (1 g, 4.27 mmol) and DMF (75 μL) was dissolved in SOCl<sub>2</sub> (15 mL). The solution was stirred at 90 °C for 2 h; after, it was cooled down to room temperature. The reaction mixture was extracted between water and CHCl<sub>2</sub>. The aqueous phase was further extracted with CHCl<sub>2</sub> (2×), and the combined organic phases were dried over anhydrous sodium sulfate and concentrated in vacuo to afford a yellow solid (yield 98.4%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.51 (s, 1H), 7.82 (s, 1H), 7.36 (s, 1H), 3.94 (s, 3H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O) δ 169.07, 164.29, 156.34, 159.15, 149.17, 144.13, 118.26, 115.83, 107.9, 55.85, 20.33. HRMS (ESI) <i>m</i>/<i>z</i> calcd. for C<sub>11</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>3</sub>[M + H]<sup>+</sup>: 397.0396. Found: 397.0391.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (<b>5a–o</b>)</h4><div class="NLM_p">General procedure for syntheses of <b>5a</b>–<b>o</b>. A mixture of 4-chloro-7-methoxyquinazolin-6-yl acetate (<b>4</b>) (1.1 g, 4.36 mmol) and 3-chloro-4-fluoroaniline (0.96 g, 6.62 mmol, 1.2 equiv) was dissolved in CH<sub>3</sub>CN (150 mL). The solution was stirred at 90 °C for 1 h. The sediment was filtered under vacuum and washed with acetonitrile. The solid was dried under vacuum for 1 day to afford the yellow solid.</div><div class="NLM_p last">A mixture of product above (1 g, 2.77 mmol) and NH<sub>3</sub>·H<sub>2</sub>O (2 mL) was dissolved in CH<sub>3</sub>OH (40 mL). The solution was stirred at 75 °C for 2 h. The sediment was filtered under vacuum and washed with methanol. The solid was dried under vacuum for 1 day to give <b>5a</b> as yellow solid (yield 72%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.69 (s, 1H), 9.47 (s, 1H), 8.47 (s, 1H), 8.22–8.20 (dd, <i>J</i> = 6.87, 2.75 Hz, 1H), 7.84–7.82 (m, 1H), 7.77 (s, 1H), 7.41–7.38 (t, <i>J</i> = 9.02 Hz, 1H), 7.21 (s, 1H), 3.97 (s, 3H).</div></div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Cell Lines and Reagents</h3><div class="NLM_p last">The human epidermal carcinoma cell line A431 and human nonsmall cell lung cancer cell line A549 cell lines were obtained from China Infrastructure of Cell Line Resources. The cells were maintained at 37 °C in 5% CO<sub>2</sub> incubator in DMEM (Corning) containing 10% fetal bovine serum (Corning). The EGFR gene of every cell line was sequenced before use. Gefitinib and Lapatinib were purchased from Damas-beta.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Cell Proliferation Assay</h3><div class="NLM_p last">The human epidermal carcinoma cell line A431 and human nonsmall cell lung cancer cell line A549 were used to evaluate the potency of synthesized analogues in cell-based level. Assays were performed using the MTT assay. A431 and A549 cells were seeded in density of 8000 cells/well and 6000 cells/well, respectively, in 96-well plates (Corning) for 12 h. Duplicate wells were treated with test or reference compounds for 72 h at various concentrations or DMSO (Sigma) as control. Plates were incubated at 37 °C in 5% CO<sub>2</sub> atmosphere. Cell proliferation was measured according to the manufacturer’s protocol. The IC<sub>50</sub> was calculated using GraphPad Prism 5.0.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Kinase Inhibition Assay</h3><div class="NLM_p last">The assays used an ULight-labeled peptide substrate and an appropriate Europium-labeled antiphospho antibody. EGFR, HER2, and EGFR<sup>T790M</sup> were purchased from Carna, and ATP was purchased from Promega. Compounds with concentration ranging from 2.5 μM to 0.04 nM, and kinases were added into the assay plate and centrifuged for 1 min to mix them. Then ATP–substrate mixture was added to start the enzyme reaction. The assays were conducted at room temperature for 1 h and stopped by EDTA buffer. Finally, detected solution was added and incubated for 1 h. For HPE (hundred percent effect) wells, no kinase or compound but ATP, substrate, and 1% DMSO were contained. ZPE (zero percent effect) wells contained no compound, but kinase, ATP, substrate, and 1% DMSO were contained. The IC<sub>50</sub> was calculated using GraphPad Prism 5.0. Compound inhibition rate (%) = (ZPE – “compound” reading)/(ZPE – HPE) × 100.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Cellular ATP Measurement</h3><div class="NLM_p last">Cellular ATP was detected with the ATP assay kit (BioAssay) according to the manufacturer’s instructions. Briefly, 4000 cells (A549) per well were plated in white opaque 96-well plates (Corning). After incubated for 12 h, the cells were treated with compound or DMSO (as negative control) for 24 or 72 h. The culture medium was removed immediately before adding the reconstitution reagent. For each 96-well plate, 95 μL of Assay Buffer with 1 μL of substrate and 1 μL of ATP enzyme were mixed, and 90 μL of reconstituted reagent was added to each well. Luminescence was determined by a microplate reader (Flexstation 3) within 1 min after adding reconstitution reagent.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Flow Cytometry Analysis</h3><div class="NLM_p last">A549 Cells (5 × 10<sup>5</sup> cells/mL) were seeded in six-well plates and treated with compounds at different concentrations for 72 h. The cells were then harvested by trypsinization and washed twice with cold PBS. After centrifugation and removal of the supernatants, cells were resuspended in 300 μL of binding buffer, which was then added to 5 μL of annexin V-FITC and 10 μL of PI, then the cells were incubated at room temperature for another 15 min in the dark. The stained cells were analyzed by a flow cytometer (FACS-MolFlo XDP Beckman Coulter, USA). The result was analyzed using Summit 5.2.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Mouse Tumor Xenograft Efficacy Study</h3><div class="NLM_p last">The A549 is considered as a highly metastatic cancer cell line.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Six-week-old female BALB/c nude mice were purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China). All animal experiments were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals. Therefore, an exponential rapid increase is observed in the tumor volume for the control group. A549 NSCLC xenografts were established by 2.0 × 10<sup>6</sup> cells subcutaneously inoculated in nude mice. Treatments were initiated when tumors reached a mean group size of 200–400 mm<sup>3</sup>. All 21 mice were randomized to control (30 mL/kg, water, ig administration), Gefitinib (30 mg/kg, ig administration), and <b>1f</b> (30 mg/kg, ig administration), every 2 days for 19 days. The size of tumors were measured individually twice a week with microcalipers. Tumor volume (<i>V</i>) was calculated as <i>V</i> = length × width<sup>2</sup>/2. Tumor growth inhibition (TGI) was calculated using the following formula: TGI (%) = [1 – (<i>T</i> – <i>T</i><sub>0</sub>)/(<i>C</i> – <i>C</i><sub>0</sub>)] × 100, where <i>T</i> and <i>T</i><sub>0</sub> are the mean tumor weight on a specific experimental day and on the first day of treatment, respectively, for the experimental groups, and likewise, where <i>C</i> and <i>C</i><sub>0</sub> are the mean tumor weight for the control group.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> H&E Staining</h3><div class="NLM_p last">H&E staining was carried out according to a previous publication.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> First, the sections were hydrated and then the slide was dipped into a Coplin jar containing Mayer’s hematoxylin and agitated for 30 s. After rinsing the slide in H<sub>2</sub>O for 1 min, it was stained with 1% eosin Y solution for 10–30 s with agitation. Subsequently, the sections were dehydrated by using 95% alcohol and 100% alcohol twice for 30 s each, and then the alcohol was extracted using xylene twice. Finally, one or two drops of mounting medium was added and covered with a coverslip.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Molecular Docking</h3><div class="NLM_p last">All the calculations were carried out on a Dell PC with Windows 7.0 system using OMEGA (version 2.4.6; OpenEye Scientific Software, Inc.: Santa Fe, USA, 2016) and Hybrid (version 3.0.1; OpenEye Scientific Software, Inc.: Santa Fe, USA), 2016. The crystal structural data of EGFR kinase domain complexed with Gefitinib (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>) and Lapatinib (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>) were obtained from RCSB Protein Data Bank. Molecular docking was carried out as previous reported.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01612" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41283" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41283" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01612" class="ext-link">10.1021/acs.jmedchem.8b01612</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS spectra, and HPLC analysis of all compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound characterization checklist (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_002.xls" class="ext-link">XLS</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Compound <b>1f</b> with EGFR compared to Gefitinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>1f</b> with EGFR compared to Lapatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_005.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_001.pdf">jm8b01612_si_001.pdf (12.12 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_002.xls">jm8b01612_si_002.xls (95.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_003.csv">jm8b01612_si_003.csv (3.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_004.pdb">jm8b01612_si_004.pdb (230.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_005.pdb">jm8b01612_si_005.pdb (163.34 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01612" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#aec2c7cdc6cfc1eec3cfc7c280ccdbcdda80cbcadb80cdc0"><span class="__cf_email__" data-cfemail="2c40454f444d436c414d4540024e594f5802494859024f42">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renzhong Qiao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100871, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6672-9609" title="Orcid link">http://orcid.org/0000-0002-6672-9609</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5a2b333b35053d28352f2a1a6b6c6974393537"><span class="__cf_email__" data-cfemail="1968707876467e6b766c6959282f2a377a7674">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yilan Ju</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jintao Wu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xi Yuan</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luqing Zhao</span> - <span class="hlFld-Affiliation affiliation">Digestive Disease Center and , Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital
Medical University, Beijing 100010, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ganlin Zhang</span> - <span class="hlFld-Affiliation affiliation">Oncology Department and , Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital
Medical University, Beijing 100010, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.J. and J.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China [Nos 21672021, 21572018, 21372024, and 21232005]; the State Key Laboratory of Natural and Biomimetic Drugs; the Fundamental Research Funds for the Central Universities (PYBZ1824); Beijing Municipal Administration of Hospitals’ Youth Programme [No. 20161002]; Xu-Xia Fund for Young Scholars [No. XX-201703].</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">MerTK</td><td class="NLM_def"><p class="first last">mer tyrosine kinase</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin and eosin</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64234" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64234" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwknowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Untangling the ErbB signaling network</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwknowski&title=Untangling+the+ErbB+signaling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lhrsuXU68Lz8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwknowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signaling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">ErbB receptors and cancer: the complexity of targeted inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ErbB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lhrsuXU68Lz8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DErbB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span> <span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0707704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=18337605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciardielloauthor=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment&doi=10.1056%2FNEJMra0707704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antagonists in cancer treatment</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1160-1174</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on epidermal growth factor receptor (EGFR) in human carcinogenesis, development of EGFR antagonists for anticancer therapy, and clin. efficacy of EGFR antagonists in human cancers.  Predicting the response to anti-EGFR drugs and future directions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNHvRENSffLVg90H21EOLACvtfcHk0lhrsuXU68Lz8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D&md5=2834999545fd643c6f727d80d357134d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174%26doi%3D10.1056%2FNEJMra0707704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0lg2TnSWipxBUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2787</span>– <span class="NLM_lpage">2799</span>, <span class="refDoi"> DOI: 10.1200/JCO.2003.01.504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2003.01.504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12860957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2787-2799&author=J.+Mendelsohnauthor=J.+Baselga&title=Status+of+epidermal+growth+factor+receptor+antagonists+in+the+biology+and+treatment+of+cancer&doi=10.1200%2FJCO.2003.01.504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2787-2799</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family that is abnormally activated in many epithelial tumors.  Receptor activation leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and other tumor-promoting cellular activities.  In human tumors, receptor overexpression correlates with a more aggressive clin. course.  Taken together, these observations indicate that the EGFR is a promising target for cancer therapy.  Monoclonal antibodies directed at the ligand-binding extracellular domain and low-mol. wt. inhibitors of the receptor's tyrosine kinase are currently in advanced stages of clin. development.  These agents prevent ligand-induced receptor activation and downstream signaling, which results in cell cycle arrest, promotion of apoptosis, and inhibition of angiogenesis.  They also enhance the antitumor effects of chemotherapy and radiation therapy.  In patients, anti-EGFR agents can be given safely at doses that fully inhibit receptor signaling, and single-agent activity has been obsd. against a variety of tumor types, including colon carcinoma, non-small-cell lung cancer, head and neck cancer, ovarian carcinoma, and renal cell carcinoma.  Although antitumor activity is significant, responses have been seen in only a minority of the patients treated.  In some clin. trials, anti-EGFR agents enhanced the effects of conventional chemotherapy and radiation therapy.  Ongoing research efforts are directed at the selection of patients with EGFR-dependent tumors, identification of the differences among the various classes of agents, and new clin. development strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ewrBjS4q5LVg90H21EOLACvtfcHk0lg2TnSWipxBUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D&md5=17a81c50a8787512b24865bbe50de257</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.01.504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.01.504%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DStatus%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520antagonists%2520in%2520the%2520biology%2520and%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2787%26epage%3D2799%26doi%3D10.1200%2FJCO.2003.01.504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lg2TnSWipxBUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drebin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, M. I.</span></span> <span> </span><span class="NLM_article-title">ErbB receptors: from oncogenes to targeted cancer therapies</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2058</span>, <span class="refDoi"> DOI: 10.1172/JCI32278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1172%2FJCI32278" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2051-2058&author=H.+Zhangauthor=A.+Berezovauthor=Q.+Wangauthor=G.+Zhangauthor=J.+Drebinauthor=R.+Muraliauthor=M.+I.+Greene&title=ErbB+receptors%3A+from+oncogenes+to+targeted+cancer+therapies&doi=10.1172%2FJCI32278"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1172%2FJCI32278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI32278%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBerezov%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DDrebin%26aufirst%3DJ.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DErbB%2520receptors%253A%2520from%2520oncogenes%2520to%2520targeted%2520cancer%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D2051%26epage%3D2058%26doi%3D10.1172%2FJCI32278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khong, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodstad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span> <span> </span><span class="NLM_article-title">Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3689</span>– <span class="NLM_lpage">3701</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fonc.2009.229" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=3689-3701&author=Y.+H.+Zhaoauthor=M.+Zhouauthor=H.+Liuauthor=Y.+Dingauthor=H.+T.+Khongauthor=D.+Yuauthor=O.+Fodstadauthor=M.+Tan&title=Upregulation+of+lactate+dehydrogenase+A+by+ErbB2+through+heat+shock+factor+1+promotes+breast+cancer+cell+glycolysis+and+growth&doi=10.1038%2Fonc.2009.229"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.229%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BH.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DKhong%26aufirst%3DH.%2BT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DFodstad%26aufirst%3DO.%26aulast%3DTan%26aufirst%3DM.%26atitle%3DUpregulation%2520of%2520lactate%2520dehydrogenase%2520A%2520by%2520ErbB2%2520through%2520heat%2520shock%2520factor%25201%2520promotes%2520breast%2520cancer%2520cell%2520glycolysis%2520and%2520growth%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3D3689%26epage%3D3701%26doi%3D10.1038%2Fonc.2009.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: gefitinib (zd1839) (iressa) tablets</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.8-4-303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1634%2Ftheoncologist.8-4-303" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=303-306&author=M.+H.+Cohenauthor=G.+A.+Williamsauthor=R.+Sridharaauthor=G.+Chenauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+gefitinib+%28zd1839%29+%28iressa%29+tablets&doi=10.1634%2Ftheoncologist.8-4-303"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-4-303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-4-303%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%2BA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520gefitinib%2520%2528zd1839%2529%2520%2528iressa%2529%2520tablets%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D303%26epage%3D306%26doi%3D10.1634%2Ftheoncologist.8-4-303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereislova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span> <span> </span><span class="NLM_article-title">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2250</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.10.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2002.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11980995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=2240-2250&author=M.+Ransonauthor=L.+A.+Hammondauthor=D.+Ferryauthor=M.+Krisauthor=A.+Tulloauthor=P.+I.+Murrayauthor=V.+Millerauthor=S.+Averbuchauthor=J.+Ochsauthor=C.+Morrisauthor=A.+Feyereislovaauthor=H.+Swaislandauthor=E.+K.+Rowinsky&title=ZD1839%2C+a+selective+oral+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitor%2C+is+well+tolerated+and+active+in+patients+with+solid%2C+malignant+tumors%3A+results+of+a+phase+I+trial&doi=10.1200%2FJCO.2002.10.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span></div><div class="casAuthors">Ranson, Malcolm; Hammond, Lisa A.; Ferry, David; Kris, Mark; Tullo, Andrew; Murray, Philip I.; Miller, Vince; Averbuch, Steve; Ochs, Judy; Morris, Charles; Feyereislova, Andrea; Swaisland, Helen; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2240-2250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.  Patients and Methods: This was an open, phase I, escalating multiple-dose tolerability and pharmacokinetic trial.  ZD1839 was administered once daily for 14 consecutive days followed by 14 days off treatment.  Dose escalation started at 50 mg/d and continued to 925 mg or until consistent dose-limiting toxicity (DLT) was obsd.  Results: Sixty-four patients were entered at eight dose levels.  The most frequent dose-related grade 1 and 2 adverse events were an acne-like (or folliculitis) rash, nausea, and diarrhea.  Three of nine patients treated at 700 mg/d developed DLT (reversible grade 3 diarrhea); grade 3 and 4 events were uncommon.  Exposure to ZD1839 was dose proportional, and the mean terminal half-life was 48 h (range, 37 to 65).  Four of 16 patients with non-small-cell lung cancer (NSCLC) had objective partial responses obsd. from ZD1839 300 to 700 mg/d.  Overall, 16 patients remained on study for ≥ 3 mo, with seven of these patients (five with NSCLC, including three of the patients with partial response) remaining on study for ≥ 6 mo.  Conclusion: ZD1839 was well tolerated, with DLT obsd. at a dose well above that at which antitumor activity was seen.  Pharmacokinetic anal. confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation.  Phase II monotherapy and phase III combination trials in NSCLC are being conducted to investigate further the efficacy, tolerability, and optimal daily dose of ZD1839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgNViETgVS7Vg90H21EOLACvtfcHk0lhmsqStxkf_MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D&md5=b2de082b8b9292bb6cc62e4ea0a7b166</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DFerry%26aufirst%3DD.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DTullo%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DP.%2BI.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DOchs%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DZD1839%252C%2520a%2520selective%2520oral%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitor%252C%2520is%2520well%2520tolerated%2520and%2520active%2520in%2520patients%2520with%2520solid%252C%2520malignant%2520tumors%253A%2520results%2520of%2520a%2520phase%2520I%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D2240%26epage%3D2250%26doi%3D10.1200%2FJCO.2002.10.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span> <span> </span><span class="NLM_article-title">Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3815</span>– <span class="NLM_lpage">3825</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.03.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2002.03.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12228201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=3815-3825&author=R.+S.+Herbstauthor=A.+M.+Maddoxauthor=M.+L.+Rothenbergauthor=E.+J.+Smallauthor=E.+H.+Rubinauthor=J.+Baselgaauthor=F.+Rojoauthor=W.+K.+Hongauthor=H.+Swaislandauthor=S.+D.+Averbuchauthor=J.+Ochsauthor=P.+M.+LoRusso&title=Selective+oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+ZD1839+is+generally+well-tolerated+and+has+activity+in+non-small-cell+lung+cancer+and+other+solid+tumors%3A+results+of+a+phase+I+trial&doi=10.1200%2FJCO.2002.03.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial</span></div><div class="casAuthors">Herbst, Roy S.; Maddox, Anne-Marie; Rothenberg, Mace L.; Small, Eric J.; Rubin, Eric H.; Baselga, Jose; Rojo, Federico; Hong, Waun Ki; Swaisland, Helen; Averbuch, Steven D.; Ochs, Judith; LoRusso, Patricia Mucci</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3815-3825</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The objective of this study was to investigate safety, tolerability, dose-related pharmacol. properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with solid tumor types known to express or highly express EGFR.  This was an open-label, phase I, dose escalation safety/tolerability trial of oral ZD1839 (150 to 1,000 mg/day), administered once daily for 28-continuous-day cycles until disease progression or undue toxicity.  Of 71 (69 assessable for safety; 58 for efficacy) patients at seven dose levels, most had non-small-cell lung (n = 39) or head and neck (n = 18) cancer, and 68 of 71 patients received prior cancer therapy (two or more regimens in 54 patients [78%]).  Diarrhea and rash, the primary dose-limiting toxicities (DLTs), occurred at 800 mg.  Frequent treatment-related grade 1/2 adverse events were diarrhea (55%), asthenia (44%), and acne-like follicular rash (46%).  At doses ≥ 800 mg, 45% of patients required dose redns.  No increased or cumulative toxicity was obsd. over 250 patient-months of exposure.  Pharmacokinetic anal. showed that steady-state occurred by day 7, inter-patient exposure was more variable than intra-patient exposure, and variability of exposure did not change with dose.  One patient experienced a partial response, but antitumor activity manifested mainly as prolonged stable disease (45% of patients ≥ 3 mo, 22% ≥ 6 mo, and 7.2% ≥ 1 yr).  No relationship between dose, response, or duration on study was obsd.  Rash and diarrhea, generally mild and tolerable at doses ≤ 600 mg/d, were DLTs at 800 mg/day (max.-tolerated dose).  Antitumor activity was obsd. at all doses.  Pharmacokinetic analyses confirmed suitability of once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsbGKNBaq-rVg90H21EOLACvtfcHk0lhmsqStxkf_MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVyns7s%253D&md5=778f4e1e39ba26453b8243922d0a06ee</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.03.038%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DMaddox%26aufirst%3DA.%2BM.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DOchs%26aufirst%3DJ.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DSelective%2520oral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ZD1839%2520is%2520generally%2520well-tolerated%2520and%2520has%2520activity%2520in%2520non-small-cell%2520lung%2520cancer%2520and%2520other%2520solid%2520tumors%253A%2520results%2520of%2520a%2520phase%2520I%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D3815%26epage%3D3825%26doi%3D10.1200%2FJCO.2002.03.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieback, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjork, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereislova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albanell, J.</span></span> <span> </span><span class="NLM_article-title">Phase I safety, pharmacokinetic, and pharmacodynamics trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4292</span>– <span class="NLM_lpage">4302</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.03.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2002.03.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12409327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1CjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=4292-4302&author=J.+Baselgaauthor=D.+Rischinauthor=M.+Ransonauthor=H.+Calvertauthor=E.+Raymondauthor=D.+G.+Kiebackauthor=S.+B.+Kayeauthor=L.+Gianniauthor=A.+Harrisauthor=T.+Bjorkauthor=S.+D.+Averbuchauthor=A.+Feyereislovaauthor=H.+Swaislandauthor=F.+Rojoauthor=J.+Albanell&title=Phase+I+safety%2C+pharmacokinetic%2C+and+pharmacodynamics+trial+of+ZD1839%2C+a+selective+oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+in+patients+with+five+selected+solid+tumor+types&doi=10.1200%2FJCO.2002.03.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor</span></div><div class="casAuthors">Baselga, J.; Rischin, D.; Ranson, M.; Calvert, H.; Raymond, E.; Kieback, D. G.; Kaye, S. B.; Gianni, L.; Harris, A.; Bjork, T.; Averbuch, S. D.; Feyereislova, A.; Swaisland, H.; Rojo, F.; Albanell, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4292-4302</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic and pharmacodynamic effects in patients with selected solid tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdInzEw2L7DbVg90H21EOLACvtfcHk0liLouA5HjkcJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1CjtLo%253D&md5=bd1cf851a7ccd165f757ad5a63d0ad9a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.03.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.03.100%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DCalvert%26aufirst%3DH.%26aulast%3DRaymond%26aufirst%3DE.%26aulast%3DKieback%26aufirst%3DD.%2BG.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DBjork%26aufirst%3DT.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DAlbanell%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520safety%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamics%2520trial%2520of%2520ZD1839%252C%2520a%2520selective%2520oral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520five%2520selected%2520solid%2520tumor%2520types%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D4292%26epage%3D4302%26doi%3D10.1200%2FJCO.2002.03.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douillard, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereislova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1200/JCO.2003.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2003.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12748244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVGqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2237-2246&author=M.+Fukuokaauthor=S.+Yanoauthor=G.+Giacconeauthor=T.+Tamuraauthor=K.+Nakagawaauthor=J.+Y.+Douillardauthor=Y.+Nishiwakiauthor=J.+Vansteenkisteauthor=S.+Kudohauthor=D.+Rischinauthor=R.+Eekauthor=T.+Horaiauthor=K.+Nodaauthor=I.+Takataauthor=E.+Smitauthor=S.+Averbuchauthor=A.+Macleodauthor=A.+Feyereislovaauthor=R.+P.+Dongauthor=J.+Baselga&title=Multiinstitutional+randomized+phase+II+trial+of+gefitinib+for+previously+treated+patients+with+advanced+non-small-cell+lung+cancer+%28The+IDEAL+1+Trial%29&doi=10.1200%2FJCO.2003.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Fukuoka, Masahiro; Yano, Seiji; Giaccone, Giuseppe; Tamura, Tomohide; Nakagawa, Kazuhiko; Douillard, Jean-Yves; Nishiwaki, Yutaka; Vansteenkiste, Johan; Kudoh, Shinzoh; Rischin, Danny; Eek, Richard; Horai, Takeshi; Noda, Kazumasa; Takata, Ichiro; Smit, Edbert; Averbuch, Steven; Macleod, Angela; Feyereislova, Andrea; Dong, Rui-Ping; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2237-2246</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim was to evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC).  This was a randomized, double-blind, parallel-group, multicenter phase II trial.  Two hundred ten patients with advanced NSCLC who were previously treated with one or two chemotherapy regimens (at least one contg. platinum) were randomized to receive either 250-mg or 500-mg oral doses of gefitinib once daily.  Efficacy was similar for the 250- and 500-mg/d groups.  Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 mo; and median overall survival times were 7.6 and 8.0 mo, resp.  Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.  Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.  Drug-related toxicities were more frequent in the higher-dose group.  Withdrawal due to drug related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, resp.  Gefitinib showed clin. meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.  At 250 mg/d, gefitinib had a favorable AE profile.  Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqGtTEH41T7Vg90H21EOLACvtfcHk0liLouA5HjkcJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVGqu7w%253D&md5=7334e656e0ee16bd6bd14b4cc0a52f93</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DYano%26aufirst%3DS.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DEek%26aufirst%3DR.%26aulast%3DHorai%26aufirst%3DT.%26aulast%3DNoda%26aufirst%3DK.%26aulast%3DTakata%26aufirst%3DI.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DMacleod%26aufirst%3DA.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DR.%2BP.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DMultiinstitutional%2520randomized%2520phase%2520II%2520trial%2520of%2520gefitinib%2520for%2520previously%2520treated%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528The%2520IDEAL%25201%2520Trial%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2237%26epage%3D2246%26doi%3D10.1200%2FJCO.2003.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prager, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiridonidis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albain, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial</span>. <i>Jama.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">2149</span>– <span class="NLM_lpage">2158</span>, <span class="refDoi"> DOI: 10.1001/jama.290.16.2149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1001%2Fjama.290.16.2149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=14570950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2003&pages=2149-2158&author=M.+G.+Krisauthor=R.+B.+Nataleauthor=R.+S.+Herbstauthor=T.+J.+Lynchauthor=D.+Pragerauthor=C.+P.+Belaniauthor=J.+H.+Schillerauthor=K.+Kellyauthor=H.+Spiridonidisauthor=A.+Sandlerauthor=K.+S.+Albainauthor=D.+Cellaauthor=M.+K.+Wolfauthor=S.+D.+Averbuchauthor=J.+J.+Ochsauthor=A.+C.+Kay&title=Efficacy+of+gefitinib%2C+an+inhibitor+of+the+epidermal+growth+factor+receptor+tyrosine+kinase%2C+in+symptomatic+patients+with+non-small+cell+lung+cancer%3A+a+randomized+trial&doi=10.1001%2Fjama.290.16.2149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial</span></div><div class="casAuthors">Kris, Mark G.; Natale, Ronald B.; Herbst, Roy S.; Lynch, Thomas J., Jr.; Prager, Diane; Belani, Chandra P.; Schiller, Joan H.; Kelly, Karen; Spiridonidis, Harris; Sandler, Alan; Albain, Kathy S.; Cella, David; Wolf, Michael K.; Averbuch, Steven D.; Ochs, Judith J.; Kay, Andrea C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2149-2158</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined.  In preclin. testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiog. tumor shrinkages with gefitinib.  The aim was to assess differences in symptomatic and radiog. response among patients with NSCLC receiving 250-mg and 500-mg daily doses of gefitinib.  Double-blind, randomized phase 2 trial conducted from Nov. 2000 to Apr. 2001 in 30 US academic and community oncol. centers.  Patients (N=221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens.  Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo).  Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies).  Of 221 patients enrolled, 216 received gefitinib as randomized.  Symptoms of NSCLC improved in 43% (95% confidence interval [Cl], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% Cl, 26%-45%) of patients receiving die from 500 mg.  These benefits were obsd. within 3 wk in 75% of patients.  Partial radidiog. responses occurred in 12% (95% Cl, 6%-20%) of individuals receiving ung can 250 mg of gefitinib and in 9% (95% Cl, 4%-16%) of those receiving 500 mg.  Symptoms improved in 96% of patients with partial radiog. responses.  The overall survival at 1 yr was 25%.  There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P=.26), radiog. tumor regression (P=.51), and projected 1-yr survival (P=.54). The 500-mg dose was assocd. more frequently with transient acne-like rash (P=.04) and diarrhea (P=.006).  Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiog. tumor regressions in patients with NSCLC persisting after chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXPfLtolIxV7Vg90H21EOLACvtfcHk0liLouA5HjkcJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D&md5=bf16f1bfa8dc61f5f6e4e9ea287c75a3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjama.290.16.2149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.290.16.2149%26sid%3Dliteratum%253Aachs%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DPrager%26aufirst%3DD.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSpiridonidis%26aufirst%3DH.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DCella%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DM.%2BK.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DOchs%26aufirst%3DJ.%2BJ.%26aulast%3DKay%26aufirst%3DA.%2BC.%26atitle%3DEfficacy%2520of%2520gefitinib%252C%2520an%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%252C%2520in%2520symptomatic%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520randomized%2520trial%26jtitle%3DJama.%26date%3D2003%26volume%3D290%26spage%3D2149%26epage%3D2158%26doi%3D10.1001%2Fjama.290.16.2149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCollum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlmann, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span> <span> </span><span class="NLM_article-title">First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic egfr mutations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2442</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.14.8494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2007.14.8494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=18458038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2442-2449&author=L.+V.+Sequistauthor=R.+G.+Martinsauthor=D.+Spigelauthor=S.+M.+Grunbergauthor=A.+Spiraauthor=P.+A.+J%C3%A4nneauthor=V.+A.+Joshiauthor=D.+McCollumauthor=T.+L.+Evansauthor=A.+Muzikanskyauthor=G.+L.+Kuhlmannauthor=M.+Hanauthor=J.+S.+Goldbergauthor=J.+Settlemanauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=D.+A.+Haberauthor=B.+E.+Johnsonauthor=T.+J.+Lynch&title=First-line+gefitinib+in+patients+with+advanced+non%E2%80%93small-cell+lung+cancer+harboring+somatic+egfr+mutations&doi=10.1200%2FJCO.2007.14.8494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations</span></div><div class="casAuthors">Sequist, Lecia V.; Martins, Renato G.; Spigel, David; Grunberg, Steven M.; Spira, Alexander; Janne, Pasi A.; Joshi, Victoria A.; McCollum, David; Evans, Tracey L.; Muzikansky, Alona; Kuhlmann, Georgiana L.; Han, Moon; Goldberg, Jonathan S.; Settleman, Jeffrey; Iafrate, A. John; Engelman, Jeffrey A.; Haber, Daniel A.; Johnson, Bruce E.; Lynch, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2442-2449</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs).  The multicenter iTARGET trial prospectively examd. first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms.  Patients and Methods: Chemotherapy-naive patients with advanced NSCLC with ≥ 1 clin. characteristic assocd. with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21.  Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity.  The primary outcome was response rate.  Results: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%).  EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21 % of mutation-pos. cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q.  Thirty-one patients received gefitinib.  The response rate was 55% (95% Cl, 33 to 70) and median progression-free survival was 9.2 mo (95% Cl, 6.2 to 11.8).  Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis.  Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually assocd. with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification.  Conclusion: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clin. outcomes with good tolerance.  This strategy should be compared with combination chemotherapy, the current std. of care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiwzD0aI4fP7Vg90H21EOLACvtfcHk0lhxnh5YFtw47w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D&md5=70e6f1208215e4f3ea141216cd80688d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.8494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.8494%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DSpigel%26aufirst%3DD.%26aulast%3DGrunberg%26aufirst%3DS.%2BM.%26aulast%3DSpira%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DJoshi%26aufirst%3DV.%2BA.%26aulast%3DMcCollum%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DT.%2BL.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DG.%2BL.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DJ.%2BS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26atitle%3DFirst-line%2520gefitinib%2520in%2520patients%2520with%2520advanced%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520harboring%2520somatic%2520egfr%2520mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2442%26epage%3D2449%26doi%3D10.1200%2FJCO.2007.14.8494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+progress+of+small-molecule+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+C797S+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lhxnh5YFtw47w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520of%2520small-molecule%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520C797S%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6580</span>– <span class="NLM_lpage">6594</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6580-6594&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+perspectives+on+the+development+of+small-molecule+EGFR+inhibitors+against+T790M-mediated+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Song, Zhendong; Ge, Yang; Wang, Changyuan; Huang, Shanshan; Shu, Xiaohong; Liu, Kexin; Zhou, Youwen; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6580-6594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the development of drug-resistance mutations, particularly the "gatekeeper" threonine790-to-methionine790 (T790M) mutation in the ATP-binding pocket of the epidermal growth factor receptor (EGFR), the current generation of EGFR tyrosine kinase inhibitors lost their clin. efficacy.  Recently, a large no. of small-mol. inhibitors with striking inhibitory potency against EGFR mutants with the T790M change have been identified.  In particular, the inhibitors rociletinib and osimertinib, which can selectively target both sensitizing mutations and the T790M resistance while sparing the wild-type (WT) form of the receptor, have been designated as breakthrough therapies in the treatment of mutant non-small-cell lung cancer (NSCLC) by the U.S.  FDA in 2014.  We hope that this review on the small-mol. EGFR T790M inhibitors, along with their discovery strategies, will assist in the design of future T790M-contg. EGFR inhibitors with high levels of selectivity over WT EGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEcAydAIVpNbVg90H21EOLACvtfcHk0lg1d-EPS5QG1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D&md5=2112d52e116494f61b1c8bd3f8f383d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520perspectives%2520on%2520the%2520development%2520of%2520small-molecule%2520EGFR%2520inhibitors%2520against%2520T790M-mediated%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6580%26epage%3D6594%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulake, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Optimization of gefitinib analogues with potent anticancer activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5247</span>– <span class="NLM_lpage">5250</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.09.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2Fj.bmcl.2014.09.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5247-5250&author=K.+H.+Yinauthor=Y.+H.+Hsiehauthor=R.+S.+Sulakeauthor=S.+P.+Wangauthor=J.+I.+Chaoauthor=C.+Chen&title=Optimization+of+gefitinib+analogues+with+potent+anticancer+activity&doi=10.1016%2Fj.bmcl.2014.09.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.09.056%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DK.%2BH.%26aulast%3DHsieh%26aufirst%3DY.%2BH.%26aulast%3DSulake%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DS.%2BP.%26aulast%3DChao%26aufirst%3DJ.%2BI.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DOptimization%2520of%2520gefitinib%2520analogues%2520with%2520potent%2520anticancer%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5247%26epage%3D5250%26doi%3D10.1016%2Fj.bmcl.2014.09.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Q.</span></span> <span> </span><span class="NLM_article-title">Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3221</span>– <span class="NLM_lpage">3227</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.04.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2Fj.bmc.2015.04.065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3221-3227&author=S.+N.+Liauthor=Y.+Y.+Xuauthor=J.+Y.+Gaoauthor=H.+R.+Yinauthor=S.+L.+Zhangauthor=H.+Q.+Li&title=Combination+of+4-anilinoquinazoline+and+rhodanine+as+novel+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmc.2015.04.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.04.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.04.065%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%2BN.%26aulast%3DXu%26aufirst%3DY.%2BY.%26aulast%3DGao%26aufirst%3DJ.%2BY.%26aulast%3DYin%26aufirst%3DH.%2BR.%26aulast%3DZhang%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26atitle%3DCombination%2520of%25204-anilinoquinazoline%2520and%2520rhodanine%2520as%2520novel%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3221%26epage%3D3227%26doi%3D10.1016%2Fj.bmc.2015.04.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamed, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, A. E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abadi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, M.</span></span> <span> </span><span class="NLM_article-title">6-aryl and heterocycle quinazoline derivatives as potent egfr inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1504</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fcmdc.201300147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=23847159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1495-1504&author=M.+M.+Hamedauthor=A.+E.+E.+Daauthor=A.+B.+Keetonauthor=G.+A.+Piazzaauthor=A.+H.+Abadiauthor=R.+W.+Hartmannauthor=M.+Engel&title=6-aryl+and+heterocycle+quinazoline+derivatives+as+potent+egfr+inhibitors+with+improved+activity+toward+gefitinib-sensitive+and+-resistant+tumor+cell+lines&doi=10.1002%2Fcmdc.201300147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib-Sensitive and -Resistant Tumor Cell Lines</span></div><div class="casAuthors">Hamed, Mostafa M.; Abou El Ella, Dalal A.; Keeton, Adam B.; Piazza, Gary A.; Abadi, Ashraf H.; Hartmann, Rolf W.; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1495-1504</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Anilinoquinazolinyl benzaldimines I [R = R1CH:N; R1 = 4-HOC6H4, 2,4-(HO)2C6H3, 3-O2NC6H4, 4-O2NC6H4, 2-MeOC6H4], thioureas I [R = R1NHC(:S)NH; R1 = PhCH2, 2-(4-morpholinyl)ethyl], aminoacetamides and aminopropanamides II [R = R1NHCH2CONH, R1NHCH2CH2CONH; R1 = PhCH2, 4-(2-thiazolylaminosulfonyl)phenyl], and amides [R = R1CONH; R1 = 4-H2NC6H4, 4-NCC6H4, 4-MeCONHC6H4, 4-O2NC6H4, 3,5-(O2N)2C6H3, 4-MeOC6H4, 3,4-(MeO)2C6H3, 4-morpholinyl, 2-furyl, 3-pyridinyl, 4-pyridinyl] were prepd. as inhibitors of wild-type and mutant epidermal growth factor receptor (EGFR) for potential use as antitumor agents.  Most of the compds. inhibited wild-type EGFR with IC50 values of 4-62 nM; I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] also retained significant activity toward the gefitinib-insensitive EGFRT790M/L858R mutant, displaying up to 24-fold greater potency than gefitinib.  The inhibition of the growth of cancer cells with wild-type and mutant EGFR was detd.; I [R = BnNHC(:S)NH, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] inhibited cancer cell growth more effectively than the std. gefitinib.  Mol. docking calcns. of I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] in double mutant EGFR and of I (R = PhCH2NHCH2CONH, 2-furylcarbonylamino) in wild-type EGFR were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9J8DhyAlHb7Vg90H21EOLACvtfcHk0lg1d-EPS5QG1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF&md5=c951d913a38a5062783da74c4cf6afef</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300147%26sid%3Dliteratum%253Aachs%26aulast%3DHamed%26aufirst%3DM.%2BM.%26aulast%3DDa%26aufirst%3DA.%2BE.%2BE.%26aulast%3DKeeton%26aufirst%3DA.%2BB.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3D6-aryl%2520and%2520heterocycle%2520quinazoline%2520derivatives%2520as%2520potent%2520egfr%2520inhibitors%2520with%2520improved%2520activity%2520toward%2520gefitinib-sensitive%2520and%2520-resistant%2520tumor%2520cell%2520lines%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1495%26epage%3D1504%26doi%3D10.1002%2Fcmdc.201300147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4738</span>– <span class="NLM_lpage">4748</span>, <span class="refDoi"> DOI: 10.1021/jm400463q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400463q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4738-4748&author=C.+Hanauthor=Z.+Huangauthor=C.+Zhengauthor=L.+Wanauthor=L.+Zhangauthor=S.+Pengauthor=K.+Dingauthor=H.+Jiauthor=J.+Tianauthor=Y.+Zhang&title=Novel+hybrids+of+%28phenylsulfonyl%29furoxan+and+anilinopyrimidine+as+potent+and+selective+epidermal+growth+factor+receptor+inhibitors+for+intervention+of+non-small-cell+lung+cancer&doi=10.1021%2Fjm400463q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400463q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400463q%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DNovel%2520hybrids%2520of%2520%2528phenylsulfonyl%2529furoxan%2520and%2520anilinopyrimidine%2520as%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520for%2520intervention%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4738%26epage%3D4748%26doi%3D10.1021%2Fjm400463q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, R. B.</span></span> <span> </span><span class="NLM_article-title">Anion receptor molecules. synthesis and anion-binding properties of polyammonium macrocycles</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1282</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1021/ja00395a077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00395a077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADyaL3MXhtl2ktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1981&pages=1282-1283&author=B.+Dietrichauthor=M.+W.+Hosseiniauthor=J.+M.+Lehnauthor=R.+B.+Sessions&title=Anion+receptor+molecules.+synthesis+and+anion-binding+properties+of+polyammonium+macrocycles&doi=10.1021%2Fja00395a077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Anion receptor molecules.  Synthesis and anion-binding properties of polyammonium macrocycles</span></div><div class="casAuthors">Dietrich, B.; Hosseini, M. W.; Lehn, J. M.; Sessions, R. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1282-3</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The polyaza-macrocycles I (n = 3,5) and II were prepd.  Their protonated forms bind a variety of mol. anions, displaying high stability and characteristic selectivity sequences.  Electrostatic and geometric effects play a role in these anion binding features.  Particularly stable complexes are obtained with complex anions like Fe(CN)64- and Co(CN)63-.  AMP, ADP and ATP are also strongly bound forming either 1:1 or 2:1 complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA43rQXqMA2LVg90H21EOLACvtfcHk0lhx-kMfg7TAkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhtl2ktbw%253D&md5=f57d3bd76d90824b48f6dbe89cd96f25</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00395a077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00395a077%26sid%3Dliteratum%253Aachs%26aulast%3DDietrich%26aufirst%3DB.%26aulast%3DHosseini%26aufirst%3DM.%2BW.%26aulast%3DLehn%26aufirst%3DJ.%2BM.%26aulast%3DSessions%26aufirst%3DR.%2BB.%26atitle%3DAnion%2520receptor%2520molecules.%2520synthesis%2520and%2520anion-binding%2520properties%2520of%2520polyammonium%2520macrocycles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1981%26volume%3D103%26spage%3D1282%26epage%3D1283%26doi%3D10.1021%2Fja00395a077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIver, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of macrocyclic pyrimidines as MerTK-specific inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fcmdc.201600589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=28032464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=207-213&author=A.+L.+McIverauthor=W.+Zhangauthor=Q.+Liuauthor=X.+Jiangauthor=M.+A.+Stashkoauthor=J.+Nicholsauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=M.+Machiusauthor=D.+DeRyckereauthor=E.+Woodauthor=D.+K.+Grahamauthor=H.+S.+Earpauthor=D.+Kireevauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+macrocyclic+pyrimidines+as+MerTK-specific+inhibitors&doi=10.1002%2Fcmdc.201600589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors</span></div><div class="casAuthors">McIver, Andrew L.; Zhang, Weihe; Liu, Qingyang; Jiang, Xinpeng; Stashko, Michael A.; Nichols, James; Miley, Michael J.; Norris-Drouin, Jacqueline; Machius, Mischa; DeRyckere, Deborah; Wood, Edgar; Graham, Douglas K.; Earp, H. Shelton; Kireev, Dmitri; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocycles have attracted significant attention in drug discovery recently.  In fact, a few de novo designed macrocyclic kinase inhibitors are currently in clin. trials with good potency and selectivity for their intended target.  In this study, we successfully engaged a structure-based drug design approach to discover macrocyclic pyrimidines as potent Mer tyrosine kinase (MerTK)-specific inhibitors.  An ELISA (ELISA) in 384-well format was employed to evaluate the inhibitory activity of macrocycles in a cell-based assay assessing tyrosine phosphorylation of MerTK.  Through structure-activity relationship (SAR) studies, analog 11 [UNC2541; (S)-7-amino-N-(4-fluorobenzyl)-8-oxo-2,9,16-triaza-1(2,4)-pyrimidinacyclohexadecaphane-1-carboxamide] was identified as a potent and MerTK-specific inhibitor that exhibits sub-micromolar inhibitory activity in the cell-based ELISA.  In addn., an X-ray structure of MerTK protein in complex with 11 was resolved to show that these macrocycles bind in the MerTK ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOfJewlO7H8bVg90H21EOLACvtfcHk0lhx-kMfg7TAkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D&md5=09a963efb36d595e3f4a301676b685f1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600589%26sid%3Dliteratum%253Aachs%26aulast%3DMcIver%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520macrocyclic%2520pyrimidines%2520as%2520MerTK-specific%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D207%26epage%3D213%26doi%3D10.1002%2Fcmdc.201600589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel macrocyclic Mer tyrosine kinase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1044</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWjurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1044-1049&author=X.+Wangauthor=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=J.+Nicholsauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=Z.+Chenauthor=M.+Machiusauthor=D.+DeRyckereauthor=E.+Woodauthor=D.+K.+Grahamauthor=H.+S.+Earpauthor=D.+Kireevauthor=S.+V.+Frye&title=Design+and+synthesis+of+novel+macrocyclic+Mer+tyrosine+kinase+inhibitors&doi=10.1021%2Facsmedchemlett.6b00221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Wang, Xiaodong; Liu, Jing; Zhang, Weihe; Stashko, Michael A.; Nichols, James; Miley, Michael J.; Norris-Drouin, Jacqueline; Chen, Zhilong; Machius, Mischa; DeRyckere, Deborah; Wood, Edgar; Graham, Douglas K.; Earp, H. Shelton; Kireev, Dmitri; Frye, Stephen V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1044-1049</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mer tyrosine kinase (MerTK) is aberrantly elevated in various tumor cells and has a normal anti-inflammatory role in the innate immune system.  Inhibition of MerTK may provide dual effects against these MerTK-expressing tumors through reducing cancer cell survival and redirecting the innate immune response.  Recently, the authors have designed novel and potent macrocyclic pyrrolopyrimidines as MerTK inhibitors using a structure-based approach.  The most active macrocycles had an EC50 below 40 nM in a cell-based MerTK phosphor-protein ELISA assay.  The x-ray structure ofa macrocyclic analog complexed with MerTK was also resolved and demonstrated macrocycles binding in the ATP binding pocket of the MerTK protein as anticipated.  In addn., the lead compd. I (UNC3133) had a 1.6 h half-life and 16% oral bioavailability in a mouse PK study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprnta6NWkqnrVg90H21EOLACvtfcHk0lhx-kMfg7TAkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWjurzM&md5=159daa2a423f50f99f0f625fa235435e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00221%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520macrocyclic%2520Mer%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1044%26epage%3D1049%26doi%3D10.1021%2Facsmedchemlett.6b00221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichosyt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dydio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, J.</span></span> <span> </span><span class="NLM_article-title">Azulene-based macrocyclic receptors for recognition and sensing of phosphate anions</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">17673</span>– <span class="NLM_lpage">17680</span>, <span class="refDoi"> DOI: 10.1002/chem.201603555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fchem.201603555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=27778403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCgtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=17673-17680&author=D.+Lichosytauthor=P.+Dydioauthor=J.+Jurczak&title=Azulene-based+macrocyclic+receptors+for+recognition+and+sensing+of+phosphate+anions&doi=10.1002%2Fchem.201603555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Azulene-based macrocyclic receptors for recognition and sensing of phosphate anions</span></div><div class="casAuthors">Lichosyt, Dawid; Dydio, Pawel; Jurczak, Janusz</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17673-17680</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the synthesis and detailed studies of the anion-binding properties of two 20-membered macrocyclic tetramide receptors: one sym., contg. two identical azulene-based bisamide units, the other a hybrid, contg. a dipicolinic bisamide unit and an azulene-based bisamide unit.  Anal. of the crystal structures of the macrocyclic receptors revealed their preference for adopting similar well-preorganized bent-sheet conformations, both as free receptors and in their complexes with anions.  Studies of the optical properties of both receptors revealed abilities to selectively sense phosphate anions (H2PO4-, HP2O73-), allowing for naked-eye detection of the presence of these guests in DMSO.  Binding studies in soln. confirmed that the receptors bind strongly to a series of anions even in highly demanding media, such as mixts. of DMSO with water or with methanol.  Comparison of the anion affinity of linear analogs with that of the macrocyclic receptors evidenced the importance of macrocyclic topol.  Quant. anal. revealed that the macrocyclic receptors are selective for H2PO4- over other anions.  The affinity to H2PO4- seen for the sym. receptor, contg. two azulene-based subunits, is much higher than for the hybrid macrocycle contg. both the azulene-based and pyridine-derived subunits.  This highlights that the azulene-based building block serves efficiently as both a binding site and a structure-preorganizing motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHVTTJ1I1j9rVg90H21EOLACvtfcHk0lgNcJlXBIEoxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCgtL3P&md5=f5755698ed4df1bb15ee1cb41826b4e4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fchem.201603555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201603555%26sid%3Dliteratum%253Aachs%26aulast%3DLichosyt%26aufirst%3DD.%26aulast%3DDydio%26aufirst%3DP.%26aulast%3DJurczak%26aufirst%3DJ.%26atitle%3DAzulene-based%2520macrocyclic%2520receptors%2520for%2520recognition%2520and%2520sensing%2520of%2520phosphate%2520anions%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26spage%3D17673%26epage%3D17680%26doi%3D10.1002%2Fchem.201603555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddy, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span> <span> </span><span class="NLM_article-title">Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=271-277&author=X.+Luauthor=J.+Erringtonauthor=V.+J.+Chenauthor=N.+J.+Curtinauthor=A.+V.+Boddyauthor=D.+R.+Newell&title=Cellular+ATP+depletion+by+LY309887+as+a+predictor+of+growth+inhibition+in+human+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DErrington%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DV.%2BJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DBoddy%26aufirst%3DA.%2BV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26atitle%3DCellular%2520ATP%2520depletion%2520by%2520LY309887%2520as%2520a%2520predictor%2520of%2520growth%2520inhibition%2520in%2520human%2520tumor%2520cell%2520lines%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D6%26spage%3D271%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batrakova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alakhov, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabanov, A. V.</span></span> <span> </span><span class="NLM_article-title">Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1987</span>– <span class="NLM_lpage">1997</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2001.2165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1054%2Fbjoc.2001.2165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11747344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVWnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=1987-1997&author=E.+V.+Batrakovaauthor=S.+Liauthor=W.+F.+Elmquistauthor=D.+W.+Millerauthor=V.+Y.+Alakhovauthor=A.+V.+Kabanov&title=Mechanism+of+sensitization+of+MDR+cancer+cells+by+pluronic+block+copolymers%3A+selective+energy+depletion&doi=10.1054%2Fbjoc.2001.2165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: Selective energy depletion</span></div><div class="casAuthors">Batrakova, E. V.; Li, S.; Elmquist, W. F.; Miller, D. W.; Alakhov, V. Y.; Kabanov, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1987-1997</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">This paper, for the first time, demonstrates that exposure of cells to the poly(ethylene oxide)-poly(propylene oxide) block copolymer, Pluronic P85, results in a substantial decrease in ATP levels selectively in MDR cells.  Cells expressing high levels of functional P-glycoprotein (MCF-7/ADR, KBv; LLC-MDR1; Caco-2, bovine brain microvessel endothelial cells [BBMECs]) are highly responsive to Pluronic treatment, while cells with low levels of P-glycoprotein expression (MCF-7, KB, LLC-PK1, human umbilical vein endothelial cells [HUVECs] C2C12 myoblasts) are much less responsive to such treatment.  Cytotoxicity studies suggest that Pluronic acts as a chemosensitizer and potentiates cytotoxic effects of doxorubicin in MDR cells.  The ability of Pluronic to inhibit P-glycoprotein and sensitize MDR cells appears to be a result of ATP depletion.  Because many mechanisms of drug resistance are energy dependent, a successful strategy for treating MDR cancer could be based on selective energy depletion in MDR cells.  Therefore, the finding of the energy-depleting effects of Pluronic P85, in combination with its sensitization effects is of considerable theor. and practical significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLFYe0vqJcLVg90H21EOLACvtfcHk0lgNcJlXBIEoxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVWnu7c%253D&md5=ac4e38757f1fe3c6bc4b9ab93ddfdf39</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.2165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.2165%26sid%3Dliteratum%253Aachs%26aulast%3DBatrakova%26aufirst%3DE.%2BV.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26aulast%3DMiller%26aufirst%3DD.%2BW.%26aulast%3DAlakhov%26aufirst%3DV.%2BY.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26atitle%3DMechanism%2520of%2520sensitization%2520of%2520MDR%2520cancer%2520cells%2520by%2520pluronic%2520block%2520copolymers%253A%2520selective%2520energy%2520depletion%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D1987%26epage%3D1997%26doi%3D10.1054%2Fbjoc.2001.2165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frydman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drandarov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guggisberg, A.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic polyamines deplete cellular ATP levels and inhibit cell growth in human prostate cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1059</span>, <span class="refDoi"> DOI: 10.1021/jm030437s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030437s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1051-1059&author=B.+Frydmanauthor=S.+Bhattacharyaauthor=A.+Sarkarauthor=K.+Drandarovauthor=S.+Chesnovauthor=A.+Guggisberg&title=Macrocyclic+polyamines+deplete+cellular+ATP+levels+and+inhibit+cell+growth+in+human+prostate+cancer+cells&doi=10.1021%2Fjm030437s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm030437s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030437s%26sid%3Dliteratum%253Aachs%26aulast%3DFrydman%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DA.%26aulast%3DDrandarov%26aufirst%3DK.%26aulast%3DChesnov%26aufirst%3DS.%26aulast%3DGuggisberg%26aufirst%3DA.%26atitle%3DMacrocyclic%2520polyamines%2520deplete%2520cellular%2520ATP%2520levels%2520and%2520inhibit%2520cell%2520growth%2520in%2520human%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1051%26epage%3D1059%26doi%3D10.1021%2Fjm030437s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span> <span> </span><span class="NLM_article-title">Cyclam, complexes and their applications in medicine</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1039/b313659k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1039%2Fb313659k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2004&pages=246-266&author=X.+Liangauthor=P.+J.+Sadler&title=Cyclam%2C+complexes+and+their+applications+in+medicine&doi=10.1039%2Fb313659k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2Fb313659k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb313659k%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DCyclam%252C%2520complexes%2520and%2520their%2520applications%2520in%2520medicine%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2004%26volume%3D35%26spage%3D246%26epage%3D266%26doi%3D10.1039%2Fb313659k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Sayed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licchelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Manez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancenon, F.</span></span> <span> </span><span class="NLM_article-title">Anions as triggers in controlled release protocols from mesoporous silica nanoparticles functionalized with macrocyclic copper(II) complexes</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">13935</span>– <span class="NLM_lpage">13945</span>, <span class="refDoi"> DOI: 10.1002/chem.201601024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fchem.201601024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=27530898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOgu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=13935-13945&author=S.+El%0ASayedauthor=M.+Milaniauthor=C.+Milaneseauthor=M.+Licchelliauthor=R.+Martinez-Manezauthor=F.+Sancenon&title=Anions+as+triggers+in+controlled+release+protocols+from+mesoporous+silica+nanoparticles+functionalized+with+macrocyclic+copper%28II%29+complexes&doi=10.1002%2Fchem.201601024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Anions as Triggers in Controlled Release Protocols from Mesoporous Silica Nanoparticles Functionalized with Macrocyclic Copper(II) Complexes</span></div><div class="casAuthors">El Sayed, Sameh; Milani, Michele; Milanese, Chiara; Licchelli, Maurizio; Martinez-Manez, Ramon; Sancenon, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">13935-13945</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three different mesoporous silica nano-sized materials (SC1, SC2, and SC3), loaded with [Ru(bipy)3]2+ dye (bipy=bipyridine) and functionalized on the external surface with three macrocyclic copper(II) complexes (C1, C2, and C3), were synthesized and characterized.  When SC1, SC2, and SC3 were suspended in water, the entrapped [Ru(bipy)3]2+ dye was free to diffuse from the inner pores to the soln.  However, addn. of anions induced certain degrees of pore blockage, with subsequent dye release inhibition.  Small monovalent and divalent anions were unable to induce complete pore blockage, whereas bulky and highly charged anions induced marked redns. in [Ru(bipy)3]2+ delivery.  The best [Ru(bipy)3]2+ delivery inhibitors were ATP and hexametaphosphate anions.  Inhibition was ascribed to the interaction of the anions with the grafted CuII complexes on the surface of the SC1, SC2, and SC3 supports.  The hexametaphosphate anion was selected to prep. two capped materials (SC1-mPh and SC3-mPh).  Studies of the [Ru(bipy)3]2+ dye release from solids SC1-mPh and SC3-mPh alone and in the presence of a collection of selected anions (HS-, F-, Br-, Cl-, I-, CN-, HPO42-, AcO-, citrate, NO32-, HCO3-, SO42-, and S2O82-), amino acids (alanine and histidine), thiol-contg. biomols. (cysteine, methylcysteine, homocysteine, and glutathione (GSH)), and oxidants (H2O2) were performed.  None of the chems. tested, except hydrogen sulfide, was able to induce remarkable cargo delivery in both solids.  The obsd. dye release was ascribed to a demetalation reaction of the C1 and C3 complexes induced by the hydrogen sulfide anion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWlD9MZjQ2p7Vg90H21EOLACvtfcHk0lgVS7p6FUWJKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOgu7fP&md5=6fa5c0c3399370dfd3537273ac16f552</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fchem.201601024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201601024%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BSayed%26aufirst%3DS.%26aulast%3DMilani%26aufirst%3DM.%26aulast%3DMilanese%26aufirst%3DC.%26aulast%3DLicchelli%26aufirst%3DM.%26aulast%3DMartinez-Manez%26aufirst%3DR.%26aulast%3DSancenon%26aufirst%3DF.%26atitle%3DAnions%2520as%2520triggers%2520in%2520controlled%2520release%2520protocols%2520from%2520mesoporous%2520silica%2520nanoparticles%2520functionalized%2520with%2520macrocyclic%2520copper%2528II%2529%2520complexes%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26spage%3D13935%26epage%3D13945%26doi%3D10.1002%2Fchem.201601024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deodato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfilippo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arezzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posteraro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeputte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanglard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docquier, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanguinetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Biological characterization and in vivo assessment of the activity of a new synthetic macrocyclic antifungal compound</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3854</span>– <span class="NLM_lpage">3866</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3854-3866&author=D.+Deodatoauthor=G.+Maccariauthor=F.+De+Lucaauthor=S.+Sanfilippoauthor=A.+Casianauthor=R.+Martiniauthor=S.+D%E2%80%99Arezzoauthor=C.+Bonchiauthor=F.+Bugliauthor=B.+Posteraroauthor=P.+Vandeputteauthor=D.+Sanglardauthor=J.-D.+Docquierauthor=M.+Sanguinettiauthor=P.+Viscaauthor=M.+Botta&title=Biological+characterization+and+in+vivo+assessment+of+the+activity+of+a+new+synthetic+macrocyclic+antifungal+compound&doi=10.1021%2Facs.jmedchem.6b00018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00018%26sid%3Dliteratum%253Aachs%26aulast%3DDeodato%26aufirst%3DD.%26aulast%3DMaccari%26aufirst%3DG.%26aulast%3DDe%2BLuca%26aufirst%3DF.%26aulast%3DSanfilippo%26aufirst%3DS.%26aulast%3DCasian%26aufirst%3DA.%26aulast%3DMartini%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Arezzo%26aufirst%3DS.%26aulast%3DBonchi%26aufirst%3DC.%26aulast%3DBugli%26aufirst%3DF.%26aulast%3DPosteraro%26aufirst%3DB.%26aulast%3DVandeputte%26aufirst%3DP.%26aulast%3DSanglard%26aufirst%3DD.%26aulast%3DDocquier%26aufirst%3DJ.-D.%26aulast%3DSanguinetti%26aufirst%3DM.%26aulast%3DVisca%26aufirst%3DP.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DBiological%2520characterization%2520and%2520in%2520vivo%2520assessment%2520of%2520the%2520activity%2520of%2520a%2520new%2520synthetic%2520macrocyclic%2520antifungal%2520compound%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3854%26epage%3D3866%26doi%3D10.1021%2Facs.jmedchem.6b00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggiora, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, M. P.</span></span> <span> </span><span class="NLM_article-title">Supramolecular catalysis in the hydrolysis of ATP facilitated by macrocyclic polyamines: mechanistic studies</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1021/ja00236a036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00236a036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=537-544&author=M.+W.+Hosseiniauthor=J.+M.+Lehnauthor=L.+Maggioraauthor=K.+B.+Mertesauthor=M.+P.+Mertes&title=Supramolecular+catalysis+in+the+hydrolysis+of+ATP+facilitated+by+macrocyclic+polyamines%3A+mechanistic+studies&doi=10.1021%2Fja00236a036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fja00236a036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00236a036%26sid%3Dliteratum%253Aachs%26aulast%3DHosseini%26aufirst%3DM.%2BW.%26aulast%3DLehn%26aufirst%3DJ.%2BM.%26aulast%3DMaggiora%26aufirst%3DL.%26aulast%3DMertes%26aufirst%3DK.%2BB.%26aulast%3DMertes%26aufirst%3DM.%2BP.%26atitle%3DSupramolecular%2520catalysis%2520in%2520the%2520hydrolysis%2520of%2520ATP%2520facilitated%2520by%2520macrocyclic%2520polyamines%253A%2520mechanistic%2520studies%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D537%26epage%3D544%26doi%3D10.1021%2Fja00236a036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, K. B.</span></span> <span> </span><span class="NLM_article-title">Polyammonium macrocycles as catalysts for phosphoryl transfer: the evolution of an enzyme mimic</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1021/ar00180a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00180a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1990&pages=413-418&author=M.+P.+Mertesauthor=K.+B.+Mertes&title=Polyammonium+macrocycles+as+catalysts+for+phosphoryl+transfer%3A+the+evolution+of+an+enzyme+mimic&doi=10.1021%2Far00180a003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Far00180a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00180a003%26sid%3Dliteratum%253Aachs%26aulast%3DMertes%26aufirst%3DM.%2BP.%26aulast%3DMertes%26aufirst%3DK.%2BB.%26atitle%3DPolyammonium%2520macrocycles%2520as%2520catalysts%2520for%2520phosphoryl%2520transfer%253A%2520the%2520evolution%2520of%2520an%2520enzyme%2520mimic%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1990%26volume%3D23%26spage%3D413%26epage%3D418%26doi%3D10.1021%2Far00180a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bencini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Espana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deffo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takusagawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span> <span> </span><span class="NLM_article-title">Potential ATPase mimics by polyammonium macrocycles: criteria for catalytic activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/0045-2068(92)90022-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2F0045-2068%2892%2990022-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADyaK38XltVOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1992&pages=8-29&author=A.+Benciniauthor=A.+Bianchiauthor=E.+Garcia-Espanaauthor=E.+C.+Scottauthor=L.+Moralesauthor=B.+Wangauthor=T.+Deffoauthor=F.+Takusagawaauthor=M.+P.+Mertesauthor=K.+B.+Mertesauthor=P.+Paoletti&title=Potential+ATPase+mimics+by+polyammonium+macrocycles%3A+criteria+for+catalytic+activity&doi=10.1016%2F0045-2068%2892%2990022-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Potential ATPase mimics by polyammonium macrocycles:  criteria for catalytic activity</span></div><div class="casAuthors">Bencini, Andrea; Bianchi, Antonio; Garcia-Espana, Enrique; Scott, Edmund C.; Morales, Luis; Wang, Binghe; Deffo, Tamboue; Takusagawa, Fusao; Mertes, Mathias P.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-29</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    </div><div class="casAbstract">A series of polyammonium macrocycles, ranging in size from the 18-membered ring [18]aneN6 to the 36-membered [36]aneN12 were examd. as potential ATPase mimics.  The rates of hydrolysis of ATP were followed at pH 3.0 and 7.0 using 31P NMR and HPLC techniques.  Stability consts. as a function of degree of protonation, distribution curves for the ligands as a function of pH, and distribution curves for the mixed species of nucleotides, inorg. phosphate, and macrocycle were also detd.  All of the macrocycles catalyzed the hydrolysis of ATP to some extent compared to noncatalyzed hydrolysis.  A crit. dependence on macrocycle ring size was obsd., with [21]aneN- being the best catalyst at both pH values.  Stability consts. of the complexes formed between the phosphate species and macrocycle increased with increasing degree of protonation and decreasing ring size.  The trend in stability consts. for phosphate species was found to be PO43- > P2O74- > ATP4- > ADP3- > AMP2- for a given degree of protonation.  The crystal structure of tetraprotonated [21]laneN7 was detd.  The compd. N-C14Cl4H41O crystd. in monoclinic space group P21 (#4) with unit cell dimensions a = 7.472, b = 19.480, c = 8.3638 Å, β = 100.38, and V = 1197.4 Å3.  The structure was solved by direct methods and refined using full-matrix least-squares techniques to give a final R = 0.041 and Rw = 0.055.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Y3QK4qh_27Vg90H21EOLACvtfcHk0ljvwz86FDCHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVOisrk%253D&md5=84db38d35a748786853e5029917fda2a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0045-2068%2892%2990022-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0045-2068%252892%252990022-U%26sid%3Dliteratum%253Aachs%26aulast%3DBencini%26aufirst%3DA.%26aulast%3DBianchi%26aufirst%3DA.%26aulast%3DGarcia-Espana%26aufirst%3DE.%26aulast%3DScott%26aufirst%3DE.%2BC.%26aulast%3DMorales%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DDeffo%26aufirst%3DT.%26aulast%3DTakusagawa%26aufirst%3DF.%26aulast%3DMertes%26aufirst%3DM.%2BP.%26aulast%3DMertes%26aufirst%3DK.%2BB.%26aulast%3DPaoletti%26aufirst%3DP.%26atitle%3DPotential%2520ATPase%2520mimics%2520by%2520polyammonium%2520macrocycles%253A%2520criteria%2520for%2520catalytic%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D1992%26volume%3D20%26spage%3D8%26epage%3D29%26doi%3D10.1016%2F0045-2068%2892%2990022-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER2</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1114</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2008-0816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1634%2Ftheoncologist.2008-0816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=1114-1119&author=Q.+Ryanauthor=A.+Ibrahimauthor=M.+H.+Cohenauthor=J.+Johnsonauthor=C.+W.+Koauthor=R.+Sridharaauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+lapatinib+in+combination+with+capecitabine+for+previously+treated+metastatic+breast+cancer+that+overexpresses+HER2&doi=10.1634%2Ftheoncologist.2008-0816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2008-0816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2008-0816%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DQ.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DKo%26aufirst%3DC.%2BW.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520lapatinib%2520in%2520combination%2520with%2520capecitabine%2520for%2520previously%2520treated%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D1114%26epage%3D1119%26doi%3D10.1634%2Ftheoncologist.2008-0816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shindo-Okada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamachi, Y.</span></span> <span> </span><span class="NLM_article-title">Establishment of cell lines with high and low metastatic potential from A549 human lung adenocarcinoma</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2002.tb01200.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1111%2Fj.1349-7006.2002.tb01200.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11802808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XisVKmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=50-60&author=N.+Shindo-Okadaauthor=K.+Takeuchiauthor=B.+S.+Hanauthor=Y.+Nagamachi&title=Establishment+of+cell+lines+with+high+and+low+metastatic+potential+from+A549+human+lung+adenocarcinoma&doi=10.1111%2Fj.1349-7006.2002.tb01200.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of cell lines with high and low metastatic potential from A549 human lung adenocarcinoma</span></div><div class="casAuthors">Shindo-Okada, Nobuko; Takeuchi, Kaori; Han, Beom-Seok; Nagamachi, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-60</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">This article reports the establishment of variant cell lines with high and low metastatic potential by the diln. plating technique.  Two clones with high metastatic potential, 2S Lu-4 and 11S Lu-1 and two clones with low metastatic potential, 8S and 16S were established from A549 human lung adenocarcinoma.  The high-metastatic cell lines produced enhanced lung metastases, but the low-metastatic cell lines did not produce lung metastasis after injection into the tail vein of 5-wk-old BALB/c nude mice.  The primary tumors produced by the two high-metastatic cells grew fast and showed enhanced angiogenesis.  The high-metastatic cells were small and flat-shaped, while the low-metastatic cells were large and flat-shaped.  When the four variant cell lines and original A549 cells were embedded in collagen gels, the colonies of 2S Lu-4, 11S Lu-1 and A549 grew actively, whereas almost of all the colonies of 8S and 16S did not survive after 35 days in culture.  These four cloned cell lines originated from heterogeneous populations of the parental A549 cells should be an excellent tool for studying the process of metastasis of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRRfQ6nbhuzrVg90H21EOLACvtfcHk0ljvwz86FDCHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisVKmur0%253D&md5=89a62575e5aa3d5097f62466eb050353</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2002.tb01200.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2002.tb01200.x%26sid%3Dliteratum%253Aachs%26aulast%3DShindo-Okada%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DB.%2BS.%26aulast%3DNagamachi%26aufirst%3DY.%26atitle%3DEstablishment%2520of%2520cell%2520lines%2520with%2520high%2520and%2520low%2520metastatic%2520potential%2520from%2520A549%2520human%2520lung%2520adenocarcinoma%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D2002%26volume%3D93%26spage%3D50%26epage%3D60%26doi%3D10.1111%2Fj.1349-7006.2002.tb01200.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0ljvwz86FDCHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, A.</span></span> <span> </span><span class="NLM_article-title">Identification of novel aurora kinase A (AURKA) inhibitors via hierarchical ligand-based virtual screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.7b00300</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00300" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=36-47&author=Y.+Kongauthor=A.+Benderauthor=A.+Yan&title=Identification+of+novel+aurora+kinase+A+%28AURKA%29+inhibitors+via+hierarchical+ligand-based+virtual+screening&doi=10.1021%2Facs.jcim.7b00300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Aurora Kinase A (AURKA) Inhibitors via Hierarchical Ligand-Based Virtual Screening</span></div><div class="casAuthors">Kong, Yue; Bender, Andreas; Yan, Aixia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-47</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aurora kinases are essential for cell mitosis, amplified, and overexpressed in various human malignancies.  Therefore, Aurora kinases have been promising targets for anticancer therapies, which has prompted an intensive search for their small-mol. inhibitors.  In this work, we performed a hierarchical and time-efficient virtual screening cascade for scaffold hopping, aiming to obtain structurally novel and highly potent hit compds. targeting Aurora kinases.  The cascade consisted of a shape- and an electrostatic-based protocol, combined with a QSAR-based selection protocol.  This virtual screening cascade was used to screen two databases, one com. database named the J&K database contg. about 5.2 million diverse mols. and the Drugbank database.  Exptl. validations led to the identification of one structurally novel and highly potent hit compd. (hit 1, found to possess an IC50 of 8.1 and 19 nM for Aurora kinases A and B, resp.), which can be a promising starting point for further exploration.  Addnl., Aurora kinases were identified as off-targets for hits 2-6 (Crizotinib, CI-1033, Dasatinib, Bosutinib, MLN-518), which are approved or investigational drugs as listed in Drugbank, plausibly suggesting targeting Aurora kinases may even contribute to their mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7nu5Hn7IsDLVg90H21EOLACvtfcHk0ljZqnvb_SLDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bJ&md5=b1d085a79a8db7f9f584cb0b58edfb66</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00300%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DY.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520novel%2520aurora%2520kinase%2520A%2520%2528AURKA%2529%2520inhibitors%2520via%2520hierarchical%2520ligand-based%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D36%26epage%3D47%26doi%3D10.1021%2Facs.jcim.7b00300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, A.</span></span> <span> </span><span class="NLM_article-title">Self-organizing map (SOM) and support vector machine (SVM) models for the prediction of human epidermal growth factor receptor (EGFR/ErbB-1) inhibitors</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.2174/1386207319666160414105044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.2174%2F1386207319666160414105044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=27074760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=400-411&author=Y.+Kongauthor=D.+Quauthor=X.+Chenauthor=Y.+Gongauthor=A.+Yan&title=Self-organizing+map+%28SOM%29+and+support+vector+machine+%28SVM%29+models+for+the+prediction+of+human+epidermal+growth+factor+receptor+%28EGFR%2FErbB-1%29+inhibitors&doi=10.2174%2F1386207319666160414105044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Self-Organizing Map (SOM) and Support Vector Machine (SVM) Models for the Prediction of Human Epidermal Growth Factor Receptor (EGFR/ ErbB-1) Inhibitors</span></div><div class="casAuthors">Kong, Yue; Qu, Dan; Chen, Xiaoyan; Gong, Ya-Nan; Yan, Aixia</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">400-411</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">EGFR (ErbB-1/HER1) kinase plays an important role in cancer therapy.  Two classification models were established to predict whether a compd. is an inhibitor or a decoy of human EGFR (ErbR-1) by using Kohonen's self-organizing map (SOM) and support vector machine (SVM).  A dataset contg. 1248 ATP binding site inhibitors and 3090 decoys was collected and randomly divided into a training set (831 inhibitors and 2064 decoys) and a test set (417 inhibitors and 1029 decoys).  The descriptors that represent mol. structures were calcd. by software ADRIANA.Code.  Thirteen significant descriptors including five global descriptors and eight 2D property autocorrelation descriptors were selected by Pearson correlation anal. and stepwise anal.  The prediction accuracies on training set and test set are 98.5% and 96.3% for SOM model, 99.0% and 97.0% for SVM model, resp.  Both of these two classification models have good performance on distinguishing EGFR inhibitors from decoys.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_w15gyzfUTbVg90H21EOLACvtfcHk0ljZqnvb_SLDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFagtLw%253D&md5=532784817d1ea1ae033b1132f45349cf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F1386207319666160414105044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207319666160414105044%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DA.%26atitle%3DSelf-organizing%2520map%2520%2528SOM%2529%2520and%2520support%2520vector%2520machine%2520%2528SVM%2529%2520models%2520for%2520the%2520prediction%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%252FErbB-1%2529%2520inhibitors%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2016%26volume%3D19%26spage%3D400%26epage%3D411%26doi%3D10.2174%2F1386207319666160414105044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Na  Xue</span>, <span class="hlFld-ContribAuthor ">Xingang  Liu</span>, <span class="hlFld-ContribAuthor ">Qiaoyun  Wang</span>, <span class="hlFld-ContribAuthor ">Hongyi  Yan</span>, <span class="hlFld-ContribAuthor ">Yifan  Liu</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Shi</span>, <span class="hlFld-ContribAuthor ">Deying  Cao</span>, <span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.647591" title="DOI URL">https://doi.org/10.3389/fphar.2021.647591</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.647591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.647591%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DDiscovery%252Bof%252BPotent%252BEGFR%252BInhibitors%252BWith%252B6-Arylureido-4-anilinoquinazoline%252BDerivatives%26aulast%3DLi%26aufirst%3DMeng%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liu</span>, <span class="hlFld-ContribAuthor ">Shengjin  Xia</span>, <span class="hlFld-ContribAuthor ">Qingqing  Liu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113300. <a href="https://doi.org/10.1016/j.ejmech.2021.113300" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113300%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsulfamoylphenyl-quinazoline%252Bderivatives%252Bas%252Bpotential%252BEGFR%25252FCAIX%252Bdual%252Binhibitors%26aulast%3DZhang%26aufirst%3DBin%26date%3D2021%26volume%3D216%26spage%3D113300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingxiang  Guo</span>, <span class="hlFld-ContribAuthor ">Yifan  Liu</span>, <span class="hlFld-ContribAuthor ">Zhongyan  Wang</span>, <span class="hlFld-ContribAuthor ">Jiamin  Zhang</span>, <span class="hlFld-ContribAuthor ">Ganen  Mu</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Supramolecular nanofibers increase the efficacy of 10-hydroxycamptothecin by enhancing nuclear accumulation and depleting cellular ATP. </span><span class="cited-content_cbyCitation_journal-name">Acta Biomaterialia</span><span> <strong>2021,</strong> <em>122 </em>, 343-353. <a href="https://doi.org/10.1016/j.actbio.2020.12.052" title="DOI URL">https://doi.org/10.1016/j.actbio.2020.12.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.actbio.2020.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.actbio.2020.12.052%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Biomaterialia%26atitle%3DSupramolecular%252Bnanofibers%252Bincrease%252Bthe%252Befficacy%252Bof%252B10-hydroxycamptothecin%252Bby%252Benhancing%252Bnuclear%252Baccumulation%252Band%252Bdepleting%252Bcellular%252BATP%26aulast%3DGuo%26aufirst%3DQingxiang%26date%3D2021%26volume%3D122%26spage%3D343%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changding  Wang</span>, <span class="hlFld-ContribAuthor ">Xiang  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Li</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Xu</span>, <span class="hlFld-ContribAuthor ">Weichun  Ye</span>, <span class="hlFld-ContribAuthor ">Guoyu  Qiu</span>, <span class="hlFld-ContribAuthor ">Degui  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Silver mirror films deposited on well plates for SERS detection of multi-analytes: Aiming at 96-well technology. </span><span class="cited-content_cbyCitation_journal-name">Talanta</span><span> <strong>2021,</strong> <em>222 </em>, 121544. <a href="https://doi.org/10.1016/j.talanta.2020.121544" title="DOI URL">https://doi.org/10.1016/j.talanta.2020.121544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.talanta.2020.121544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.talanta.2020.121544%26sid%3Dliteratum%253Aachs%26jtitle%3DTalanta%26atitle%3DSilver%252Bmirror%252Bfilms%252Bdeposited%252Bon%252Bwell%252Bplates%252Bfor%252BSERS%252Bdetection%252Bof%252Bmulti-analytes%25253A%252BAiming%252Bat%252B96-well%252Btechnology%26aulast%3DWang%26aufirst%3DChangding%26date%3D2021%26volume%3D222%26spage%3D121544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin‐Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Hao  Liu</span>, <span class="hlFld-ContribAuthor ">Xian‐Zhang  Liao</span>, <span class="hlFld-ContribAuthor ">Lin  Dong</span>, <span class="hlFld-ContribAuthor ">Fen‐Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Fused Polycyclic 4‐Anilinoquinazolines and
              N
              ‐Quinazoline‐Indoles
              via
              Selective C−H Bond Activation. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (24)
                                     , 5645-5652. <a href="https://doi.org/10.1002/adsc.202000895" title="DOI URL">https://doi.org/10.1002/adsc.202000895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000895%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DSynthesis%252Bof%252BFused%252BPolycyclic%252B4%2525E2%252580%252590Anilinoquinazolines%252Band%252BN%252B%2525E2%252580%252590Quinazoline%2525E2%252580%252590Indoles%252Bvia%252BSelective%252BC%2525E2%252588%252592H%252BBond%252BActivation%26aulast%3DLiu%26aufirst%3DXin%25E2%2580%2590Yang%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D24%26spage%3D5645%26epage%3D5652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingxiang  Guo</span>, <span class="hlFld-ContribAuthor ">Yifan  Liu</span>, <span class="hlFld-ContribAuthor ">Ganen  Mu</span>, <span class="hlFld-ContribAuthor ">Lijun  Yang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Jinjian  Liu</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A peptide–drug hydrogel to enhance the anti-cancer activity of chlorambucil. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials Science</span><span> <strong>2020,</strong> <em>8 </em>
                                    (20)
                                     , 5638-5646. <a href="https://doi.org/10.1039/D0BM01001D" title="DOI URL">https://doi.org/10.1039/D0BM01001D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0BM01001D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0BM01001D%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%2520Science%26atitle%3DA%252Bpeptide%2525E2%252580%252593drug%252Bhydrogel%252Bto%252Benhance%252Bthe%252Banti-cancer%252Bactivity%252Bof%252Bchlorambucil%26aulast%3DGuo%26aufirst%3DQingxiang%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D20%26spage%3D5638%26epage%3D5646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parth  Bhatia</span>, <span class="hlFld-ContribAuthor ">Vrinda  Sharma</span>, <span class="hlFld-ContribAuthor ">Ozair  Alam</span>, <span class="hlFld-ContribAuthor ">Ajay  Manaithiya</span>, <span class="hlFld-ContribAuthor ">Perwaiz  Alam</span>, <span class="hlFld-ContribAuthor ">Kahksha</span>, <span class="hlFld-ContribAuthor ">Md Tauquir  Alam</span>, <span class="hlFld-ContribAuthor ">Mohd  Imran</span>. </span><span class="cited-content_cbyCitation_article-title">Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112640. <a href="https://doi.org/10.1016/j.ejmech.2020.112640" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112640%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bquinazoline-based%252BEGFR%252Bkinase%252Binhibitors%25253A%252BA%252Breview%252Bfocussing%252Bon%252BSAR%252Band%252Bmolecular%252Bdocking%252Bstudies%252B%2525282015-2019%252529%26aulast%3DBhatia%26aufirst%3DParth%26date%3D2020%26volume%3D204%26spage%3D112640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingwen  E</span>, <span class="hlFld-ContribAuthor ">Ye  Liu</span>, <span class="hlFld-ContribAuthor ">Shanshan  Guan</span>, <span class="hlFld-ContribAuthor ">Zhijian  Luo</span>, <span class="hlFld-ContribAuthor ">Fei  Han</span>, <span class="hlFld-ContribAuthor ">Weiwei  Han</span>, <span class="hlFld-ContribAuthor ">Song  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFRL858R/T790M/C797S Inhibitors: A Molecular Dynamics Simulation Study. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (4)
                                     , 895. <a href="https://doi.org/10.3390/molecules25040895" title="DOI URL">https://doi.org/10.3390/molecules25040895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25040895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25040895%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DHow%252BDifferent%252BSubstitution%252BPositions%252Bof%252BF%25252C%252BCl%252BAtoms%252Bin%252BBenzene%252BRing%252Bof%252B5-Methylpyrimidine%252BPyridine%252BDerivatives%252BAffect%252Bthe%252BInhibition%252BAbility%252Bof%252BEGFRL858R%25252FT790M%25252FC797S%252BInhibitors%25253A%252BA%252BMolecular%252BDynamics%252BSimulation%252BStudy%26aulast%3DE%26aufirst%3DJingwen%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D4%26spage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pauline  Lejault</span>, <span class="hlFld-ContribAuthor ">Katerina  Duskova</span>, <span class="hlFld-ContribAuthor ">Claire  Bernhard</span>, <span class="hlFld-ContribAuthor ">Ibai E.  Valverde</span>, <span class="hlFld-ContribAuthor ">Anthony  Romieu</span>, <span class="hlFld-ContribAuthor ">David  Monchaud</span>. </span><span class="cited-content_cbyCitation_article-title">The Scope of Application of Macrocyclic Polyamines Beyond Metal Chelation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (36)
                                     , 6146-6157. <a href="https://doi.org/10.1002/ejoc.201900870" title="DOI URL">https://doi.org/10.1002/ejoc.201900870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900870%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DThe%252BScope%252Bof%252BApplication%252Bof%252BMacrocyclic%252BPolyamines%252BBeyond%252BMetal%252BChelation%26aulast%3DLejault%26aufirst%3DPauline%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D36%26spage%3D6146%26epage%3D6157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pan  Li</span>, <span class="hlFld-ContribAuthor ">Meihong  Ge</span>, <span class="hlFld-ContribAuthor ">Dongyue  Lin</span>, <span class="hlFld-ContribAuthor ">Liangbao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalized acupuncture needle as a SERS-active platform for rapid and sensitive determination of adenosine triphosphate. </span><span class="cited-content_cbyCitation_journal-name">Analytical and Bioanalytical Chemistry</span><span> <strong>2019,</strong> <em>411 </em>
                                    (22)
                                     , 5669-5679. <a href="https://doi.org/10.1007/s00216-019-01945-5" title="DOI URL">https://doi.org/10.1007/s00216-019-01945-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00216-019-01945-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00216-019-01945-5%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520and%2520Bioanalytical%2520Chemistry%26atitle%3DFunctionalized%252Bacupuncture%252Bneedle%252Bas%252Ba%252BSERS-active%252Bplatform%252Bfor%252Brapid%252Band%252Bsensitive%252Bdetermination%252Bof%252Badenosine%252Btriphosphate%26aulast%3DLi%26aufirst%3DPan%26date%3D2019%26date%3D2019%26volume%3D411%26issue%3D22%26spage%3D5669%26epage%3D5679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Montaruli</span>, <span class="hlFld-ContribAuthor ">Domenico  Alberga</span>, <span class="hlFld-ContribAuthor ">Fulvio  Ciriaco</span>, <span class="hlFld-ContribAuthor ">Daniela  Trisciuzzi</span>, <span class="hlFld-ContribAuthor ">Anna Rita  Tondo</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search †. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2233. <a href="https://doi.org/10.3390/molecules24122233" title="DOI URL">https://doi.org/10.3390/molecules24122233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122233%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAccelerating%252BDrug%252BDiscovery%252Bby%252BEarly%252BProtein%252BDrug%252BTarget%252BPrediction%252BBased%252Bon%252Ba%252BMulti-Fingerprint%252BSimilarity%252BSearch%252B%2525E2%252580%2525A0%26aulast%3DMontaruli%26aufirst%3DMichele%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of Gefitinib, Lapatinib, and newly designed quinazoline derivatives as potential EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of macrocyclic polyamines on the intracellular ATP levels of A549 cells after incubating for (A) 24 h and (B) 72 h. The treated cells for each concentration of macrocycle were run in quadruplicate. ATP concentrations were determined using Enlitten reagent, and luminescence was read after a 1 min mixture time. Finally, relative light units were converted to ATP concentrations using a reference plot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell apoptosis analysis on A549 cells treated with compound <b>1f</b>, Gefitinib, and Lapatinib at indicated concentrations detected by flow cytometer. The inserted table showed quantitative early/late cellular apoptosis for tested compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antitumor efficacy of compound <b>1f</b> in the A549 xenografts mouse model. (A) Body weight and (B) tumor volume measurements from A549 xenografts mice after 19 days of <b>1f</b> administration. (C) Representative photographs of tumors in each group. (D) Comparison of the final tumor weights in each group after the 19 days treatment period of <b>1f</b>. *<i>p</i> < 0.05 compared with the control group. (E) H&E staining images of tumor tissue from each treatment group. The scale bar is 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/medium/jm-2018-01612b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking modes of compounds <b>1f</b> (green) with EGFR comparing with (A) Gefitinib (gray, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>) and (B) Lapatinib (gray, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>), respectively. Selected residues MET793 in EGFR are shown. Green dashed lines indicate hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01612/20181226/images/large/jm-2018-01612b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01612&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwknowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Untangling the ErbB signaling network</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwknowski&title=Untangling+the+ErbB+signaling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lhLamgnUbByaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwknowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signaling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. A.</span></span> <span> </span><span class="NLM_article-title">ErbB receptors and cancer: the complexity of targeted inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ErbB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lhLamgnUbByaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DErbB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciardiello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortora, G.</span></span> <span> </span><span class="NLM_article-title">EGFR antagonists in cancer treatment</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">1160</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0707704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1056%2FNEJMra0707704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=18337605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1160-1174&author=F.+Ciardielloauthor=G.+Tortora&title=EGFR+antagonists+in+cancer+treatment&doi=10.1056%2FNEJMra0707704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR antagonists in cancer treatment</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1160-1174</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on epidermal growth factor receptor (EGFR) in human carcinogenesis, development of EGFR antagonists for anticancer therapy, and clin. efficacy of EGFR antagonists in human cancers.  Predicting the response to anti-EGFR drugs and future directions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNHvRENSffLVg90H21EOLACvtfcHk0lg9iqxnfbnFog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1ahsL4%253D&md5=2834999545fd643c6f727d80d357134d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0707704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0707704%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DEGFR%2520antagonists%2520in%2520cancer%2520treatment%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1160%26epage%3D1174%26doi%3D10.1056%2FNEJMra0707704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0lg9iqxnfbnFog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2787</span>– <span class="NLM_lpage">2799</span>, <span class="refDoi"> DOI: 10.1200/JCO.2003.01.504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2003.01.504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12860957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2787-2799&author=J.+Mendelsohnauthor=J.+Baselga&title=Status+of+epidermal+growth+factor+receptor+antagonists+in+the+biology+and+treatment+of+cancer&doi=10.1200%2FJCO.2003.01.504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2787-2799</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family that is abnormally activated in many epithelial tumors.  Receptor activation leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and other tumor-promoting cellular activities.  In human tumors, receptor overexpression correlates with a more aggressive clin. course.  Taken together, these observations indicate that the EGFR is a promising target for cancer therapy.  Monoclonal antibodies directed at the ligand-binding extracellular domain and low-mol. wt. inhibitors of the receptor's tyrosine kinase are currently in advanced stages of clin. development.  These agents prevent ligand-induced receptor activation and downstream signaling, which results in cell cycle arrest, promotion of apoptosis, and inhibition of angiogenesis.  They also enhance the antitumor effects of chemotherapy and radiation therapy.  In patients, anti-EGFR agents can be given safely at doses that fully inhibit receptor signaling, and single-agent activity has been obsd. against a variety of tumor types, including colon carcinoma, non-small-cell lung cancer, head and neck cancer, ovarian carcinoma, and renal cell carcinoma.  Although antitumor activity is significant, responses have been seen in only a minority of the patients treated.  In some clin. trials, anti-EGFR agents enhanced the effects of conventional chemotherapy and radiation therapy.  Ongoing research efforts are directed at the selection of patients with EGFR-dependent tumors, identification of the differences among the various classes of agents, and new clin. development strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ewrBjS4q5LVg90H21EOLACvtfcHk0lg9iqxnfbnFog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlCktbo%253D&md5=17a81c50a8787512b24865bbe50de257</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.01.504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.01.504%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DStatus%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520antagonists%2520in%2520the%2520biology%2520and%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2787%26epage%3D2799%26doi%3D10.1200%2FJCO.2003.01.504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhDCNN_l94azg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drebin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, M. I.</span></span> <span> </span><span class="NLM_article-title">ErbB receptors: from oncogenes to targeted cancer therapies</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2058</span>, <span class="refDoi"> DOI: 10.1172/JCI32278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1172%2FJCI32278" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2051-2058&author=H.+Zhangauthor=A.+Berezovauthor=Q.+Wangauthor=G.+Zhangauthor=J.+Drebinauthor=R.+Muraliauthor=M.+I.+Greene&title=ErbB+receptors%3A+from+oncogenes+to+targeted+cancer+therapies&doi=10.1172%2FJCI32278"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1172%2FJCI32278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI32278%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBerezov%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DDrebin%26aufirst%3DJ.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGreene%26aufirst%3DM.%2BI.%26atitle%3DErbB%2520receptors%253A%2520from%2520oncogenes%2520to%2520targeted%2520cancer%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D2051%26epage%3D2058%26doi%3D10.1172%2FJCI32278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khong, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fodstad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span> <span> </span><span class="NLM_article-title">Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3689</span>– <span class="NLM_lpage">3701</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fonc.2009.229" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=3689-3701&author=Y.+H.+Zhaoauthor=M.+Zhouauthor=H.+Liuauthor=Y.+Dingauthor=H.+T.+Khongauthor=D.+Yuauthor=O.+Fodstadauthor=M.+Tan&title=Upregulation+of+lactate+dehydrogenase+A+by+ErbB2+through+heat+shock+factor+1+promotes+breast+cancer+cell+glycolysis+and+growth&doi=10.1038%2Fonc.2009.229"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.229%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BH.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DKhong%26aufirst%3DH.%2BT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DFodstad%26aufirst%3DO.%26aulast%3DTan%26aufirst%3DM.%26atitle%3DUpregulation%2520of%2520lactate%2520dehydrogenase%2520A%2520by%2520ErbB2%2520through%2520heat%2520shock%2520factor%25201%2520promotes%2520breast%2520cancer%2520cell%2520glycolysis%2520and%2520growth%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3D3689%26epage%3D3701%26doi%3D10.1038%2Fonc.2009.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: gefitinib (zd1839) (iressa) tablets</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.8-4-303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1634%2Ftheoncologist.8-4-303" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=303-306&author=M.+H.+Cohenauthor=G.+A.+Williamsauthor=R.+Sridharaauthor=G.+Chenauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+gefitinib+%28zd1839%29+%28iressa%29+tablets&doi=10.1634%2Ftheoncologist.8-4-303"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.8-4-303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.8-4-303%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%2BA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520gefitinib%2520%2528zd1839%2529%2520%2528iressa%2529%2520tablets%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26spage%3D303%26epage%3D306%26doi%3D10.1634%2Ftheoncologist.8-4-303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereislova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowinsky, E. K.</span></span> <span> </span><span class="NLM_article-title">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2250</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.10.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2002.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11980995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=2240-2250&author=M.+Ransonauthor=L.+A.+Hammondauthor=D.+Ferryauthor=M.+Krisauthor=A.+Tulloauthor=P.+I.+Murrayauthor=V.+Millerauthor=S.+Averbuchauthor=J.+Ochsauthor=C.+Morrisauthor=A.+Feyereislovaauthor=H.+Swaislandauthor=E.+K.+Rowinsky&title=ZD1839%2C+a+selective+oral+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitor%2C+is+well+tolerated+and+active+in+patients+with+solid%2C+malignant+tumors%3A+results+of+a+phase+I+trial&doi=10.1200%2FJCO.2002.10.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span></div><div class="casAuthors">Ranson, Malcolm; Hammond, Lisa A.; Ferry, David; Kris, Mark; Tullo, Andrew; Murray, Philip I.; Miller, Vince; Averbuch, Steve; Ochs, Judy; Morris, Charles; Feyereislova, Andrea; Swaisland, Helen; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2240-2250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.  Patients and Methods: This was an open, phase I, escalating multiple-dose tolerability and pharmacokinetic trial.  ZD1839 was administered once daily for 14 consecutive days followed by 14 days off treatment.  Dose escalation started at 50 mg/d and continued to 925 mg or until consistent dose-limiting toxicity (DLT) was obsd.  Results: Sixty-four patients were entered at eight dose levels.  The most frequent dose-related grade 1 and 2 adverse events were an acne-like (or folliculitis) rash, nausea, and diarrhea.  Three of nine patients treated at 700 mg/d developed DLT (reversible grade 3 diarrhea); grade 3 and 4 events were uncommon.  Exposure to ZD1839 was dose proportional, and the mean terminal half-life was 48 h (range, 37 to 65).  Four of 16 patients with non-small-cell lung cancer (NSCLC) had objective partial responses obsd. from ZD1839 300 to 700 mg/d.  Overall, 16 patients remained on study for ≥ 3 mo, with seven of these patients (five with NSCLC, including three of the patients with partial response) remaining on study for ≥ 6 mo.  Conclusion: ZD1839 was well tolerated, with DLT obsd. at a dose well above that at which antitumor activity was seen.  Pharmacokinetic anal. confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation.  Phase II monotherapy and phase III combination trials in NSCLC are being conducted to investigate further the efficacy, tolerability, and optimal daily dose of ZD1839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgNViETgVS7Vg90H21EOLACvtfcHk0lhDCNN_l94azg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D&md5=b2de082b8b9292bb6cc62e4ea0a7b166</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DFerry%26aufirst%3DD.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DTullo%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DP.%2BI.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DOchs%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DZD1839%252C%2520a%2520selective%2520oral%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitor%252C%2520is%2520well%2520tolerated%2520and%2520active%2520in%2520patients%2520with%2520solid%252C%2520malignant%2520tumors%253A%2520results%2520of%2520a%2520phase%2520I%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D2240%26epage%3D2250%26doi%3D10.1200%2FJCO.2002.10.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddox, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P. M.</span></span> <span> </span><span class="NLM_article-title">Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3815</span>– <span class="NLM_lpage">3825</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.03.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2002.03.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12228201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=3815-3825&author=R.+S.+Herbstauthor=A.+M.+Maddoxauthor=M.+L.+Rothenbergauthor=E.+J.+Smallauthor=E.+H.+Rubinauthor=J.+Baselgaauthor=F.+Rojoauthor=W.+K.+Hongauthor=H.+Swaislandauthor=S.+D.+Averbuchauthor=J.+Ochsauthor=P.+M.+LoRusso&title=Selective+oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+ZD1839+is+generally+well-tolerated+and+has+activity+in+non-small-cell+lung+cancer+and+other+solid+tumors%3A+results+of+a+phase+I+trial&doi=10.1200%2FJCO.2002.03.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial</span></div><div class="casAuthors">Herbst, Roy S.; Maddox, Anne-Marie; Rothenberg, Mace L.; Small, Eric J.; Rubin, Eric H.; Baselga, Jose; Rojo, Federico; Hong, Waun Ki; Swaisland, Helen; Averbuch, Steven D.; Ochs, Judith; LoRusso, Patricia Mucci</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3815-3825</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The objective of this study was to investigate safety, tolerability, dose-related pharmacol. properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with solid tumor types known to express or highly express EGFR.  This was an open-label, phase I, dose escalation safety/tolerability trial of oral ZD1839 (150 to 1,000 mg/day), administered once daily for 28-continuous-day cycles until disease progression or undue toxicity.  Of 71 (69 assessable for safety; 58 for efficacy) patients at seven dose levels, most had non-small-cell lung (n = 39) or head and neck (n = 18) cancer, and 68 of 71 patients received prior cancer therapy (two or more regimens in 54 patients [78%]).  Diarrhea and rash, the primary dose-limiting toxicities (DLTs), occurred at 800 mg.  Frequent treatment-related grade 1/2 adverse events were diarrhea (55%), asthenia (44%), and acne-like follicular rash (46%).  At doses ≥ 800 mg, 45% of patients required dose redns.  No increased or cumulative toxicity was obsd. over 250 patient-months of exposure.  Pharmacokinetic anal. showed that steady-state occurred by day 7, inter-patient exposure was more variable than intra-patient exposure, and variability of exposure did not change with dose.  One patient experienced a partial response, but antitumor activity manifested mainly as prolonged stable disease (45% of patients ≥ 3 mo, 22% ≥ 6 mo, and 7.2% ≥ 1 yr).  No relationship between dose, response, or duration on study was obsd.  Rash and diarrhea, generally mild and tolerable at doses ≤ 600 mg/d, were DLTs at 800 mg/day (max.-tolerated dose).  Antitumor activity was obsd. at all doses.  Pharmacokinetic analyses confirmed suitability of once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsbGKNBaq-rVg90H21EOLACvtfcHk0lhJKcN_tLWLkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVyns7s%253D&md5=778f4e1e39ba26453b8243922d0a06ee</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.03.038%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DMaddox%26aufirst%3DA.%2BM.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DOchs%26aufirst%3DJ.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DSelective%2520oral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ZD1839%2520is%2520generally%2520well-tolerated%2520and%2520has%2520activity%2520in%2520non-small-cell%2520lung%2520cancer%2520and%2520other%2520solid%2520tumors%253A%2520results%2520of%2520a%2520phase%2520I%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D3815%26epage%3D3825%26doi%3D10.1200%2FJCO.2002.03.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieback, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjork, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereislova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albanell, J.</span></span> <span> </span><span class="NLM_article-title">Phase I safety, pharmacokinetic, and pharmacodynamics trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4292</span>– <span class="NLM_lpage">4302</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.03.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2002.03.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12409327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1CjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=4292-4302&author=J.+Baselgaauthor=D.+Rischinauthor=M.+Ransonauthor=H.+Calvertauthor=E.+Raymondauthor=D.+G.+Kiebackauthor=S.+B.+Kayeauthor=L.+Gianniauthor=A.+Harrisauthor=T.+Bjorkauthor=S.+D.+Averbuchauthor=A.+Feyereislovaauthor=H.+Swaislandauthor=F.+Rojoauthor=J.+Albanell&title=Phase+I+safety%2C+pharmacokinetic%2C+and+pharmacodynamics+trial+of+ZD1839%2C+a+selective+oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+in+patients+with+five+selected+solid+tumor+types&doi=10.1200%2FJCO.2002.03.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor</span></div><div class="casAuthors">Baselga, J.; Rischin, D.; Ranson, M.; Calvert, H.; Raymond, E.; Kieback, D. G.; Kaye, S. B.; Gianni, L.; Harris, A.; Bjork, T.; Averbuch, S. D.; Feyereislova, A.; Swaisland, H.; Rojo, F.; Albanell, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4292-4302</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic and pharmacodynamic effects in patients with selected solid tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdInzEw2L7DbVg90H21EOLACvtfcHk0lhJKcN_tLWLkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1CjtLo%253D&md5=bd1cf851a7ccd165f757ad5a63d0ad9a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.03.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.03.100%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DCalvert%26aufirst%3DH.%26aulast%3DRaymond%26aufirst%3DE.%26aulast%3DKieback%26aufirst%3DD.%2BG.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DBjork%26aufirst%3DT.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DAlbanell%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520safety%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamics%2520trial%2520of%2520ZD1839%252C%2520a%2520selective%2520oral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520five%2520selected%2520solid%2520tumor%2520types%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D4292%26epage%3D4302%26doi%3D10.1200%2FJCO.2002.03.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douillard, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereislova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1200/JCO.2003.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2003.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=12748244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVGqu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=2237-2246&author=M.+Fukuokaauthor=S.+Yanoauthor=G.+Giacconeauthor=T.+Tamuraauthor=K.+Nakagawaauthor=J.+Y.+Douillardauthor=Y.+Nishiwakiauthor=J.+Vansteenkisteauthor=S.+Kudohauthor=D.+Rischinauthor=R.+Eekauthor=T.+Horaiauthor=K.+Nodaauthor=I.+Takataauthor=E.+Smitauthor=S.+Averbuchauthor=A.+Macleodauthor=A.+Feyereislovaauthor=R.+P.+Dongauthor=J.+Baselga&title=Multiinstitutional+randomized+phase+II+trial+of+gefitinib+for+previously+treated+patients+with+advanced+non-small-cell+lung+cancer+%28The+IDEAL+1+Trial%29&doi=10.1200%2FJCO.2003.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Fukuoka, Masahiro; Yano, Seiji; Giaccone, Giuseppe; Tamura, Tomohide; Nakagawa, Kazuhiko; Douillard, Jean-Yves; Nishiwaki, Yutaka; Vansteenkiste, Johan; Kudoh, Shinzoh; Rischin, Danny; Eek, Richard; Horai, Takeshi; Noda, Kazumasa; Takata, Ichiro; Smit, Edbert; Averbuch, Steven; Macleod, Angela; Feyereislova, Andrea; Dong, Rui-Ping; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2237-2246</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim was to evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC).  This was a randomized, double-blind, parallel-group, multicenter phase II trial.  Two hundred ten patients with advanced NSCLC who were previously treated with one or two chemotherapy regimens (at least one contg. platinum) were randomized to receive either 250-mg or 500-mg oral doses of gefitinib once daily.  Efficacy was similar for the 250- and 500-mg/d groups.  Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 mo; and median overall survival times were 7.6 and 8.0 mo, resp.  Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.  Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.  Drug-related toxicities were more frequent in the higher-dose group.  Withdrawal due to drug related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, resp.  Gefitinib showed clin. meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.  At 250 mg/d, gefitinib had a favorable AE profile.  Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqGtTEH41T7Vg90H21EOLACvtfcHk0lhJKcN_tLWLkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVGqu7w%253D&md5=7334e656e0ee16bd6bd14b4cc0a52f93</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DYano%26aufirst%3DS.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DRischin%26aufirst%3DD.%26aulast%3DEek%26aufirst%3DR.%26aulast%3DHorai%26aufirst%3DT.%26aulast%3DNoda%26aufirst%3DK.%26aulast%3DTakata%26aufirst%3DI.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DMacleod%26aufirst%3DA.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DR.%2BP.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DMultiinstitutional%2520randomized%2520phase%2520II%2520trial%2520of%2520gefitinib%2520for%2520previously%2520treated%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528The%2520IDEAL%25201%2520Trial%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D2237%26epage%3D2246%26doi%3D10.1200%2FJCO.2003.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prager, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiridonidis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albain, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Averbuch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial</span>. <i>Jama.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">2149</span>– <span class="NLM_lpage">2158</span>, <span class="refDoi"> DOI: 10.1001/jama.290.16.2149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1001%2Fjama.290.16.2149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=14570950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2003&pages=2149-2158&author=M.+G.+Krisauthor=R.+B.+Nataleauthor=R.+S.+Herbstauthor=T.+J.+Lynchauthor=D.+Pragerauthor=C.+P.+Belaniauthor=J.+H.+Schillerauthor=K.+Kellyauthor=H.+Spiridonidisauthor=A.+Sandlerauthor=K.+S.+Albainauthor=D.+Cellaauthor=M.+K.+Wolfauthor=S.+D.+Averbuchauthor=J.+J.+Ochsauthor=A.+C.+Kay&title=Efficacy+of+gefitinib%2C+an+inhibitor+of+the+epidermal+growth+factor+receptor+tyrosine+kinase%2C+in+symptomatic+patients+with+non-small+cell+lung+cancer%3A+a+randomized+trial&doi=10.1001%2Fjama.290.16.2149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial</span></div><div class="casAuthors">Kris, Mark G.; Natale, Ronald B.; Herbst, Roy S.; Lynch, Thomas J., Jr.; Prager, Diane; Belani, Chandra P.; Schiller, Joan H.; Kelly, Karen; Spiridonidis, Harris; Sandler, Alan; Albain, Kathy S.; Cella, David; Wolf, Michael K.; Averbuch, Steven D.; Ochs, Judith J.; Kay, Andrea C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2149-2158</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined.  In preclin. testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiog. tumor shrinkages with gefitinib.  The aim was to assess differences in symptomatic and radiog. response among patients with NSCLC receiving 250-mg and 500-mg daily doses of gefitinib.  Double-blind, randomized phase 2 trial conducted from Nov. 2000 to Apr. 2001 in 30 US academic and community oncol. centers.  Patients (N=221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens.  Daily oral gefitinib, either 500 mg (administered as two 250-mg gefitinib tablets) or 250 mg (administered as one 250-mg gefitinib tablet and 1 matching placebo).  Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies).  Of 221 patients enrolled, 216 received gefitinib as randomized.  Symptoms of NSCLC improved in 43% (95% confidence interval [Cl], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% Cl, 26%-45%) of patients receiving die from 500 mg.  These benefits were obsd. within 3 wk in 75% of patients.  Partial radidiog. responses occurred in 12% (95% Cl, 6%-20%) of individuals receiving ung can 250 mg of gefitinib and in 9% (95% Cl, 4%-16%) of those receiving 500 mg.  Symptoms improved in 96% of patients with partial radiog. responses.  The overall survival at 1 yr was 25%.  There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P=.26), radiog. tumor regression (P=.51), and projected 1-yr survival (P=.54). The 500-mg dose was assocd. more frequently with transient acne-like rash (P=.04) and diarrhea (P=.006).  Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiog. tumor regressions in patients with NSCLC persisting after chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXPfLtolIxV7Vg90H21EOLACvtfcHk0lj3o2TdTw9tvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOnsbo%253D&md5=bf16f1bfa8dc61f5f6e4e9ea287c75a3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjama.290.16.2149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.290.16.2149%26sid%3Dliteratum%253Aachs%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DPrager%26aufirst%3DD.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSpiridonidis%26aufirst%3DH.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DAlbain%26aufirst%3DK.%2BS.%26aulast%3DCella%26aufirst%3DD.%26aulast%3DWolf%26aufirst%3DM.%2BK.%26aulast%3DAverbuch%26aufirst%3DS.%2BD.%26aulast%3DOchs%26aufirst%3DJ.%2BJ.%26aulast%3DKay%26aufirst%3DA.%2BC.%26atitle%3DEfficacy%2520of%2520gefitinib%252C%2520an%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%252C%2520in%2520symptomatic%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520randomized%2520trial%26jtitle%3DJama.%26date%3D2003%26volume%3D290%26spage%3D2149%26epage%3D2158%26doi%3D10.1001%2Fjama.290.16.2149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCollum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzikansky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlmann, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span> <span> </span><span class="NLM_article-title">First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic egfr mutations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2442</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.14.8494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1200%2FJCO.2007.14.8494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=18458038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2442-2449&author=L.+V.+Sequistauthor=R.+G.+Martinsauthor=D.+Spigelauthor=S.+M.+Grunbergauthor=A.+Spiraauthor=P.+A.+J%C3%A4nneauthor=V.+A.+Joshiauthor=D.+McCollumauthor=T.+L.+Evansauthor=A.+Muzikanskyauthor=G.+L.+Kuhlmannauthor=M.+Hanauthor=J.+S.+Goldbergauthor=J.+Settlemanauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=D.+A.+Haberauthor=B.+E.+Johnsonauthor=T.+J.+Lynch&title=First-line+gefitinib+in+patients+with+advanced+non%E2%80%93small-cell+lung+cancer+harboring+somatic+egfr+mutations&doi=10.1200%2FJCO.2007.14.8494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations</span></div><div class="casAuthors">Sequist, Lecia V.; Martins, Renato G.; Spigel, David; Grunberg, Steven M.; Spira, Alexander; Janne, Pasi A.; Joshi, Victoria A.; McCollum, David; Evans, Tracey L.; Muzikansky, Alona; Kuhlmann, Georgiana L.; Han, Moon; Goldberg, Jonathan S.; Settleman, Jeffrey; Iafrate, A. John; Engelman, Jeffrey A.; Haber, Daniel A.; Johnson, Bruce E.; Lynch, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2442-2449</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs).  The multicenter iTARGET trial prospectively examd. first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms.  Patients and Methods: Chemotherapy-naive patients with advanced NSCLC with ≥ 1 clin. characteristic assocd. with EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21.  Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity.  The primary outcome was response rate.  Results: Ninety-eight patients underwent EGFR screening and mutations were detected in 34 (35%).  EGFR mutations were primarily exon 19 deletions (53%) and L858R (26%) though 21 % of mutation-pos. cases had less common subtypes including exon 20 insertions, T790M/L858R, G719A, and L861Q.  Thirty-one patients received gefitinib.  The response rate was 55% (95% Cl, 33 to 70) and median progression-free survival was 9.2 mo (95% Cl, 6.2 to 11.8).  Therapy was well tolerated; 13% of patients had grade 3 toxicities including one grade 3 pneumonitis.  Two patients with classic activating mutations exhibited de novo gefitinib resistance and had concurrent genetic anomalies usually assocd. with acquired TKI resistance, specifically the T790M EGFR mutation and MET amplification.  Conclusion: First-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clin. outcomes with good tolerance.  This strategy should be compared with combination chemotherapy, the current std. of care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiwzD0aI4fP7Vg90H21EOLACvtfcHk0lj3o2TdTw9tvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVKhtbk%253D&md5=70e6f1208215e4f3ea141216cd80688d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.8494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.8494%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DMartins%26aufirst%3DR.%2BG.%26aulast%3DSpigel%26aufirst%3DD.%26aulast%3DGrunberg%26aufirst%3DS.%2BM.%26aulast%3DSpira%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DJoshi%26aufirst%3DV.%2BA.%26aulast%3DMcCollum%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DT.%2BL.%26aulast%3DMuzikansky%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DG.%2BL.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DGoldberg%26aufirst%3DJ.%2BS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26atitle%3DFirst-line%2520gefitinib%2520in%2520patients%2520with%2520advanced%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520harboring%2520somatic%2520egfr%2520mutations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2442%26epage%3D2449%26doi%3D10.1200%2FJCO.2007.14.8494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+progress+of+small-molecule+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+C797S+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0ljkxth6klL73g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520of%2520small-molecule%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520C797S%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6580</span>– <span class="NLM_lpage">6594</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6580-6594&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+perspectives+on+the+development+of+small-molecule+EGFR+inhibitors+against+T790M-mediated+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Song, Zhendong; Ge, Yang; Wang, Changyuan; Huang, Shanshan; Shu, Xiaohong; Liu, Kexin; Zhou, Youwen; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6580-6594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the development of drug-resistance mutations, particularly the "gatekeeper" threonine790-to-methionine790 (T790M) mutation in the ATP-binding pocket of the epidermal growth factor receptor (EGFR), the current generation of EGFR tyrosine kinase inhibitors lost their clin. efficacy.  Recently, a large no. of small-mol. inhibitors with striking inhibitory potency against EGFR mutants with the T790M change have been identified.  In particular, the inhibitors rociletinib and osimertinib, which can selectively target both sensitizing mutations and the T790M resistance while sparing the wild-type (WT) form of the receptor, have been designated as breakthrough therapies in the treatment of mutant non-small-cell lung cancer (NSCLC) by the U.S.  FDA in 2014.  We hope that this review on the small-mol. EGFR T790M inhibitors, along with their discovery strategies, will assist in the design of future T790M-contg. EGFR inhibitors with high levels of selectivity over WT EGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEcAydAIVpNbVg90H21EOLACvtfcHk0ljkxth6klL73g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D&md5=2112d52e116494f61b1c8bd3f8f383d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520perspectives%2520on%2520the%2520development%2520of%2520small-molecule%2520EGFR%2520inhibitors%2520against%2520T790M-mediated%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6580%26epage%3D6594%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulake, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Optimization of gefitinib analogues with potent anticancer activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5247</span>– <span class="NLM_lpage">5250</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.09.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2Fj.bmcl.2014.09.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=5247-5250&author=K.+H.+Yinauthor=Y.+H.+Hsiehauthor=R.+S.+Sulakeauthor=S.+P.+Wangauthor=J.+I.+Chaoauthor=C.+Chen&title=Optimization+of+gefitinib+analogues+with+potent+anticancer+activity&doi=10.1016%2Fj.bmcl.2014.09.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.09.056%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DK.%2BH.%26aulast%3DHsieh%26aufirst%3DY.%2BH.%26aulast%3DSulake%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DS.%2BP.%26aulast%3DChao%26aufirst%3DJ.%2BI.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DOptimization%2520of%2520gefitinib%2520analogues%2520with%2520potent%2520anticancer%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D5247%26epage%3D5250%26doi%3D10.1016%2Fj.bmcl.2014.09.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Q.</span></span> <span> </span><span class="NLM_article-title">Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3221</span>– <span class="NLM_lpage">3227</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.04.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2Fj.bmc.2015.04.065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3221-3227&author=S.+N.+Liauthor=Y.+Y.+Xuauthor=J.+Y.+Gaoauthor=H.+R.+Yinauthor=S.+L.+Zhangauthor=H.+Q.+Li&title=Combination+of+4-anilinoquinazoline+and+rhodanine+as+novel+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors&doi=10.1016%2Fj.bmc.2015.04.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.04.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.04.065%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%2BN.%26aulast%3DXu%26aufirst%3DY.%2BY.%26aulast%3DGao%26aufirst%3DJ.%2BY.%26aulast%3DYin%26aufirst%3DH.%2BR.%26aulast%3DZhang%26aufirst%3DS.%2BL.%26aulast%3DLi%26aufirst%3DH.%2BQ.%26atitle%3DCombination%2520of%25204-anilinoquinazoline%2520and%2520rhodanine%2520as%2520novel%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D3221%26epage%3D3227%26doi%3D10.1016%2Fj.bmc.2015.04.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamed, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, A. E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abadi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, M.</span></span> <span> </span><span class="NLM_article-title">6-aryl and heterocycle quinazoline derivatives as potent egfr inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1504</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fcmdc.201300147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=23847159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1495-1504&author=M.+M.+Hamedauthor=A.+E.+E.+Daauthor=A.+B.+Keetonauthor=G.+A.+Piazzaauthor=A.+H.+Abadiauthor=R.+W.+Hartmannauthor=M.+Engel&title=6-aryl+and+heterocycle+quinazoline+derivatives+as+potent+egfr+inhibitors+with+improved+activity+toward+gefitinib-sensitive+and+-resistant+tumor+cell+lines&doi=10.1002%2Fcmdc.201300147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib-Sensitive and -Resistant Tumor Cell Lines</span></div><div class="casAuthors">Hamed, Mostafa M.; Abou El Ella, Dalal A.; Keeton, Adam B.; Piazza, Gary A.; Abadi, Ashraf H.; Hartmann, Rolf W.; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1495-1504</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Anilinoquinazolinyl benzaldimines I [R = R1CH:N; R1 = 4-HOC6H4, 2,4-(HO)2C6H3, 3-O2NC6H4, 4-O2NC6H4, 2-MeOC6H4], thioureas I [R = R1NHC(:S)NH; R1 = PhCH2, 2-(4-morpholinyl)ethyl], aminoacetamides and aminopropanamides II [R = R1NHCH2CONH, R1NHCH2CH2CONH; R1 = PhCH2, 4-(2-thiazolylaminosulfonyl)phenyl], and amides [R = R1CONH; R1 = 4-H2NC6H4, 4-NCC6H4, 4-MeCONHC6H4, 4-O2NC6H4, 3,5-(O2N)2C6H3, 4-MeOC6H4, 3,4-(MeO)2C6H3, 4-morpholinyl, 2-furyl, 3-pyridinyl, 4-pyridinyl] were prepd. as inhibitors of wild-type and mutant epidermal growth factor receptor (EGFR) for potential use as antitumor agents.  Most of the compds. inhibited wild-type EGFR with IC50 values of 4-62 nM; I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] also retained significant activity toward the gefitinib-insensitive EGFRT790M/L858R mutant, displaying up to 24-fold greater potency than gefitinib.  The inhibition of the growth of cancer cells with wild-type and mutant EGFR was detd.; I [R = BnNHC(:S)NH, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] inhibited cancer cell growth more effectively than the std. gefitinib.  Mol. docking calcns. of I [R = BnNHC(:S)NH, 4-morpholinylethylaminothiocarbonylamino, R1NHCH2CH2CONH; R1 = 4-(2-thiazolylaminosulfonyl)phenyl] in double mutant EGFR and of I (R = PhCH2NHCH2CONH, 2-furylcarbonylamino) in wild-type EGFR were performed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9J8DhyAlHb7Vg90H21EOLACvtfcHk0liXJrMZOh_Puw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykurzF&md5=c951d913a38a5062783da74c4cf6afef</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300147%26sid%3Dliteratum%253Aachs%26aulast%3DHamed%26aufirst%3DM.%2BM.%26aulast%3DDa%26aufirst%3DA.%2BE.%2BE.%26aulast%3DKeeton%26aufirst%3DA.%2BB.%26aulast%3DPiazza%26aufirst%3DG.%2BA.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3D6-aryl%2520and%2520heterocycle%2520quinazoline%2520derivatives%2520as%2520potent%2520egfr%2520inhibitors%2520with%2520improved%2520activity%2520toward%2520gefitinib-sensitive%2520and%2520-resistant%2520tumor%2520cell%2520lines%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1495%26epage%3D1504%26doi%3D10.1002%2Fcmdc.201300147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4738</span>– <span class="NLM_lpage">4748</span>, <span class="refDoi"> DOI: 10.1021/jm400463q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400463q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4738-4748&author=C.+Hanauthor=Z.+Huangauthor=C.+Zhengauthor=L.+Wanauthor=L.+Zhangauthor=S.+Pengauthor=K.+Dingauthor=H.+Jiauthor=J.+Tianauthor=Y.+Zhang&title=Novel+hybrids+of+%28phenylsulfonyl%29furoxan+and+anilinopyrimidine+as+potent+and+selective+epidermal+growth+factor+receptor+inhibitors+for+intervention+of+non-small-cell+lung+cancer&doi=10.1021%2Fjm400463q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400463q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400463q%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DNovel%2520hybrids%2520of%2520%2528phenylsulfonyl%2529furoxan%2520and%2520anilinopyrimidine%2520as%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520for%2520intervention%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4738%26epage%3D4748%26doi%3D10.1021%2Fjm400463q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, R. B.</span></span> <span> </span><span class="NLM_article-title">Anion receptor molecules. synthesis and anion-binding properties of polyammonium macrocycles</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1282</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1021/ja00395a077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00395a077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADyaL3MXhtl2ktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1981&pages=1282-1283&author=B.+Dietrichauthor=M.+W.+Hosseiniauthor=J.+M.+Lehnauthor=R.+B.+Sessions&title=Anion+receptor+molecules.+synthesis+and+anion-binding+properties+of+polyammonium+macrocycles&doi=10.1021%2Fja00395a077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Anion receptor molecules.  Synthesis and anion-binding properties of polyammonium macrocycles</span></div><div class="casAuthors">Dietrich, B.; Hosseini, M. W.; Lehn, J. M.; Sessions, R. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1282-3</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The polyaza-macrocycles I (n = 3,5) and II were prepd.  Their protonated forms bind a variety of mol. anions, displaying high stability and characteristic selectivity sequences.  Electrostatic and geometric effects play a role in these anion binding features.  Particularly stable complexes are obtained with complex anions like Fe(CN)64- and Co(CN)63-.  AMP, ADP and ATP are also strongly bound forming either 1:1 or 2:1 complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA43rQXqMA2LVg90H21EOLACvtfcHk0liXJrMZOh_Puw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhtl2ktbw%253D&md5=f57d3bd76d90824b48f6dbe89cd96f25</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00395a077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00395a077%26sid%3Dliteratum%253Aachs%26aulast%3DDietrich%26aufirst%3DB.%26aulast%3DHosseini%26aufirst%3DM.%2BW.%26aulast%3DLehn%26aufirst%3DJ.%2BM.%26aulast%3DSessions%26aufirst%3DR.%2BB.%26atitle%3DAnion%2520receptor%2520molecules.%2520synthesis%2520and%2520anion-binding%2520properties%2520of%2520polyammonium%2520macrocycles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1981%26volume%3D103%26spage%3D1282%26epage%3D1283%26doi%3D10.1021%2Fja00395a077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIver, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of macrocyclic pyrimidines as MerTK-specific inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fcmdc.201600589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=28032464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=207-213&author=A.+L.+McIverauthor=W.+Zhangauthor=Q.+Liuauthor=X.+Jiangauthor=M.+A.+Stashkoauthor=J.+Nicholsauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=M.+Machiusauthor=D.+DeRyckereauthor=E.+Woodauthor=D.+K.+Grahamauthor=H.+S.+Earpauthor=D.+Kireevauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+macrocyclic+pyrimidines+as+MerTK-specific+inhibitors&doi=10.1002%2Fcmdc.201600589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors</span></div><div class="casAuthors">McIver, Andrew L.; Zhang, Weihe; Liu, Qingyang; Jiang, Xinpeng; Stashko, Michael A.; Nichols, James; Miley, Michael J.; Norris-Drouin, Jacqueline; Machius, Mischa; DeRyckere, Deborah; Wood, Edgar; Graham, Douglas K.; Earp, H. Shelton; Kireev, Dmitri; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocycles have attracted significant attention in drug discovery recently.  In fact, a few de novo designed macrocyclic kinase inhibitors are currently in clin. trials with good potency and selectivity for their intended target.  In this study, we successfully engaged a structure-based drug design approach to discover macrocyclic pyrimidines as potent Mer tyrosine kinase (MerTK)-specific inhibitors.  An ELISA (ELISA) in 384-well format was employed to evaluate the inhibitory activity of macrocycles in a cell-based assay assessing tyrosine phosphorylation of MerTK.  Through structure-activity relationship (SAR) studies, analog 11 [UNC2541; (S)-7-amino-N-(4-fluorobenzyl)-8-oxo-2,9,16-triaza-1(2,4)-pyrimidinacyclohexadecaphane-1-carboxamide] was identified as a potent and MerTK-specific inhibitor that exhibits sub-micromolar inhibitory activity in the cell-based ELISA.  In addn., an X-ray structure of MerTK protein in complex with 11 was resolved to show that these macrocycles bind in the MerTK ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOfJewlO7H8bVg90H21EOLACvtfcHk0liXJrMZOh_Puw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D&md5=09a963efb36d595e3f4a301676b685f1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600589%26sid%3Dliteratum%253Aachs%26aulast%3DMcIver%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520macrocyclic%2520pyrimidines%2520as%2520MerTK-specific%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D207%26epage%3D213%26doi%3D10.1002%2Fcmdc.201600589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel macrocyclic Mer tyrosine kinase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1044</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWjurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1044-1049&author=X.+Wangauthor=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=J.+Nicholsauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=Z.+Chenauthor=M.+Machiusauthor=D.+DeRyckereauthor=E.+Woodauthor=D.+K.+Grahamauthor=H.+S.+Earpauthor=D.+Kireevauthor=S.+V.+Frye&title=Design+and+synthesis+of+novel+macrocyclic+Mer+tyrosine+kinase+inhibitors&doi=10.1021%2Facsmedchemlett.6b00221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Wang, Xiaodong; Liu, Jing; Zhang, Weihe; Stashko, Michael A.; Nichols, James; Miley, Michael J.; Norris-Drouin, Jacqueline; Chen, Zhilong; Machius, Mischa; DeRyckere, Deborah; Wood, Edgar; Graham, Douglas K.; Earp, H. Shelton; Kireev, Dmitri; Frye, Stephen V.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1044-1049</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mer tyrosine kinase (MerTK) is aberrantly elevated in various tumor cells and has a normal anti-inflammatory role in the innate immune system.  Inhibition of MerTK may provide dual effects against these MerTK-expressing tumors through reducing cancer cell survival and redirecting the innate immune response.  Recently, the authors have designed novel and potent macrocyclic pyrrolopyrimidines as MerTK inhibitors using a structure-based approach.  The most active macrocycles had an EC50 below 40 nM in a cell-based MerTK phosphor-protein ELISA assay.  The x-ray structure ofa macrocyclic analog complexed with MerTK was also resolved and demonstrated macrocycles binding in the ATP binding pocket of the MerTK protein as anticipated.  In addn., the lead compd. I (UNC3133) had a 1.6 h half-life and 16% oral bioavailability in a mouse PK study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprnta6NWkqnrVg90H21EOLACvtfcHk0lhq-3FYf1nudQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWjurzM&md5=159daa2a423f50f99f0f625fa235435e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00221%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520macrocyclic%2520Mer%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1044%26epage%3D1049%26doi%3D10.1021%2Facsmedchemlett.6b00221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichosyt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dydio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, J.</span></span> <span> </span><span class="NLM_article-title">Azulene-based macrocyclic receptors for recognition and sensing of phosphate anions</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">17673</span>– <span class="NLM_lpage">17680</span>, <span class="refDoi"> DOI: 10.1002/chem.201603555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fchem.201603555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=27778403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCgtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=17673-17680&author=D.+Lichosytauthor=P.+Dydioauthor=J.+Jurczak&title=Azulene-based+macrocyclic+receptors+for+recognition+and+sensing+of+phosphate+anions&doi=10.1002%2Fchem.201603555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Azulene-based macrocyclic receptors for recognition and sensing of phosphate anions</span></div><div class="casAuthors">Lichosyt, Dawid; Dydio, Pawel; Jurczak, Janusz</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17673-17680</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the synthesis and detailed studies of the anion-binding properties of two 20-membered macrocyclic tetramide receptors: one sym., contg. two identical azulene-based bisamide units, the other a hybrid, contg. a dipicolinic bisamide unit and an azulene-based bisamide unit.  Anal. of the crystal structures of the macrocyclic receptors revealed their preference for adopting similar well-preorganized bent-sheet conformations, both as free receptors and in their complexes with anions.  Studies of the optical properties of both receptors revealed abilities to selectively sense phosphate anions (H2PO4-, HP2O73-), allowing for naked-eye detection of the presence of these guests in DMSO.  Binding studies in soln. confirmed that the receptors bind strongly to a series of anions even in highly demanding media, such as mixts. of DMSO with water or with methanol.  Comparison of the anion affinity of linear analogs with that of the macrocyclic receptors evidenced the importance of macrocyclic topol.  Quant. anal. revealed that the macrocyclic receptors are selective for H2PO4- over other anions.  The affinity to H2PO4- seen for the sym. receptor, contg. two azulene-based subunits, is much higher than for the hybrid macrocycle contg. both the azulene-based and pyridine-derived subunits.  This highlights that the azulene-based building block serves efficiently as both a binding site and a structure-preorganizing motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHVTTJ1I1j9rVg90H21EOLACvtfcHk0lhq-3FYf1nudQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCgtL3P&md5=f5755698ed4df1bb15ee1cb41826b4e4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fchem.201603555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201603555%26sid%3Dliteratum%253Aachs%26aulast%3DLichosyt%26aufirst%3DD.%26aulast%3DDydio%26aufirst%3DP.%26aulast%3DJurczak%26aufirst%3DJ.%26atitle%3DAzulene-based%2520macrocyclic%2520receptors%2520for%2520recognition%2520and%2520sensing%2520of%2520phosphate%2520anions%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26spage%3D17673%26epage%3D17680%26doi%3D10.1002%2Fchem.201603555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddy, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span> <span> </span><span class="NLM_article-title">Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=271-277&author=X.+Luauthor=J.+Erringtonauthor=V.+J.+Chenauthor=N.+J.+Curtinauthor=A.+V.+Boddyauthor=D.+R.+Newell&title=Cellular+ATP+depletion+by+LY309887+as+a+predictor+of+growth+inhibition+in+human+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DErrington%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DV.%2BJ.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DBoddy%26aufirst%3DA.%2BV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26atitle%3DCellular%2520ATP%2520depletion%2520by%2520LY309887%2520as%2520a%2520predictor%2520of%2520growth%2520inhibition%2520in%2520human%2520tumor%2520cell%2520lines%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D6%26spage%3D271%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batrakova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alakhov, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabanov, A. V.</span></span> <span> </span><span class="NLM_article-title">Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1987</span>– <span class="NLM_lpage">1997</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2001.2165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1054%2Fbjoc.2001.2165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11747344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVWnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=1987-1997&author=E.+V.+Batrakovaauthor=S.+Liauthor=W.+F.+Elmquistauthor=D.+W.+Millerauthor=V.+Y.+Alakhovauthor=A.+V.+Kabanov&title=Mechanism+of+sensitization+of+MDR+cancer+cells+by+pluronic+block+copolymers%3A+selective+energy+depletion&doi=10.1054%2Fbjoc.2001.2165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: Selective energy depletion</span></div><div class="casAuthors">Batrakova, E. V.; Li, S.; Elmquist, W. F.; Miller, D. W.; Alakhov, V. Y.; Kabanov, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1987-1997</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">This paper, for the first time, demonstrates that exposure of cells to the poly(ethylene oxide)-poly(propylene oxide) block copolymer, Pluronic P85, results in a substantial decrease in ATP levels selectively in MDR cells.  Cells expressing high levels of functional P-glycoprotein (MCF-7/ADR, KBv; LLC-MDR1; Caco-2, bovine brain microvessel endothelial cells [BBMECs]) are highly responsive to Pluronic treatment, while cells with low levels of P-glycoprotein expression (MCF-7, KB, LLC-PK1, human umbilical vein endothelial cells [HUVECs] C2C12 myoblasts) are much less responsive to such treatment.  Cytotoxicity studies suggest that Pluronic acts as a chemosensitizer and potentiates cytotoxic effects of doxorubicin in MDR cells.  The ability of Pluronic to inhibit P-glycoprotein and sensitize MDR cells appears to be a result of ATP depletion.  Because many mechanisms of drug resistance are energy dependent, a successful strategy for treating MDR cancer could be based on selective energy depletion in MDR cells.  Therefore, the finding of the energy-depleting effects of Pluronic P85, in combination with its sensitization effects is of considerable theor. and practical significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLFYe0vqJcLVg90H21EOLACvtfcHk0lhq-3FYf1nudQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVWnu7c%253D&md5=ac4e38757f1fe3c6bc4b9ab93ddfdf39</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.2165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.2165%26sid%3Dliteratum%253Aachs%26aulast%3DBatrakova%26aufirst%3DE.%2BV.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26aulast%3DMiller%26aufirst%3DD.%2BW.%26aulast%3DAlakhov%26aufirst%3DV.%2BY.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26atitle%3DMechanism%2520of%2520sensitization%2520of%2520MDR%2520cancer%2520cells%2520by%2520pluronic%2520block%2520copolymers%253A%2520selective%2520energy%2520depletion%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D1987%26epage%3D1997%26doi%3D10.1054%2Fbjoc.2001.2165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frydman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drandarov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesnov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guggisberg, A.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic polyamines deplete cellular ATP levels and inhibit cell growth in human prostate cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1059</span>, <span class="refDoi"> DOI: 10.1021/jm030437s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030437s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1051-1059&author=B.+Frydmanauthor=S.+Bhattacharyaauthor=A.+Sarkarauthor=K.+Drandarovauthor=S.+Chesnovauthor=A.+Guggisberg&title=Macrocyclic+polyamines+deplete+cellular+ATP+levels+and+inhibit+cell+growth+in+human+prostate+cancer+cells&doi=10.1021%2Fjm030437s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm030437s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030437s%26sid%3Dliteratum%253Aachs%26aulast%3DFrydman%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DSarkar%26aufirst%3DA.%26aulast%3DDrandarov%26aufirst%3DK.%26aulast%3DChesnov%26aufirst%3DS.%26aulast%3DGuggisberg%26aufirst%3DA.%26atitle%3DMacrocyclic%2520polyamines%2520deplete%2520cellular%2520ATP%2520levels%2520and%2520inhibit%2520cell%2520growth%2520in%2520human%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1051%26epage%3D1059%26doi%3D10.1021%2Fjm030437s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span> <span> </span><span class="NLM_article-title">Cyclam, complexes and their applications in medicine</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1039/b313659k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1039%2Fb313659k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2004&pages=246-266&author=X.+Liangauthor=P.+J.+Sadler&title=Cyclam%2C+complexes+and+their+applications+in+medicine&doi=10.1039%2Fb313659k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2Fb313659k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb313659k%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DCyclam%252C%2520complexes%2520and%2520their%2520applications%2520in%2520medicine%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2004%26volume%3D35%26spage%3D246%26epage%3D266%26doi%3D10.1039%2Fb313659k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Sayed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licchelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Manez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancenon, F.</span></span> <span> </span><span class="NLM_article-title">Anions as triggers in controlled release protocols from mesoporous silica nanoparticles functionalized with macrocyclic copper(II) complexes</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">13935</span>– <span class="NLM_lpage">13945</span>, <span class="refDoi"> DOI: 10.1002/chem.201601024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1002%2Fchem.201601024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=27530898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOgu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=13935-13945&author=S.+El%0ASayedauthor=M.+Milaniauthor=C.+Milaneseauthor=M.+Licchelliauthor=R.+Martinez-Manezauthor=F.+Sancenon&title=Anions+as+triggers+in+controlled+release+protocols+from+mesoporous+silica+nanoparticles+functionalized+with+macrocyclic+copper%28II%29+complexes&doi=10.1002%2Fchem.201601024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Anions as Triggers in Controlled Release Protocols from Mesoporous Silica Nanoparticles Functionalized with Macrocyclic Copper(II) Complexes</span></div><div class="casAuthors">El Sayed, Sameh; Milani, Michele; Milanese, Chiara; Licchelli, Maurizio; Martinez-Manez, Ramon; Sancenon, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">13935-13945</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three different mesoporous silica nano-sized materials (SC1, SC2, and SC3), loaded with [Ru(bipy)3]2+ dye (bipy=bipyridine) and functionalized on the external surface with three macrocyclic copper(II) complexes (C1, C2, and C3), were synthesized and characterized.  When SC1, SC2, and SC3 were suspended in water, the entrapped [Ru(bipy)3]2+ dye was free to diffuse from the inner pores to the soln.  However, addn. of anions induced certain degrees of pore blockage, with subsequent dye release inhibition.  Small monovalent and divalent anions were unable to induce complete pore blockage, whereas bulky and highly charged anions induced marked redns. in [Ru(bipy)3]2+ delivery.  The best [Ru(bipy)3]2+ delivery inhibitors were ATP and hexametaphosphate anions.  Inhibition was ascribed to the interaction of the anions with the grafted CuII complexes on the surface of the SC1, SC2, and SC3 supports.  The hexametaphosphate anion was selected to prep. two capped materials (SC1-mPh and SC3-mPh).  Studies of the [Ru(bipy)3]2+ dye release from solids SC1-mPh and SC3-mPh alone and in the presence of a collection of selected anions (HS-, F-, Br-, Cl-, I-, CN-, HPO42-, AcO-, citrate, NO32-, HCO3-, SO42-, and S2O82-), amino acids (alanine and histidine), thiol-contg. biomols. (cysteine, methylcysteine, homocysteine, and glutathione (GSH)), and oxidants (H2O2) were performed.  None of the chems. tested, except hydrogen sulfide, was able to induce remarkable cargo delivery in both solids.  The obsd. dye release was ascribed to a demetalation reaction of the C1 and C3 complexes induced by the hydrogen sulfide anion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWlD9MZjQ2p7Vg90H21EOLACvtfcHk0ljJaEUf7KpaXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOgu7fP&md5=6fa5c0c3399370dfd3537273ac16f552</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fchem.201601024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201601024%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BSayed%26aufirst%3DS.%26aulast%3DMilani%26aufirst%3DM.%26aulast%3DMilanese%26aufirst%3DC.%26aulast%3DLicchelli%26aufirst%3DM.%26aulast%3DMartinez-Manez%26aufirst%3DR.%26aulast%3DSancenon%26aufirst%3DF.%26atitle%3DAnions%2520as%2520triggers%2520in%2520controlled%2520release%2520protocols%2520from%2520mesoporous%2520silica%2520nanoparticles%2520functionalized%2520with%2520macrocyclic%2520copper%2528II%2529%2520complexes%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26spage%3D13935%26epage%3D13945%26doi%3D10.1002%2Fchem.201601024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deodato, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfilippo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arezzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posteraro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeputte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanglard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docquier, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanguinetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span> <span> </span><span class="NLM_article-title">Biological characterization and in vivo assessment of the activity of a new synthetic macrocyclic antifungal compound</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3854</span>– <span class="NLM_lpage">3866</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3854-3866&author=D.+Deodatoauthor=G.+Maccariauthor=F.+De+Lucaauthor=S.+Sanfilippoauthor=A.+Casianauthor=R.+Martiniauthor=S.+D%E2%80%99Arezzoauthor=C.+Bonchiauthor=F.+Bugliauthor=B.+Posteraroauthor=P.+Vandeputteauthor=D.+Sanglardauthor=J.-D.+Docquierauthor=M.+Sanguinettiauthor=P.+Viscaauthor=M.+Botta&title=Biological+characterization+and+in+vivo+assessment+of+the+activity+of+a+new+synthetic+macrocyclic+antifungal+compound&doi=10.1021%2Facs.jmedchem.6b00018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00018%26sid%3Dliteratum%253Aachs%26aulast%3DDeodato%26aufirst%3DD.%26aulast%3DMaccari%26aufirst%3DG.%26aulast%3DDe%2BLuca%26aufirst%3DF.%26aulast%3DSanfilippo%26aufirst%3DS.%26aulast%3DCasian%26aufirst%3DA.%26aulast%3DMartini%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Arezzo%26aufirst%3DS.%26aulast%3DBonchi%26aufirst%3DC.%26aulast%3DBugli%26aufirst%3DF.%26aulast%3DPosteraro%26aufirst%3DB.%26aulast%3DVandeputte%26aufirst%3DP.%26aulast%3DSanglard%26aufirst%3DD.%26aulast%3DDocquier%26aufirst%3DJ.-D.%26aulast%3DSanguinetti%26aufirst%3DM.%26aulast%3DVisca%26aufirst%3DP.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DBiological%2520characterization%2520and%2520in%2520vivo%2520assessment%2520of%2520the%2520activity%2520of%2520a%2520new%2520synthetic%2520macrocyclic%2520antifungal%2520compound%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3854%26epage%3D3866%26doi%3D10.1021%2Facs.jmedchem.6b00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggiora, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, M. P.</span></span> <span> </span><span class="NLM_article-title">Supramolecular catalysis in the hydrolysis of ATP facilitated by macrocyclic polyamines: mechanistic studies</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1021/ja00236a036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00236a036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=537-544&author=M.+W.+Hosseiniauthor=J.+M.+Lehnauthor=L.+Maggioraauthor=K.+B.+Mertesauthor=M.+P.+Mertes&title=Supramolecular+catalysis+in+the+hydrolysis+of+ATP+facilitated+by+macrocyclic+polyamines%3A+mechanistic+studies&doi=10.1021%2Fja00236a036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fja00236a036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00236a036%26sid%3Dliteratum%253Aachs%26aulast%3DHosseini%26aufirst%3DM.%2BW.%26aulast%3DLehn%26aufirst%3DJ.%2BM.%26aulast%3DMaggiora%26aufirst%3DL.%26aulast%3DMertes%26aufirst%3DK.%2BB.%26aulast%3DMertes%26aufirst%3DM.%2BP.%26atitle%3DSupramolecular%2520catalysis%2520in%2520the%2520hydrolysis%2520of%2520ATP%2520facilitated%2520by%2520macrocyclic%2520polyamines%253A%2520mechanistic%2520studies%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D537%26epage%3D544%26doi%3D10.1021%2Fja00236a036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, K. B.</span></span> <span> </span><span class="NLM_article-title">Polyammonium macrocycles as catalysts for phosphoryl transfer: the evolution of an enzyme mimic</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1021/ar00180a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00180a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1990&pages=413-418&author=M.+P.+Mertesauthor=K.+B.+Mertes&title=Polyammonium+macrocycles+as+catalysts+for+phosphoryl+transfer%3A+the+evolution+of+an+enzyme+mimic&doi=10.1021%2Far00180a003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Far00180a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00180a003%26sid%3Dliteratum%253Aachs%26aulast%3DMertes%26aufirst%3DM.%2BP.%26aulast%3DMertes%26aufirst%3DK.%2BB.%26atitle%3DPolyammonium%2520macrocycles%2520as%2520catalysts%2520for%2520phosphoryl%2520transfer%253A%2520the%2520evolution%2520of%2520an%2520enzyme%2520mimic%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1990%26volume%3D23%26spage%3D413%26epage%3D418%26doi%3D10.1021%2Far00180a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bencini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Espana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deffo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takusagawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertes, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, P.</span></span> <span> </span><span class="NLM_article-title">Potential ATPase mimics by polyammonium macrocycles: criteria for catalytic activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/0045-2068(92)90022-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1016%2F0045-2068%2892%2990022-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADyaK38XltVOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1992&pages=8-29&author=A.+Benciniauthor=A.+Bianchiauthor=E.+Garcia-Espanaauthor=E.+C.+Scottauthor=L.+Moralesauthor=B.+Wangauthor=T.+Deffoauthor=F.+Takusagawaauthor=M.+P.+Mertesauthor=K.+B.+Mertesauthor=P.+Paoletti&title=Potential+ATPase+mimics+by+polyammonium+macrocycles%3A+criteria+for+catalytic+activity&doi=10.1016%2F0045-2068%2892%2990022-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Potential ATPase mimics by polyammonium macrocycles:  criteria for catalytic activity</span></div><div class="casAuthors">Bencini, Andrea; Bianchi, Antonio; Garcia-Espana, Enrique; Scott, Edmund C.; Morales, Luis; Wang, Binghe; Deffo, Tamboue; Takusagawa, Fusao; Mertes, Mathias P.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-29</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    </div><div class="casAbstract">A series of polyammonium macrocycles, ranging in size from the 18-membered ring [18]aneN6 to the 36-membered [36]aneN12 were examd. as potential ATPase mimics.  The rates of hydrolysis of ATP were followed at pH 3.0 and 7.0 using 31P NMR and HPLC techniques.  Stability consts. as a function of degree of protonation, distribution curves for the ligands as a function of pH, and distribution curves for the mixed species of nucleotides, inorg. phosphate, and macrocycle were also detd.  All of the macrocycles catalyzed the hydrolysis of ATP to some extent compared to noncatalyzed hydrolysis.  A crit. dependence on macrocycle ring size was obsd., with [21]aneN- being the best catalyst at both pH values.  Stability consts. of the complexes formed between the phosphate species and macrocycle increased with increasing degree of protonation and decreasing ring size.  The trend in stability consts. for phosphate species was found to be PO43- > P2O74- > ATP4- > ADP3- > AMP2- for a given degree of protonation.  The crystal structure of tetraprotonated [21]laneN7 was detd.  The compd. N-C14Cl4H41O crystd. in monoclinic space group P21 (#4) with unit cell dimensions a = 7.472, b = 19.480, c = 8.3638 Å, β = 100.38, and V = 1197.4 Å3.  The structure was solved by direct methods and refined using full-matrix least-squares techniques to give a final R = 0.041 and Rw = 0.055.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Y3QK4qh_27Vg90H21EOLACvtfcHk0lhrQtfetQg6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVOisrk%253D&md5=84db38d35a748786853e5029917fda2a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0045-2068%2892%2990022-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0045-2068%252892%252990022-U%26sid%3Dliteratum%253Aachs%26aulast%3DBencini%26aufirst%3DA.%26aulast%3DBianchi%26aufirst%3DA.%26aulast%3DGarcia-Espana%26aufirst%3DE.%26aulast%3DScott%26aufirst%3DE.%2BC.%26aulast%3DMorales%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DDeffo%26aufirst%3DT.%26aulast%3DTakusagawa%26aufirst%3DF.%26aulast%3DMertes%26aufirst%3DM.%2BP.%26aulast%3DMertes%26aufirst%3DK.%2BB.%26aulast%3DPaoletti%26aufirst%3DP.%26atitle%3DPotential%2520ATPase%2520mimics%2520by%2520polyammonium%2520macrocycles%253A%2520criteria%2520for%2520catalytic%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D1992%26volume%3D20%26spage%3D8%26epage%3D29%26doi%3D10.1016%2F0045-2068%2892%2990022-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER2</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1114</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2008-0816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1634%2Ftheoncologist.2008-0816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=1114-1119&author=Q.+Ryanauthor=A.+Ibrahimauthor=M.+H.+Cohenauthor=J.+Johnsonauthor=C.+W.+Koauthor=R.+Sridharaauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+lapatinib+in+combination+with+capecitabine+for+previously+treated+metastatic+breast+cancer+that+overexpresses+HER2&doi=10.1634%2Ftheoncologist.2008-0816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2008-0816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2008-0816%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DQ.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DKo%26aufirst%3DC.%2BW.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520lapatinib%2520in%2520combination%2520with%2520capecitabine%2520for%2520previously%2520treated%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D1114%26epage%3D1119%26doi%3D10.1634%2Ftheoncologist.2008-0816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shindo-Okada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamachi, Y.</span></span> <span> </span><span class="NLM_article-title">Establishment of cell lines with high and low metastatic potential from A549 human lung adenocarcinoma</span>. <i>Jpn. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2002.tb01200.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1111%2Fj.1349-7006.2002.tb01200.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=11802808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XisVKmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=50-60&author=N.+Shindo-Okadaauthor=K.+Takeuchiauthor=B.+S.+Hanauthor=Y.+Nagamachi&title=Establishment+of+cell+lines+with+high+and+low+metastatic+potential+from+A549+human+lung+adenocarcinoma&doi=10.1111%2Fj.1349-7006.2002.tb01200.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of cell lines with high and low metastatic potential from A549 human lung adenocarcinoma</span></div><div class="casAuthors">Shindo-Okada, Nobuko; Takeuchi, Kaori; Han, Beom-Seok; Nagamachi, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-60</span>CODEN:
                <span class="NLM_cas:coden">JJCREP</span>;
        ISSN:<span class="NLM_cas:issn">0910-5050</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">This article reports the establishment of variant cell lines with high and low metastatic potential by the diln. plating technique.  Two clones with high metastatic potential, 2S Lu-4 and 11S Lu-1 and two clones with low metastatic potential, 8S and 16S were established from A549 human lung adenocarcinoma.  The high-metastatic cell lines produced enhanced lung metastases, but the low-metastatic cell lines did not produce lung metastasis after injection into the tail vein of 5-wk-old BALB/c nude mice.  The primary tumors produced by the two high-metastatic cells grew fast and showed enhanced angiogenesis.  The high-metastatic cells were small and flat-shaped, while the low-metastatic cells were large and flat-shaped.  When the four variant cell lines and original A549 cells were embedded in collagen gels, the colonies of 2S Lu-4, 11S Lu-1 and A549 grew actively, whereas almost of all the colonies of 8S and 16S did not survive after 35 days in culture.  These four cloned cell lines originated from heterogeneous populations of the parental A549 cells should be an excellent tool for studying the process of metastasis of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRRfQ6nbhuzrVg90H21EOLACvtfcHk0lhrQtfetQg6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisVKmur0%253D&md5=89a62575e5aa3d5097f62466eb050353</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2002.tb01200.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2002.tb01200.x%26sid%3Dliteratum%253Aachs%26aulast%3DShindo-Okada%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DB.%2BS.%26aulast%3DNagamachi%26aufirst%3DY.%26atitle%3DEstablishment%2520of%2520cell%2520lines%2520with%2520high%2520and%2520low%2520metastatic%2520potential%2520from%2520A549%2520human%2520lung%2520adenocarcinoma%26jtitle%3DJpn.%2520J.%2520Cancer%2520Res.%26date%3D2002%26volume%3D93%26spage%3D50%26epage%3D60%26doi%3D10.1111%2Fj.1349-7006.2002.tb01200.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0lhrQtfetQg6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, A.</span></span> <span> </span><span class="NLM_article-title">Identification of novel aurora kinase A (AURKA) inhibitors via hierarchical ligand-based virtual screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.7b00300</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.7b00300" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=36-47&author=Y.+Kongauthor=A.+Benderauthor=A.+Yan&title=Identification+of+novel+aurora+kinase+A+%28AURKA%29+inhibitors+via+hierarchical+ligand-based+virtual+screening&doi=10.1021%2Facs.jcim.7b00300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Aurora Kinase A (AURKA) Inhibitors via Hierarchical Ligand-Based Virtual Screening</span></div><div class="casAuthors">Kong, Yue; Bender, Andreas; Yan, Aixia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-47</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aurora kinases are essential for cell mitosis, amplified, and overexpressed in various human malignancies.  Therefore, Aurora kinases have been promising targets for anticancer therapies, which has prompted an intensive search for their small-mol. inhibitors.  In this work, we performed a hierarchical and time-efficient virtual screening cascade for scaffold hopping, aiming to obtain structurally novel and highly potent hit compds. targeting Aurora kinases.  The cascade consisted of a shape- and an electrostatic-based protocol, combined with a QSAR-based selection protocol.  This virtual screening cascade was used to screen two databases, one com. database named the J&K database contg. about 5.2 million diverse mols. and the Drugbank database.  Exptl. validations led to the identification of one structurally novel and highly potent hit compd. (hit 1, found to possess an IC50 of 8.1 and 19 nM for Aurora kinases A and B, resp.), which can be a promising starting point for further exploration.  Addnl., Aurora kinases were identified as off-targets for hits 2-6 (Crizotinib, CI-1033, Dasatinib, Bosutinib, MLN-518), which are approved or investigational drugs as listed in Drugbank, plausibly suggesting targeting Aurora kinases may even contribute to their mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7nu5Hn7IsDLVg90H21EOLACvtfcHk0lgUxP-4SEyWIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bJ&md5=b1d085a79a8db7f9f584cb0b58edfb66</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.7b00300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.7b00300%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DY.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520novel%2520aurora%2520kinase%2520A%2520%2528AURKA%2529%2520inhibitors%2520via%2520hierarchical%2520ligand-based%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26spage%3D36%26epage%3D47%26doi%3D10.1021%2Facs.jcim.7b00300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, A.</span></span> <span> </span><span class="NLM_article-title">Self-organizing map (SOM) and support vector machine (SVM) models for the prediction of human epidermal growth factor receptor (EGFR/ErbB-1) inhibitors</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.2174/1386207319666160414105044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=10.2174%2F1386207319666160414105044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=27074760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFagtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=400-411&author=Y.+Kongauthor=D.+Quauthor=X.+Chenauthor=Y.+Gongauthor=A.+Yan&title=Self-organizing+map+%28SOM%29+and+support+vector+machine+%28SVM%29+models+for+the+prediction+of+human+epidermal+growth+factor+receptor+%28EGFR%2FErbB-1%29+inhibitors&doi=10.2174%2F1386207319666160414105044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Self-Organizing Map (SOM) and Support Vector Machine (SVM) Models for the Prediction of Human Epidermal Growth Factor Receptor (EGFR/ ErbB-1) Inhibitors</span></div><div class="casAuthors">Kong, Yue; Qu, Dan; Chen, Xiaoyan; Gong, Ya-Nan; Yan, Aixia</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">400-411</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">EGFR (ErbB-1/HER1) kinase plays an important role in cancer therapy.  Two classification models were established to predict whether a compd. is an inhibitor or a decoy of human EGFR (ErbR-1) by using Kohonen's self-organizing map (SOM) and support vector machine (SVM).  A dataset contg. 1248 ATP binding site inhibitors and 3090 decoys was collected and randomly divided into a training set (831 inhibitors and 2064 decoys) and a test set (417 inhibitors and 1029 decoys).  The descriptors that represent mol. structures were calcd. by software ADRIANA.Code.  Thirteen significant descriptors including five global descriptors and eight 2D property autocorrelation descriptors were selected by Pearson correlation anal. and stepwise anal.  The prediction accuracies on training set and test set are 98.5% and 96.3% for SOM model, 99.0% and 97.0% for SVM model, resp.  Both of these two classification models have good performance on distinguishing EGFR inhibitors from decoys.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_w15gyzfUTbVg90H21EOLACvtfcHk0lgUxP-4SEyWIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFagtLw%253D&md5=532784817d1ea1ae033b1132f45349cf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F1386207319666160414105044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207319666160414105044%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DA.%26atitle%3DSelf-organizing%2520map%2520%2528SOM%2529%2520and%2520support%2520vector%2520machine%2520%2528SVM%2529%2520models%2520for%2520the%2520prediction%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%252FErbB-1%2529%2520inhibitors%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2016%26volume%3D19%26spage%3D400%26epage%3D411%26doi%3D10.2174%2F1386207319666160414105044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY','PDB','2ITY'); return false;">PDB: 2ITY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK','PDB','1XKK'); return false;">PDB: 1XKK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i59"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01612">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07673"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01612">10.1021/acs.jmedchem.8b01612</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS spectra, and HPLC analysis of all compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_002.xls">XLS</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_003.csv">CSV</a>)</p></li><li><p class="inline">Compound <b>1f</b> with EGFR compared to Gefitinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>1f</b> with EGFR compared to Lapatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_005.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_001.pdf">jm8b01612_si_001.pdf (12.12 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_002.xls">jm8b01612_si_002.xls (95.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_003.csv">jm8b01612_si_003.csv (3.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_004.pdb">jm8b01612_si_004.pdb (230.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01612/suppl_file/jm8b01612_si_005.pdb">jm8b01612_si_005.pdb (163.34 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01612&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-24%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01612%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01612" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5fe3b8cd2388","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
